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AP-1   Activator Protein-1
BCII   Bovine Collagen type II
cDNA   complementary DNA
CIA    Collagen-Induced Arthritis 
CMV   Cytomegalovirus
ECM    Extra Cellular Matrix
HE   Heamatoxylin/Eosin 
I.a    Intra-articular
ICE    Interleukin-1 Converting Enzyme
I.p    Intraperitoneal
IRAK    IL-1 Receptor Activating Kinase
I.v    Intravenous 
IVIS    In Vivo Imaging System 
IL-1    Interleukin-1
IL-17   Interleukin-17 
IL-18    Interleukin-18
IL-1Ra    Interleukin-1 Receptor antagonist 
IL-1RAcP   Interleukin-1 Receptor Accessory Protein
IL-1RI    Interleukin-1 Receptor type I
IL-1RII   Interleukin-1 Receptor type II
IL-18BP  Interleukin-18 Binding Protein
IL-18Rα  Interleukin-18 Receptor α  (Interleukin-1 Receptor related protein (IL-1 rp))
IL-18Rβ  Interleukin-18 Receptor β (Accessory Protein Like (AcPL))
MyD88   Myeloid diﬀerentiation factor 88
NFκB    Nuclear Factor-κB 
PBMC   Peripheral Blood Mononuclear Cell
PBS   Phosphate Buﬀered Saline 
PFU   Plaque Forming Unit
PG   Proteoglycan
RT   Room temperature
SCW   Streptococcal Cell Wall 
SiRNA   Short interference RNA
sIL-1RI   soluble Interleukin-1 Receptor type I
sIL-1RII   soluble Interleukin-1 Receptor type II
sIL-1RAcP   soluble Interleukin-1 Receptor Accessory Protein
sIL-18Rβ   soluble Interleukin-18 Receptor β
Th1    T helper-1 
Th2    T helper-2
TNFα   Tumor Necrosis Factor α
TRAF6   TNF Receptor Activating Factor 6
Treg    Regulatory T-cell (CD4+CD25+)
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General Introduction
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a 
common systemic disorder with a chronic 
inﬂammatory character mainly localized 
to joints, affecting ~ 1% of the population 
worldwide [1]. The disease is associated 
with auto immunity although the etiology 
remains unknown. In many patients suffer-
ing from RA the disease is characterized by 
exacerbations and remissions. The metacar-
pophalangeal and proximal interphalangeal 
diarthrodial joints of ﬁngers and toes, but 
also wrist are ﬁrst and most severely affected 
joints, and the destructive nature of RA will 
ultimately lead to loss of articular function. 
Since RA cannot be cured this disorder has 
substantial personal, social and economic 
impact. The long-term prognosis is rather 
poor, give the fact that 80% of the patients 
are disabled after 20 years and life expec-
tancy is reduced by an average 3 to 18 years 
[2,3]. Treatment of RA is mainly focused on 
decelerating the destructive effects on bone 
and cartilage, with the ultimate resort being 
joint replacement surgery. 
It is generally accepted that pro-inﬂam-
matory cytokines play an important role 
in the pathogenesis of RA [4].  Therefore 
strategies controlling cytokine activity and 
production are of great interest, which could 
have a therapeutic potential in the future. 
In the following chapters we will discuss 
the role of the pro-inﬂammatory cytokines 
IL-1 and IL-18 in experimental models of 
arthritis. Furthermore, we try to modulate 
IL-1 and IL-18 cytokine sensitivity using a 
soluble receptor approach. 
Pathogenesis of RA
The chronic inﬂammatory manifesta-
tion of RA results in the destruction of the 
articular cartilage and bone. Characteris-
tics of RA are schematically presented in 
ﬁgure 1. In the course of the destructive 
process, the synovium plays an important 
role. The synovial membrane is a one to two 
cell layers thick lining, which encloses the 
inside of diarthrodial joints and functions as 
a physical barrier between the intra-articular 
cavity and the underlying synovium. This 
synovial intima is composed out of macro-
phage-like type-A-synoviocytes and ﬁbro-
blast-like type-B-synoviocytes [5,6]. This 
type-A-synoviocyte can actively phagocy-
tose foreign components, which are retained 
in the joint cavity. Furthermore, these cells 
possess an antigen-presenting capability 
[5,7]. The type-B-synovocytes are respon-
sible for maintenance of the specialized 
synovial matrix and are the main producers 
of the synovial ﬂuid which functions as a 
joint lubricant, enabling smooth movement 
[6,8-10]. The underlying synovial sub-
intima functions as supporting tissue and is 
highly vascular. The synovial membrane in 
patients suffering from RA is characterized 
by hyperplasia, increased vascularity and is 
highly inﬁltrated by macrophages, plasma 
cells and T-cells (Figure 1) [11-13]. These 
latter cells are the main orchestrators of cell-
mediated immune responses, which result 
in the production of a surplus of cytokines, 
oxygen radicals and enzymes [14-16], which 
play an important role in the continuation 
of inﬂammation and degradation of cartilage 
and bone, as observed in RA. 
Healthy cartilage is crucial for the 
normal functioning of articular joints [17]. 
This cartilage consists out of chondrocytes 
surrounded by large amounts of extracel-
lular matrix. These chondrocytes are the 
exclusive resident cells of the cartilage and 
are responsible for the maintenance of the 
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extracellular matrix (ECM). The ECM is 
composed out of a tightly organized collagen 
type II network, which encloses proteo-
glycans (PGs) associated with hydrophilic 
glycosaminoglycan. Due to this hydrophilic 
property, cartilage contains large amounts of 
water, giving it its exceptional weight bear-
ing capacity. The disruption of the cartilage 
structure will results in the loss of carti-
lage function. Reversible and irreversible 
processes characterize this process of disrup-
tion. First signs of damage can be observed 
as depletion of PGs from the cartilage matrix 
[18], which is reversible and can be visual-
ized on histological sections using a safranin-
O-staining [19]. This process can occur as a 
result of enzymatic degradation and reduced 
de novo synthesis of PGs by resident chondro-
cytes [20-22].  The enzymatic destruction 
of the collagen network will result in total 
and irreversible disruption of the cartilage, 
which will develop into erosive cartilage 
damage [23]. 
Although the etiology of RA is yet 
unknown, it is suggested that the disease is 
the result of cross-reactivity between viral or 
bacterial components and self antigens result-
ing in generation of auto-antigen speciﬁc 
T-cell clones, which are in turn responsible 
for the perpetuation of the disease when 
activated [24]. There is a general consensus 
that improper immunological regulation is 
at the basis of development of the disease, 
which is shown in the excessive production 
Figure 1. 
Schematic presentation of a healthy knee joint and the processes that take 
place during development of arthritis, ultimately leading to joint destruction 
and loss of function.
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of (pro)inﬂammatory cytokines [25,26]. 
This skewed balance between pro- and anti-
inﬂammatory cytokine production can be 
corrected by strategies, modulating cytokine 
signaling. 
Gene therapy for RA
Efﬁcient drug delivery is one of the main 
tribulations of today’s anti-rheumatic thera-
pies. In order to achieve stable levels of the 
therapeutic compound repeated systemic 
administrations are a prerequisite. Through 
insertion of genes, encoding for therapeu-
tic proteins, long-lasting expression of the 
biologics could be achieved through one 
single injection. For effective gene delivery, 
adenoviral vectors (sero type 5) are an effec-
tive strategy and have been extensively used 
as gene therapeutical approach for experi-
mental arthritis [27-31]. Adenoviruses have 
proved to be potential vectors, efﬁciently 
transducing dividing and non-dividing cells. 
Adenoviruses are icosahedral particles with 
a diameter of ~70-100 nm [32,33]. The 
adenoviral virion consists of a non-envel-
oped icosahedral protein shell, or capsid, 
enclosing a double stranded DNA-protein 
core complex.  The capsid comprises 240 
hexon and 12 pentons, which are major coat 
proteins. The serotype 5 adenovirus targets 
the cell by interacting with the coxsackievi-
rus and adenovirus receptor (CAR) [34-37]. 
This receptor is a member of the immuno-
globulin superfamily, however its function 
remains unclear [35,37]. Internalization is 
achieved by binding of the RGD motive 
present in the penton base of the capsid, 
which interacts with the αvβ3 and 5 [38-40]. 
Subsequently, the viral DNA translocates to 
the nucleus where it does not integrate into 
the host genome, but remains episomal [41-
43]. The recombinant adenoviral genome 
is deleted from 3 early transcriptional units, 
called the E1A, E1B and E3, which provides 
room for the insertion of the gene of inter-
est [44-46]. As the E1 genes are essential 
for viral replication, the E3 region encodes 
for proteins responsible for evasion of the 
immunesystem by the adenovirus [32,33]. 
These deletions prevent the adenovirus from 
replicating in target cells, thus provide a safe 
expression of the transgene, which can last 
up to two weeks.
Pro-inflammatory cytokines 
IL-1 and IL-18 in arthritis.
The IL-1 ligand superfamily is an impor-
tant family of structural related cytokines, 
which also share a functional similarity in 
that they all appear to be involved in regu-
lating inﬂammation. To date, ten members 
of this IL-1 gene superfamily have been 
described, of which four gene products 
thoroughly. The four primary members 
of this family are IL-1α (IL-1F1), IL-1β 
(IL-1F2) and IL-18 (IL-1F4), which all have 
agonistic actions and the IL-1Ra (IL-1F3), 
which is the speciﬁc receptor antagonist for 
IL-1α and β [47,48]. The other six members 
have been described, although their role in 
inﬂammatory disease remains unknown. 
Analogous to the close structural and func-
tional relationship between IL-1 and IL-18, 
their receptor complexes are also remarkably 
similar [49]. 
Molecular aspects of Interleukin-1
In 1984 cDNAs for the two forms of 
IL-1 were cloned and described [50].  Both 
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genes of IL-1α and -β are located on chro-
mosome 2 of man and mouse [51]. A large 
number of different biological actions were 
attributed to this molecule, giving it its plei-
tropic character. IL-1α and -β are synthesized 
as precursor protein of approximately 31 kDa 
[52]. Appropriate cell stimulation results in 
the enzymatic processing of pro-IL-1β to its 
mature and biological active 17 kDa form, 
by the speciﬁc enzyme IL-1β converting 
enzyme (ICE also called Caspase-1) [53,54]. 
Although ICE is primarily responsible for 
intracellular cleavage of pro-IL-1β, other 
extracellular proteases which are commonly 
found in inﬂammatory ﬂuids, such as elas-
tase [55], proteinase-3 [56] and mast cell 
chymase [57] can also activate IL-1β. Pro-
IL-1α, also called membrane IL-1α [58,59] 
and its mature form, which is processed by 
membrane-associated cysteine proteases 
called calpains [60,61], are both biologically 
active. The mature forms of IL-1α and -β 
comprise similar three-dimensional struc-
ture consisting entirely of β-pleated sheets 
[62,63]. Although both forms of IL-1 show 
great structural homology and share the 
same receptor, their role in T-cell dependent 
antibody production appears to be distinct 
[64,65].
The IL-1 Receptor antagonist (IL-1Ra)
A third ligand of the IL-1 family is IL-
1Ra [52], which binds to the IL-1R type 
I, but fails to activate cells [66,67]. IL-1Ra 
is produced by mainly monocytes, macro-
phages [68] and neutrophils [69] as a glyco-
silated protein of ~22 kDa [70-73]. To date, 
at least three intracellular isoforms of IL-1Ra 
(icIL-1Ra) have been described, resulting 
from alternative transcriptional mRNA 
splicing [74]. Production of icIL-1Ra is 
stimulated in inﬂamed synovium during 
experimental arthritis [75] and although the 
exact function remains to be determined, it 
is suggested that these intracellular IL-1Ra 
variants function as intracellular antagonist 
of IL-1 [75,76]. 
IL-1 receptor complex and 
signal transduction
The IL-1 Receptor type I (IL-1Rtype I)
Signaling through the IL-1 type I recep-
tor is required for all actions of IL-1 [77,78]. 
This receptor is a single spanning 80 kDa 
glycosilated type I transmembrane protein 
which comprises three immunoglobulin 
(Ig)–like domains extracellularly and a 213 
amino acid cytoplasmic portion exhibiting a 
domain shared with other members of the 
IL-1 and Toll-like receptor family, generally 
known as the TIR-domain (for Toll/IL-1 
receptor) [49,79]. IL-1 binding to this recep-
tor has been resolved using crystallography 
of IL-1β bound to the exracellular portion 
of the IL-1R type I [80]. This data shows 
that IL-1 binds the IL-1R type I at a large 
contact area in the groove between the ﬁrst 
and second Ig-like domain, whereas only a 
small area of the third membrane-proximal 
Ig-like domain contacts and wraps around 
IL-1 [49,80,81].
The IL-1 Receptor Accessory 
Protein (IL-1RAcP)
A homologue of the type I receptor has 
been described, known as the IL-1R Acces-
sory Protein (IL-1RAcP), which is required 
for IL-1 signaling [82-85]. This accessory 
molecule has no afﬁnity on its own for IL-1α 
or IL-1β. However, once IL-1 has bound the 
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IL-1R type I, IL-1RAcP is recruited to the 
ligand-bound IL-1R type I, in order to form 
a high afﬁnity receptor complex. No experi-
mental data has been provided showing the 
mechanism by which IL-1RAcP interacts 
with ligand bound IL-1R type I. However, 
experiments using antibodies directed 
against the third Ig-like domain of the IL-
1R type I preferentially blocked IL-1 activity, 
suggesting that this domain is crucial for the 
docking of the IL-1RAcP [86]. Recently, 
a model has been proposed by which IL-
1RAcP interacts with the IL-1/IL-1R type 
I by wrapping around the rear surface of the 
dimeric complex [81]. Unfortunately, an 
experimental determined crystallography of 
the trimeric receptor complex, consiting out 
of IL-1, IL-R type I and the IL-1RAcP has 
not yet been produced. IL-1 signaling is sche-
matically presented in ﬁgure 2, showing the 
formation of the trimeric receptor complex, 
consisting out of IL-1, IL-1R type I and 
the IL-1RAcP. This event results in  asso-
ciation of the intracellular TIR domains, 
Figure 2. 
Intracellular signaling pathways of Interleukin-1 and Interleukin-18 
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which induces signal transduction through 
recruitment of the adapter protein MyD88 
[87,88]. The presence of a death domain in 
the adaptor molecule allows recruitment of 
other death-domain containing molecules 
like the IL-1 Receptor Activated Kinases 
(IRAK-1 and -4) [83,87,89,90]. IRAK-1 
then associates with another adapter, called 
TNF-associated Factor-6 (TRAF6), which 
leads to activation of several protein kinases 
( JNK, ERKs and IKK), eventually resulting 
in activation of transcription factors (NFκB, 
AP-1) involved in regulation of inﬂammation 
related gene expression (signal transduction 
reviewed in [79]. 
In contrast to IL-1α/β, IL-1Ra fails to 
induce IL-1 signaling, although it binds 
the IL-1R type I. When IL-1Ra is bound, 
no recruitment of the IL-1RAcP will take 
place. This ﬁnding is probably related to 
the X-ray crystallography data of IL-1Ra 
bound to the IL-1R type I, which reveals 
that IL-1Ra binds to the same N-terminal 
Ig-like domains. However, it fails to interact 
with the third Ig-like domain as IL-1β does 
[91,92]. This inability of IL-1Rα to recruit 
IL-1RAcP, and its ability to occupy the 
IL-1α/β binding pocket of the IL-1R type I, 
gives IL-1Ra its IL-1 antagonistic capacity.
The IL-1 Receptor type II (IL-1Rtype-II)
Another structural homologue of the IL-
1R type I is the IL-1R type II [93]. Like 
the type I receptor gene the type II recep-
tor gene is also located on chromosome 
2. While the IL-1R type I is universally 
expressed, the IL-1R type II is expressed 
by a restricted panel of cell types, primarily 
B-cells, monocytes and neutrophils [93-96]. 
Unlike the IL-1R type I, the IL-1R type II 
possesses only a short 29 amino acids long 
cytoplasmic portion, which does not contain 
a TIR domain [93,97,98]. The IL-1 R type 
II has never been demonstrated to mediate 
any biological responses [97].  This asset of 
efﬁcient IL-1 binding, but failing to signal, 
makes the IL-1R type II a negative regulator 
of IL-1 signaling or also referred to as “decoy 
receptor” [98,99]. Interestingly, the IL-1R 
type II has a high afﬁnity for IL-1β, but a 
much lower afﬁnity for IL-1α and the IL-1 
Receptor antagonist [100]. This low afﬁnity 
of the IL-1R type I for IL-1Ra rules out the 
possibility of counter activity of both nega-
tive regulators of IL-1 signaling [101]. 
Recently it has become clear that not only 
the IL-1R type I can interact with the IL-
1RAcP, but also the IL-1R type II [102,103], 
greatly increasing its afﬁnity for IL-1β [100]. 
With this capability the IL-1R type II does 
not only sequester IL-1β, it also increases 
the inhibitory potency of IL-1R type II, by 
keeping the IL-1RAcP away from forming a 
signal transducing complex with the IL-1R 
type I. 
Soluble IL-1 Receptors 
Also a soluble variant of IL-1R type 
II (sIL-1R type II) has been described 
[104].  This soluble receptor can be gener-
ated through active cleavage from the cell 
membrane surface by metalloproteinases, 
in order to generate soluble IL-1R type II 
which can antagonize IL-1 action [105,106]. 
Elevated levels of the soluble IL-1R type II 
can be found in the circulation and synovial 
ﬂuid of patients suffering from RA. Soluble 
IL-1R type I can also be detected although 
to a much lesser extent [107].
In addition, a natural occurring soluble 
form of the IL-1RAcP has been described, 
which is the result of alternative mRNA 
14
C
ha
pt
er
 1
General Introduction
splicing [82,108]. Recently, it was shown 
that the soluble IL-1RAcP (sIL-1RAcP) was 
able to inhibit IL-1 signaling when artiﬁcial-
ly anchored to the cell membrane, although 
its in vivo physiological role remained unclear 
[108].  
Since membrane associated IL-1R type II 
can interact with the IL-1RAcP, it would 
not be unimaginable that sIL-1RAcP could 
also interact with the sIL-1R type II. This 
phenomenon was observed by Smith et al 
who described increased IL-1 inhibitory 
potency of the sIL-1R type II in the presence 
of sIL-1RAcP [100].
Cellular sources and role of IL-1 in RA
The role of IL-1 in the pathogenesis of 
RA was originally observed by Dayer et al 
who described a lymphocyte factor, which 
increased collagenase production by synovial 
RA ﬁbroblasts [109]. Studies by Saklatvala 
et al showed that a secreted factor from pig 
synovium, which he referred to as catabo-
lin, was able to stimulate lymphocytes and 
induce cartilage proteoglycan depletion 
[110]. With the production of recombinant 
IL-1 it was shown that the factor identiﬁed 
by Dayer and Saklatvala was indeed IL-1. 
Unlike IL-1α, IL-1β is frequently found in 
the circulation of patients suffering from RA 
and the levels of IL-1β correlated with disease 
activity [111,112]. IL-1 can be expressed by 
a wide variety of cells, including monocytes, 
macrophages, dendritic cells, ﬁbroblasts, 
T- and B-cells [113]. Macrophages resident 
in synovial tissue of RA patients constitu-
tively express IL-1, and IL-1 can be found 
in elevated levels in synovial ﬂuid of RA 
patients [112]. IL-1 induces inﬂammation 
by activating synovial cells, endothelial cells, 
lymphocytes and macrophages to produce a 
wide variety of chemokines, cytokines and 
inﬂammatory mediators, including IL-1 
itself, IL-6, TNFα, IL-8, cyclooxygenase-
(COX)2,  and iNOS [114]. From RA and 
experimental arthritis models, it has become 
clear that IL-1 promotes synoviocyte prolif-
eration and activation of synoviocytes and 
osteoclasts to produce metalloproteases and 
collagenases [115,116]. Injection of puriﬁed 
recombinant IL-1 into rabbit and mouse 
knee joints resulted in accumulation of poly-
morphonuclear and mononuclear leukocytes 
into the joint cavity and induced proteogly-
can depletion from the articular cartilage 
[117,118]. Furthermore, continuous infusion 
of IL-1 was able to induce arthritis [119] and 
IL-1 injection resulted in exacerbation of 
experimental arthritis, revealing its role as a 
regulator of inﬂammation [120,121]. Beside 
its role in attraction of polymorphonuclear 
cells, a direct involvement of this cytokine 
was found on cartilage ECM homeostasis. 
IL-1 enhanced proteoglycan degradation 
and severely inhibited de novo proteogly-
can synthesis by articular chondrocytes 
[122,123]
In line with these results it was shown that 
treatment of bovine collagen type II immu-
nized mice with anti-IL-1 α/β signiﬁcantly 
ameliorated the collagen-induced arthritis 
(CIA) [124,125] and protected cartilage 
against proteoglycan depletion in the anti-
gen induced arthritis (AIA) [126]. With the 
development of IL-1-deﬁcient mice it was 
shown that IL-1 indeed plays a crucial role 
in the development of arthritis, since no CIA 
developed in immunized IL-1α/β -/- mice 
[127]. These studies show the importance of 
IL-1 in the development of arthritis, but also 
in the later stages during full-blown arthritis. 
Interestingly, IL-1Ra-deﬁcient mice spon-
taneously develop polyarthritis, already at 
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the age of ﬁve weeks [128]. Histopathologi-
cal analysis of the joints of IL-1Ra-/- mice 
showed severe synovial and periarticular 
inﬂammation. Furthermore, development 
of the poly arthritis coincided with cartilage 
and bone erosion.  Total immunoglobulin 
levels as well as autoantibody levels against 
dsDNA and type II collagen were elevated in 
these mice, revealing the importance of IL-1 
regulation in development of T-cell immu-
nity. Proliferative response and cytokine 
production of T-cells, mediated by APCs 
were markedly impaired in IL-1α/β-/- mice, 
and enhanced in IL-1Ra-/- mice [128]. With 
these studies, the authors showed that exces-
sive IL-1 signaling causes autoimmunity, 
through direct sensitization and activation of 
T-cell immunity. Together with the direct 
effects of IL-1 on cartilage homeostasis, poly-
morphonuclear cell attraction and the effect 
of IL-1 of T-cell activity, it has been shown 
that IL-1 plays an important role in joint 
speciﬁc inﬂammation and bone destruction 
as can be observed during RA.
Molecular aspects of 
Interleukin-18
Although IL-18 is a member of the IL-1 
ligand family, it appears to have unique 
characteristics that distinguish IL-18 from 
IL-1. IL-18, formerly known as Interferon 
(IFN)-γ-inducing factor (IGIF), was ﬁrst 
described in 1989 as a factor, which induced 
IFNγ in propionibacterium acnes conditioned 
mice [129-132]. More than any other cyto-
kine IL-18 is related to IL-1. The similarities 
between IL-1 and IL-18 exist at several levels. 
First of all, IL-18 is produced in a pro-IL-18 
form, which requires cleavage to an active 
18 kDa cytokine by ICE [133-136]. IL-1 and 
IL-18 are also structurally related since both 
cytokines are primarily all β-pleated sheet 
folded molecules [137,138]. Finally, at recep-
tor level, the activity of IL-18 is mediated 
through formation of a heterodimeric recep-
tor complex, which is structurally related to 
the IL-1 receptor complex. This complex 
comprises an IL-18 binding receptor called 
the IL-18Rα and an accessory receptor called 
the IL-18Rβ (Accessory protein like, AcPL). 
IL-18 receptor complex and 
signal transduction
IL-18 Receptor α (IL-1Receptor 
related protein)
The activity of IL-18 starts by bind-
ing of IL-18 to the IL-18Rα (also called 
IL-1R related protein, IL-1Rrp) [139]. 
The IL-18Rα is also a member of the IL-1 
receptor family, which contains three Ig-like 
domains in its extracellular portion of the 
receptor and a TIR domain intracellularly. 
The IL-18Rα is not able to bind IL-1α, IL-1β 
or IL-1Ra [140].
IL-18 Receptor β (IL-18 Receptor 
Accessory protein-like)
Similar to IL-1 signal transduction, IL-18 
signaling is achieved through formation of a 
heterodimeric receptor complex, composed 
of the IL-18Rα, its accessory chain IL-18Rβ 
plus IL-18. This accessory chain, structurally 
related to the IL-1RAcP, was initially named 
the IL-1 Receptor Accessory protein-like 
(AcPL) chain [141]. The IL-18Rβ is not only 
structurally related to the IL-1RAcP [82], 
but also functionally. The IL-18Rβ itself 
does not bind IL-18, but is recruited to IL-18 
bound to the IL-18Rα chain. In the absence 
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Figure 3.
Methods of blocking inﬂammatory cytokine activity. (Adapted from EH Choy and GS Panayi; Cytokine pathways and joint 
inﬂammation in rheumatoid arthritis. N Engl J Med 2001, 344: 907-916.)
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of IL-18Rβ, the binding of IL-18 to the IL-
18Rα is of low afﬁnity. By recruiting the 
IL-18Rβ, the receptor complex forms into a 
high afﬁnity and signal transducting recep-
tor complex [141,142].  No IL-18 signal can 
be generated in the absence of the IL-18Rβ, 
revealing its crucial function in activation of 
intracellular signal transduction. Also intra-
cellular, the IL-18 signal transduction greatly 
resembles the IL-1 signal cascade. Like in 
IL-1 signaling, the intracellular adapter 
protein MyD88 plays a important role in IL-
18 signaling (Figure 2), given the fact that 
MyD88-deﬁcient mice do not respond either 
IL-1 or IL-18 [143].  Therefore MyD88 is 
an essential component in the signal trans-
duction following IL-1 and IL-18 binding. 
Also in IL-18 signaling, MyD88 assists in the 
docking of IRAKs to the receptor complex 
[144]. This docking of MyD88 to the IL-18R 
complex is a critical step, which facilitates the 
phosphorylation of IRAKs. Eventually and 
also via TRAF6, different regulators of gene 
transcription are activated including NFκB 
and MAPK [141,144] 
Soluble IL-18 Receptors
IL-18Rα and IL-18Rβ
Recently, a soluble form of the IL-18Rβ 
has been described in rat and sequenced 
from murine lung tissue (gene acces-
sion number ak053176) [145]. Although 
the IL-18Rβ chain is required for signal 
transduction, the extracellular domain 
does not bind IL-18. Therefore the role 
of soluble IL-18Rβ in IL-18 signaling 
remains unclear. Studies using soluble 
IL-18Rα and soluble IL-18Rβ as a strat-
egy for neutralizing IL-18, revealed that 
the extracellular portions of both ligand 
binding α-chain and non-ligand binding 
β-chain are required for inhibition of IL-
18 signaling [146].
IL-18 Binding Protein (IL-18BP)
The naturally occurring IL-18BP is a 
secreted IL-18 neutralizing protein, which 
has a high afﬁnity for IL-18. In contrast to 
genuine soluble receptors, IL-18BP is only 
distant related to the IL-18Rα, given the 
fact that it only comprises one single Ig-
like domain [147,148]. The IL-18BP gene 
encodes for a ~38 kDa protein, which is 
highly expressed in immuologically active 
tissue, like the spleen [149]. IL-18BP appears 
to be speciﬁc for mature IL-18, in that no 
IL-18 precursor can be bound [147,150]. 
Four human (IL-18BPa, b, c and d) and two 
murine isotypes (IL-18BPc and d) of IL-
18BP have been described [147,149]. These 
isoforms all result of alternative mRNA 
splicing.  In human, only the IL-18BPa 
and c possess an intact IL-18 binding Ig-
like domain, which gives them their IL-18 
neutralizing ability. The exact function of 
the isoform b and d remains unclear. 
The mouse IL-18BPc and d are both IL-
18 neutralizing proteins, which can scav-
enge >95% of biologically active IL-18 on a 
1:1 molar ratio. In healthy humans IL-18BP 
circulates at average concentrations of 2.15 
ng/ml and can be produced by macrophages 
and endothelial cells of the gastrointestinal 
tract upon stimulation with IFNγ [150,151]. 
Interestingly, the human sequence for the 
IL-18BP shows great homology with genes 
found in various pox viruses [149,152]. 
The recombinant proteins of these viral 
IL-18BP-like genes, were able to neutral-
ize mammalian IL-18 [152]. Since IL-18 is 
an important pro-inﬂammatory cytokine 
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involved in the innate and acquired immu-
nity, viral IL-18BP could be the evading 
mechanism which avoids triggering of the 
host defense system, targeting viral elimi-
nation [153]. 
Cellular sources and role of IL-18 in RA
IL-18 plays a major role in regulation of 
the innate and acquired immunity. Macro-
phages, as being the most important source 
of endogenous cytokine production, secrete 
IL-18 upon challenge with microbial compo-
nents, such as LPS and viral particles [153]. 
IL-18 is also constitutively expressed by 
monocytes and dendritic cells, but also non-
inﬂammation derived cell types such as kera-
tinocytes and chondrocytes express IL-18 
[154-156]. Until the discovery of IL-18, the 
major IFNγ-inducing factor from macro-
phages was IL-12 [157]. Although, IL-18 is 
involved in IFNγ production from T-helper 
1 (Th1) cells and Natural Killer (NK) cells, 
IL-18 does not induce IFNγ production from 
naive T-cells, which is due to the absence 
of the IL-18 receptor on these cells [158]. 
However, a marked increase in IFNγ produc-
tion can be observed on naive T-cells after 
addition of IL-12 in the presence of IL-18. 
This IL-12 dependent synergistic effect on 
IFNγ production by T-cells is due to IL-12 
induced upregulation of the IL-18 receptor 
complex on these cells [159-161]. Compared 
to the IL-18 induced Th1 response, no effect 
can be observed on Th2 response, which was 
conﬁrmed by the absence of the IL-18R on 
Th2 cell, revealing the relevance of IL-18 
in development of a Th1 mediated response 
[144]. In contrast with these effects, IL-18 
also directly induces effects on T-cells and 
NK-cells, independently of IL-12. IL-18 
induces the development of a cytotoxic 
T-cell response through FAS-ligand expres-
sion on T- and NK-cells [162]. 
In human disorders, IL-18 is highly 
expressed in the synovial lining of patients 
suffering from RA, and the expression 
correlated with IL-1 and TNFα expression 
[163,164]. In models of experimental 
arthritis it became clear that not all IL-18 medi-
ated effects were IFNγ dependent. Injection of 
IL-18 induced accumulation and activation of 
polymorphonuclear cells, thereby promoting 
early innate immunity [165]. Mice suffering 
from streptococcal cell wall (SCW)-induced 
arthritis treated with neutralizing anti-IL-18 
antibodies revealed a signiﬁcant reduction in 
joint swelling, which was accompanied with 
decreased synovial ﬂuid levels of TNFα and 
IL-1 [166]. Furthermore anti-IL-18 treatment 
protected against SCW-induced inhibition 
of chondrocyte proteoglycan synthesis. Since 
IFNγ-deﬁcient mice treated with anti-IL-18 
antibodies revealed similar results, the patho-
logic role for IL-18 in this experimental arthritis 
model appears to be IFNγ-independent. 
IL-18 also plays an important role in CIA. 
IL-18 injection aggravated the arthritis, result-
ing in a more severe erosive destruction of 
the affected joints [167].  Induction of CIA 
in IL-18-deﬁcient mice, revealed a less severe 
arthritis compared to the controls, which was 
observed by decreased joint inﬂammation 
and erosive destruction [168]. Other studies 
in CIA, using wild-type DBA/1 mice treated 
with either IL-18 neutralizing antibodies or 
the IL-18BP, revealed signiﬁcant reduction of 
disease progression, which was associated with 
reduced cartilage and bone erosion [169]. Both 
strategies reduced serum levels of IL-6 and 
inhibited TNFα, IL-6 and IFNγ secretion by 
macrophages. Taken together, these studies 
clearly indicate the likely pathological role for 
IL-18 in RA
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Therapeutic targeting of IL-1 
and IL-18 
Cytokine signaling in general can be 
modulated at different levels of interaction. 
A diversity of therapeutic interventions is 
being developed for the treatment of RA. 
These strategies include the neutralization of 
cytokines, receptor blockage and activation 
of anti-inﬂammatory pathways (Figure 3, 
page 16). 
Cytokine neutralization
There are different approaches, which 
could be applied for neutralization of cyto-
kines such as IL-1 and IL-18 in RA. Since 
soluble receptors play an important physi-
ological role in neutralization of cytokines, 
this strategy is now being applied for efﬁ-
cient neutralization of TNFα. Using a fusion 
protein, called Etanercept, which consists 
of two p75 soluble TNFα receptors fused to 
the Fc portion of IgG1, TNFα can be efﬁ-
ciently scavenged. This treatment of patients 
suffering from RA resulted in a signiﬁcant 
improvement [170]. Until recently no such 
treatment of RA had been developed for 
IL-1. With the development of an IL-1 trap, 
consisting out the IL-1R type I fused to the 
IL-1RAcP, a novel IL-1 scavenging biological 
has been developed [171]. Another approach 
of preventing the cytokine from interac-
tion with its signaling receptor is to direct 
monoclonal antibodies against the cytokine 
of interest. Also for TNFα,  successful RA 
treatments have been developed, using either 
chimeric monoclonal IgG1 anti-TNFα 
antibodies (inﬂiximab) [172] or recombi-
nant human monoclonal IgG1 anti-TNFα 
antibodies (adalimumab) [173] (reviewed 
in [174]). In animal models of experimen-
tal arthritis, antibody mediated cytokine 
neutralization has already been shown to be 
effective for IL-1 [125,175], although this 
approach has not yet been brought to the 
clinic. 
For IL-18, the IL-18BP could be an efﬁ-
cient strategy for neutralization of IL-18 
in patients suffering from RA. Both the 
neutralizing antibody strategy and the solu-
ble receptor approach are techniques, which 
take place extracellular (Figure 3) and scav-
enge the cytokines before interaction with 
the membrane receptor can take place.
Receptor blockade
Neutralizing the ability of the membrane 
receptor to bind its ligand can be another 
approach to interfere with cytokine signal 
transduction. This can be accomplished by 
three different strategies, which all take place 
at membrane level. First of all, signaling can 
be abolished through application of receptor 
antagonists, which competes with the ligand 
for receptor occupation. For IL-1, the IL-
1Ra has been shown to be a very efﬁcient 
antagonist of IL-1 signaling, which is now 
tested as a therapeutic approach (anakinra) 
for treatment of RA patients [176,177]. One 
small drawback is the relatively high amounts 
of IL-1Ra, which have to be administered in 
order to obtain a therapeutic level of receptor 
occupation [178,179]. 
Another approach for modulating signal 
transduction at the level of the cell membrane 
is the use of neutralizing antibodies directed 
against the signaling receptor. Since receptors 
are normally expressed throughout the body, 
on a wide variety of cells, one can imagine 
the relative large amounts of neutralizing 
antibody required for optimal inhibition/
occupation of the signaling receptor.
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The ﬁnal approach for modulation of 
cytokine signaling could be the expression of 
decoy receptors, such as the IL-1R type II on 
the cell membranes of target cells. A potent 
solution for general expression of the decoy 
receptors on the membranes of target cells 
could be gene therapy, resulting in prolonged 
expression of the gene of interest. 
Activation of anti-inflammatory 
pathways or intracellular mediators
The ﬁnal layer of interaction is the intra-
cellular cytokine modulation. This way of 
modulation can be achieved through the 
application of immuneregulatory cytokines, 
such as IL-4 and IL-10, which can suppress 
IL-1 production and thereby reduce inﬂam-
mation [180,181]. Furthermore, intracel-
lular overexpression of inhibitors of second 
mediators or dominant negative analogues 
regulating the inﬂammatory transcriptional 
activity can result in reduced cellular activa-
tion by pro-inﬂammatory cytokines. This 
approach has been shown to be effective for 
inhibition of IL-6 signaling using SOCS-3 
in models of experimental arthritis [182]. 
Somewhat more recent it was shown that 
intracellular inhibition of MyD88, through 
overexpression of a dominant negative short 
form of the MyD88, lead to inhibition of 
IL-1 induced NFκB activation [183]. Taken 
together, these results could lead to novel 
approaches to inhibit signal transduction of 
NFκB inducing cytokines in vivo.
Outline of the thesis
Both IL-1 and IL-18 are important pro-
inﬂammatory cytokines, which play an 
important role in the initiation and mainte-
nance of inﬂammatory processes for instance 
during RA. As it appears, this process of 
IL-1/IL-18 signal transduction is tightly 
regulated at receptor level, by membrane 
associated decoy receptors and soluble recep-
tor antagonists. However, the exact physi-
ological role of the recently described 
natural occurring murine soluble recep-
tors, like sIL-1RAcP, sIL-18Rβ and the 
IL-18BP, which are partial analogues of 
the membrane signaling receptors, needs 
to be further elucidated. In this thesis 
we describe the role of IL-1 and IL-18 
in experimental arthritis and show the 
results of gene therapeutic soluble receptor 
overexpression in models of experimental 
arthritis, revealing their role in modula-
tion of IL-1 and IL-18 signaling. 
In Chapter 2 we investigated the direct 
role of IL-18 in joint inﬂammation and 
cartilage destruction, as can be observed 
during experimental arthritis in mice. We 
used intra-articular adenoviral overex-
pression of IL-18 in TNF- and IL-1-deﬁ-
cient mice and found that IL-18 can induce 
joint inﬂammation independent of IL-1, 
although IL-18 induced IL-1β production 
was essential in IL-18 driven cartilage 
destruction. In the chapters thereafter we 
tried to modulate IL-1 and IL-18 signal-
ing in experimental arthritis using a gene 
therapeutic approach for overexpression 
of their soluble receptors
In Chapter 3 we elucidated the function 
of the soluble form of interleukin-1 (IL-1) 
receptor accessory protein (sIL-1RAcP), 
whose physiologic role remains to be estab-
lished. Using recombinant sIL-1RAcP, 
we were able to show that sIL-1RAcP is a 
natural inhibitor of IL-1 signaling in vitro. 
Adenoviral overexpression of sIL-1RAcP 
in the murine collagen-induced arthrirtis 
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model ameliorated the disease, although 
the exact mechanism of action remained 
unclear. 
In Chapter 4 we scrutinize the in 
vivo mechanism of action, by which 
sIL-1RAcP ameliorates experimental 
arthritis. Systemic overexpression of sIL-
1RAcP modulated humoral immunity 
without affecting T-cell activity. This 
in contrast to IL-1Ra, which modu-
lated both T-cell immunity and humoral 
immunity. Since sIL-1RAcP and IL-1Ra 
appear to have a distinct mechanism of 
IL-1 antagonistic action, we combined 
sIL-1RAcP and IL-1Ra in order to evalu-
ate the possibility of additive therapeutic 
effects (Chapter 5).
Since IL-18 has an important role 
as a pro-inﬂammatory cytokine in the 
onset of arthritis, we wanted to evalu-
ate the applicability of local inhibition of 
IL-18 before onset of arthritis. Chapter 
6 describes the therapeutical value of 
local intra-articular inhibition of IL-18. 
Adenoviral mediated gene transfer of the 
highly potent natural occurring IL-18 
neutralizing Binding Protein reduced 
incidence and severity of CIA, revealing 
the importance of IL-18 in the induction 
of local inﬂammation. 
Recently a soluble analogue for the 
IL-18Rβ has been described in the rat 
brain. Since this soluble variant shares 
similarity with the sIL-1RAcP, we cloned 
and characterized the murine variant. 
Chapter 7 describes the expression of 
this protein in various murine tissues. 
Furthermore, we show its function and 
regulation during CIA, giving sIL-18Rβ 
a role as a putative regulator of IL-18 
sensitivity in experimental arthritis. 
The ﬁnal two Chapters 8 and 9 
describe and characterize stable trans-
fected NFκB regulated luciferase report-
er cell lines, derived from different cell 
types such as thymocytes, ﬁbroblasts and 
chondrocytes. These cell lines have been 
used for in vitro and in vivo validation of 
therapeutic efﬁcacy of the soluble recep-
tors, which were used in the preceding 
chapters. 
In the ﬁnal chapter (Chapter 10) the 
results described in this thesis are summa-
rized and discussed. 
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Interleukin (IL)-18 is a recently discovered 
cytokine and is a member of the IL-1 cyto-
kine family, originally identiﬁed as interfer-
on-γ-inducing factor [1-3]. The biologically 
inactive precursor of IL-18 is intracellularly 
cleaved by IL-1β-converting enzyme (ICE 
or caspase-1) to yield an active 18 kDa 
glycoprotein [4-6]. Pro-IL-18 can also be 
activated by ICE-independent mechanisms, 
such as enzymatic cleavage by gelatinase-B 
(MMP-9) and neutrophil proteinase-3 [7-9]. 
In addition, FasL-stimulated macrophages 
produce active IL-18 in the absence of ICE 
or caspase-1 [10]. IL-18 expression has been 
detected in several cell types including acti-
vated macrophages, Kupffer cells, dendritic 
cells, Langerhans cells as well as osteoblasts 
and chondrocytes [11-15]. The receptor for 
IL-18, IL-18R, is comprised of unique α 
(IL-1rp) and non binding β (AcPL) signal-
ing chains. This receptor is expressed on 
many cell types, involved in both innate 
and adaptive immune responses, and signals 
through a pathway that involves MyD88 
(myeloid differentiation 88), IRAK-1/4 
(IL-1 receptor-associated kinases), TRAF6 
(tumor necrosis factor receptor-associated 
factor 6) and NF-κB (nuclear factor κ B) 
[16,17]. Recently, it was demonstrated that 
IL-18 could activate gene transcription inde-
pendently from the MyD88/IRAK pathway. 
PI3K/Akt (phosphatidylinositol 3 kinase) as 
well as mitogen-activated protein kinases 
(MAPK) Erk-1 and Erk-2 signaling cascades 
seem to be involved in IL-18 signaling [18-
20]. IL-18 signaling is regulated in vivo by 
naturally occurring IL-18 binding protein 
(IL-18BP) that binds and neutralizes IL-18 
Interleukin (IL)-18 is a member of the IL-1 family of proteins that exerts pro-inﬂammatory eﬀects and is a pivotal cytokine for the development of Th1 responses. The goal of the present study was to investigate whether IL-18 induces joint inﬂammation and joint destruction, directly or via induction 
of other cytokines such as IL-1 and tumor necrosis factor (TNF). 
 To this end we performed both in vitro and in vivo kinetic studies. For in vivo IL-18 exposure studies 
C57/Bl6, TNF-deﬁcient and IL-1-deﬁcient mice were injected intra-articularly with 1x107 pfu mIL-18 
adenovirus followed by histopathological examination. Local overexpression of IL-18 resulted in 
pronounced joint inﬂammation and cartilage proteoglycan loss in control mice. Of high interest, 
IL-18 gene transfer in IL-1-deﬁcient mice did not show cartilage damage, although joint inﬂamma-
tion was similar to that in wild-type animals. Overexpression of IL-18 in TNF-deﬁcient mice showed 
that TNF was partly involved in IL-18-induced joint swelling and inﬂux of inﬂammatory cells, but 
cartilage proteoglycan loss occurred independent of TNF. In vitro cartilage degradation by IL-18 was 
found after a 72h-culture period. Blocking of IL-1 with IL-1Ra or an ICE-inhibitor resulted in complete 
protection against IL-18 mediated cartilage degradation. The present study demonstrated that IL-
18 induces joint inﬂammation independently of IL-1. In addition, we showed that IL-1β generation, 
because of IL-18 exposure was essential for marked cartilage degradation both in vitro and in vivo. 
These ﬁndings implicate that IL-18, in contrast to TNF, contributes through separate pathways to 
joint inﬂammation and cartilage destruction.  
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[21]. The fact that there are several splice 
variants of IL-18BP may indicate a complex 
extracellular regulation of IL-18 signaling 
[22].     
Several studies have elucidated a broad 
spectrum of effector functions beyond 
lymphocyte activation that implicate IL-18 
as an important regulator of chronic inﬂam-
mation in human autoimmune diseases 
[22,23]. IL-18 induces tumor necrosis factor 
(TNF)-α, GM-CSF, interferon (IFN)-γ 
and nitric oxide production by synovial 
cells isolated from patients with rheumatoid 
arthritis (RA) through a direct, IFNγ-inde-
pendent pathway, via constitutive IL-18Rα 
expression [23]. The IL-18-induced cyto-
kine production by synovial macrophages 
was potentiated by IL-12 and/or IL-15, 
and suppressed by IL-10 and transforming 
growth factor (TGF)-β. Furthermore, IL-18 
expression in synovial tissue biopsies from 
RA patients with clinically active disease is 
associated with enhanced IL-1β and TNFα 
levels [25]. In addition, IL-18 induces the 
expression of CXC chemokines by synovial 
ﬁbroblasts, stimulates angiogenesis, and is 
involved in leukocyte recruitment by up-
regulation of vascular adhesion molecule–1 
(VCAM-1) through NFκB-dependent 
mechanisms [19, 26-28]. 
Preclinical studies have shown that IL-18 
is a primary cytokine that promotes both 
systemic and local cytokine production 
[29,30]. Administration of IL-18 alone or 
in combination with IL-12 increased the 
severity of murine type II collagen (CIA) 
arthritis [31]. Blockade of endogenous IL-18 
during the onset of disease in an acute model 
of joint inﬂammation, signiﬁcantly reduced 
local TNFα and IL-1β levels [30]. In line 
with these ﬁndings, blockade of IL-18 with 
antibodies or with the endogenous inhibitor 
IL-18BP suppressed the disease activity in 
murine CIA [32]. Interestingly, intraarticular 
overexpression of IL-18BP using an adenovi-
ral vector for murine IL-18BPc ameliorated 
disease activity and suppressed joint destruc-
tion in CIA. Neutralization of local IL-18 
activity was accompanied by reduction of 
TNFα and IL-6 levels in the joint [33].  
It was demonstrated previously that 
IL-18 induces chondrocyte proliferation; 
upregulates mRNA expression of inducible 
nitric oxide synthetase (iNOS), stromelysin 
(MMP-3), and cyclo-oxygenase 2 (COX-2) 
in cultured chondrocytes; and increases 
cartilage glycosaminoglycan (GAG) release 
in vitro [15]. In contrast to these observa-
tions, several investigations have shown 
that IL-18 exposure of different cell types, 
such as peripheral blood mononuclear cells 
(PBMC’s) and macrophages, did not lead 
to the production of nitric oxide (NO), 
COX-2 or PGE2 [34]. In the present study 
we examined whether IL-18 induces inhibi-
tion of chondrocyte proteoglycan synthesis 
and cartilage proteoglycan depletion directly 
or via induction of other mediators, such 
as IL-1 and TNF. Local gene transfer tech-
nology was used to explore the direct pro-
inﬂammatory role of IL-18 in naive murine 
knee joints. In vitro studies with cartilage 
explants were performed to get more insight 
in IL-18-driven cartilage destruction.
Materials and Methods
Animals 
Male C57/BL6 mice were obtained from 
Charles River, Sulzfeld, Germany. Breeder 
pairs of TNFα-deﬁcient mice were kindly 
provided by Prof. Dr. G. Kollias, Athens, 
Greece [35]. IL-1β gene-deﬁcient mice [36] 
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were a kind gift from Merck, Rahway, NJ, 
USA. Breeder pairs of IL-1α,β-deﬁcient 
mice were provided by Prof. Dr. Y. Iwakura, 
Tokyo, Japan [37]. The breeder pairs were 
controlled for cytokine deﬁciency by geno-
typing, according standard protocols. The 
mice were housed in ﬁlter top cages, and 
water and food were provided ad libitum. The 
mice were used at the age of 10-12 weeks. 
Care was taken to house all the deﬁcient 
and control littermate mice under identical 
conditions. All animal experiments conduct-
ed in this study were cared for accordance 
with the institutional ethics committee.  
Materials 
Bovine serum albumin was purchased 
from Sigma Chemicals, St Louis, MO, USA. 
RPMI 1640 medium was obtained from 
Life Technologies, Breda, The Netherlands. 
Recombinant murine IL-1β, IL-1Ra, IL-
18 and TNFα were purchased from R&D 
systems, Abingdon, UK. The ICE inhibi-
tor Boc-Asp(Obz)-CMK (N-1430) was 
obtained from Bachem AG, Bubendorf, 
Switzerland. Recombinant human IGF-1 
was purchased from Preprotech, Rocky Hill, 
NJ, USA. Radioactive 35S-sulphate was 
purchased from NEN Life Sciences Products, 
Boston, MSA, USA. Bioplex kits for multi-
cytokine determination were purchased 
from Bio-Rad, Hercules, CA, USA. 
Adenoviral mIL-18 vector and 
intraarticular gene transfer 
Recombinant adenovirus AdmIL-18 was 
constructed with insertion of the murine pro-
IL-18 cDNA in the early regions 1 (E1) and 3 
(E3), respectively [38]. Expression of cDNA 
was driven by the human cytomegalovirus 
(HCMV) immediate early gene promoter 
and terminated by the polyadenylation 
sequence of SV40. The virus was produced 
by cotransfection of 293 cells with the plas-
mid. Large scale production was performed 
in conjunction with Prof. Dr. J. Kolls from 
the department of medicine, Louisiana State 
University, New Orleans, LA, USA. Trans-
fection with this adenoviral construct results 
in active mIL-18 production, both in vitro and 
in vivo. As control we used the empty recom-
binant replication-defective adenovirus 
Ad5del70-3. Gene transfer was performed by 
intra-articular injection of naive mice with 
1x107pfu/6 µl of AdmIL-18 or Ad5del70-3. 
At different time points, patellae with 
adjacent tissue were dissected and patellae 
washouts were used for the determination of 
IL-18, IL-1β or TNFα levels. In addition, we 
examined joint swelling (days 2, 4 and 7) and 
histopathology (days 7 and 14) after mIL-18 
gene transfer.
Measurement of joint 
inflammation 
Joint inﬂammation was quantiﬁed by 
99mTc-uptake method [39]. This method 
measures by external gamma counting the 
accumulation of a small radioisotope at 
the site of inﬂammation because of local 
increased blood ﬂow and tissue swelling. 
The severity of inﬂammation is expressed 
as the ratio of the 99mTc-uptake in the right 
(inﬂamed) over the left (control) knee joint. 
All values exceeding 1.10 were assigned as 
inﬂammation.
Cytokine measurements 
To determine levels of several cytokines, 
including IL-1β, IL-18, TNFα in patel-
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lae washouts, patellae were isolated from 
inﬂamed knee joints as previously described 
[40]. Patellae were cultured in RPMI 
1640 medium containing 0.1% BSA (200 
µl/patella) for 1 hour at room teperature 
(RT). Thereafter supernatant was harvested 
and centrifuged for 5 minutes at 1000g. 
Cytokine levels were determined using the 
Luminex multi-analyte technology [41]. 
The BioPlex system in combination with 
multiplex cytokine kits was used. Cytokines 
were measured in 50 µl patellae washout 
medium. The sensitivity of the multiplex 
kit was for IL-1β, IL-18 or TNFα 5, 20 and 
5 pg/ml respectively. 
Histology 
Mice were sacriﬁced by ether anes-
thesia. Thereafter, whole knee joints 
were removed and ﬁxed for 4 days in 4% 
formaldehyde. After decalciﬁcation in 5% 
formic acid the specimens were processed 
for parafﬁn embedding. Tissue sections 
(7 µm) were stained with haematoxylin & 
eosin (cell inﬂux) or safranin-O (cartilage 
proteoglycan depletion). Histopathological 
changes were scored using to the follow-
ing parameters. Inﬁltration of cells was 
scored on a scale of 0 to 3, depending on 
the amount of inﬂammatory cells in the 
synovial cavity and synovial tissues. The 
loss of proteoglycans was scored on a scale 
of 0-3, ranging from full stained cartilage 
to destained cartilage or complete loss 
of articular cartilage. Histopathological 
changes in the knee joints were scored in 
the patella/femur region on ﬁve semi serial 
sections of the joint, spaced 70 µm apart. 
Scoring was performed on decoded slides 
by two observers, as described previously 
[42,43].
Chondrocyte proteoglycan 
synthesis 
Patellae with minimal surrounding tissue 
were isolated from knee joints of naive C57/
Bl6 mice [44,29]. Thereafter, patellae were 
cultured in RPMI 1640 medium (glutamax, 
gentmycin (50 µg/ml) supplemented with 
rhIGF-1 (250 ng/ml) with or without IL-1 (10 
ng/ml), IL-18 (10 to 100 ng/ml) for either 24, 
48 or 72 hours. Thereafter the patellae were 
placed in RPMI 1640 medium with gluta-
max, gentamycin (50µg/ml) and 35S-sulfate 
(0.74 MBq/ml). After 3h incubation at 37oC 
in a CO2 incubator, patellae were washed in 
saline 3 times, ﬁxed in 4% formaldehyde and 
subsequently decalciﬁed in 5% formic acid for 
4 hours. Patellae were punched out of the adja-
cent tissue, dissolved in 0.25 ml LumaSolve at 
65oC (Ominlabo, Breda, The Netherlands) 
and after addition of 1 ml Lipoluma (Omni-
labo) the 35S content was measured by liquid 
scintillation counting (Trilux 1450 microbeta, 
EG&G Wallac, Turku, Finland). Values are 
presented as percentage 35S incorporation of 
the left control joint.
In vitro proteoglycan degradation 
assay 
Patellae with minimal surrounding tissue 
were placed in RPMI 1640 medium with 
glutamax, gentmycin (50 µg/ml) and 35S-
sulfate (0.74 MBq/ml). After 3 hours incuba-
tion at 37oC in a CO2 incubator, patellae were 
extensively washed in sterile saline 3 times 
and were cultured for 24, 48 or 72 hours in 
either RPMI 1640 medium or 0.1% bovine 
serum albumin and 250 ng/ml of recombi-
nant human IGF-1. Patellae were exposed to 
IL-1β or IL-18 with or without inhibitors/
antagonists. Thereafter, patellae were ﬁxed 
in 4% formaldehyde and subsequently decalci-
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ﬁed in 5% formic acid for 4 hours. Patellae were 
punched out of the adjacent tissue, dissolved in 
0.25 ml LumaSolve at 65oC (Ominlabo) and 
after addition of 1 ml Lipoluma (Omnilabo) the 
35S content was measured by liquid scintillation 
counting. Values are presented as percentage 35S 
incorporation of the left control joint.
Statistical analysis 
Differences between experimental groups 
were tested using the Mann-Whitney U-test, 
unless stated otherwise.
RESULTS
Intra-articular overexpression of IL-18 
results in delayed joint swelling and 
suppression of chondrocyte metabolic 
function. 
To investigate the effect of prolonged 
IL-18 exposure in vivo, an adenovirus coding 
for murine IL-18 was injected in the right 
knee joint of naive C57/Bl6 mice. Table 1 
shows that IL-18 was highly expressed in a 
mouse knee joint after adenoviral gene trans-
fer, using 1x107pfu of AdmIL-18. Enhanced 
levels of IL-18 could be found up to day 14 
after injection of the adenovirus coding for 
IL-18. Although not vehemently, levels of 
both IL-1β and TNFα were locally elevated 
after injection of AdmIL-18 (Table 1). In 
contrast, injection of control adenovirus 
(Ad5del70-3) did lead to slightly enhanced 
levels of IL-1β, IL-18 or TNFα, only detect-
able at day 1 after virus injection (Table 1). 
Local overexpression of IL-18 in wild-type 
mice resulted in protracted joint inﬂam-
mation, as determined by joint swelling 
assessment (Figure 1, A and B). A gradu-
ally increased joint swelling was observed 
after local injection of AdmIL-18. At day 2 
we noted a right/left ratio of 1.2±0.05 that 
increased to 1.4±0.08 at day 14. In addition, 
we analyzed the suppressive effect of high 
Table 1. Local cytokine production after IL-18 gene transfer
Male C57/Bl6 mice were intraarticularly injected at day 0 with 1x107 pfu of either AdmIL-18 or Ad5Del70-3. At several time points, patellae with adjacent synovial tissue 
were isolated and cultured for 1h at room temperature in RPMI 1640 medium (completed with 1% bovine serum albumin). Thereafter the levels IL-18, IL-1β or TNFα 
were determined by using the Luminex bead array system. The sensitivity of the kits was below 10 picogram/ml for each cytokine. The data represents the mean±SD 
of 6 patellae washout per time point. ND = not detectable.  
  IL-18   IL-1β   TNFα
  AdmIL-18 Ad5Del70-3  AdmIL-18 Ad5Del70-3  AdmIL-18 Ad5Del70-3
Day 1  820±122 49±26  45±15 21±14  100±34 39±24
Day 2  512±78 N.D.  76±34 N.D.  74±23 N.D.
Day 4  325±56 N.D.  178±65 N.D.  56±41 N.D.
Day 7  200±49 N.D.  137±41 N.D.  34±29 N.D.
Day 14  125±23 N.D.  32±28 N.D.  21±18 N.D.
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Figure 2. Joint inﬂammation 
induced by prolonged IL-18 overex-
pression. 
At day 0 1x107 pfu control virus 
(Ad5del70-3) or 1x107 pfu AdmIL-18 was 
intraarticularly injected in wild-type, 
IL-1 or TNF-deﬁcient mice. At day 7 knee 
joints were removed and processed for 
histological analysis. A, inﬂammation 
found after injection of Ad5del70-3 
control virus. B, IL-18 induced joint 
inﬂammation in a wild-type mouse. C, 
IL-18 induced joint inﬂammation in IL-1 
gene-deﬁcient mouse. D, IL-18 induced 
joint inﬂammation in TNF knockout 
mouse. H&E staining, original magni-
ﬁcation 200x. P= patella, F=femur, 
JC=joint cavity, and C=cartilage.
Figure 1. IL-18 driven joint inﬂammation in wild-type, IL-1-/- and TNF-
/- mice. 
IL-18 was overexpressed in the right knee of C57/Bl6mice by intraarticular 
injection of 1x107 pfu AdmIL-18. At several time points both joint swelling 
(99mTc-uptake) and chondrocyte proteoglycan synthesis (35S-sulphate incorpo-
ration) was assessed (A). To examine the role of either IL-1 or TNF, IL-18 was 
overexpressed in IL-1 or TNF-deﬁcient mice (B). Data expressed the mean±sd 
of at least 8 mice per group. The experiment was repeated once with roughly 
the same outcome. *P<0.01, Mann-Whitney U-test compared to C57/Bl6 wild-
type mice control group.
IL-18 levels on chondrocyte proteoglycan 
metabolism. Despite of high IL-18 levels at 
days 1 and 2, no inhibition of chondrocyte 
proteoglycan synthesis was noted (Figure 1A). 
Signiﬁcant suppression of chondrocyte 
proteoglycan synthesis was found after day 4. 
This was in line with the increasing IL-1β and 
TNFα levels found in patellar washouts after 
injection of admIL-18 virus. 
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To examine the role of either IL-1 or TNF 
in the IL-18-driven joint swelling we injected 
1x107pfu AdmIL-18 in IL-1- or TNFα−deﬁ-
cient mice. Lack of TNFα resulted in 
suppressed joint swelling after local injection 
of the IL-18 adenoviral vector, as visualized in 
Figure 1B. In contrast to TNF-deﬁcient mice, 
mice lacking both forms of IL-1 did not differ 
from the wild-type animals at all examined 
days after application of the IL-18 vector, indi-
cating no role of IL-1α or IL-1β in the IL-18-
driven joint swelling (Figure 1B).  
IL-18 drives influx of 
inflammatory cells and cartilage 
degradation by separate pathways. 
Because extended IL-18 exposure in 
vivo caused enhanced joint swelling we 
examined whether IL-18 overexpression 
initiated inﬂux of inﬂammatory cells and 
cartilage degradation. Figure 2B shows 
clearly that IL-18 generated an inﬂux of cells 
in the joint cavity of wild-type C57/Bl6 
mice. Both at days 7 and 14 enhanced cell 
inﬂux was noted, although the number of 
cells was less pronounced at day 14 (data 
not shown). Remarkably lower numbers of 
inﬂammatory cells were found in the joint 
cavity of TNF-deﬁcient mice compared to 
wild-type animals (Figure 2D). In contrast 
to TNF gene knockout mice, overexpression 
of IL-18 in IL-1α,β-deﬁcient mice resulted 
in a similar inﬂux of inﬂammatory cells in 
synovial tissue as wild control mice (Figure 
2C). These data indicate that inﬂux of 
inﬂammatory cells, induced by local IL-18 
application, is driven mainly by TNFα. 
In addition, we analyzed the catabolic 
effect of extended IL-18 exposure in vivo 
on cartilage. Figure 3B demonstrates nicely 
that IL-18 gene transfer resulted in loss of 
matrix proteoglycans from the cartilage of 
a wild-type mouse. Both at days 7 and 14 
Figure 3. Cartilage degradation 
after IL-18 gene transfer in wild-
type, IL-1 or TNF-deﬁcient mice. 
IL-18-driven cartilage proteoglycan 
loss was analyzed on day 14 after 
intraarticular injection of 1x107 pfu 
Ad5del70-3 or AdmIL-18. A, wild-
type mouse injected with control 
virus. B, AdmIL-18 injection in a wild-
type mouse. C, IL-18 overexpression 
in an IL-1α/β-deﬁcient mouse. D, 
IL-18 overexpression in a TNF-deﬁ-
cient mouse. Safranin-O-staining, 
original magniﬁcation 400x.   
For details see Figure 2. Note the en-
hanced cartilage proteoglycan loss 
in wild-type and TNF-deﬁcient mice 
(arrows) 
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enhanced cartilage proteoglycan degrada-
tion was seen, although the strongest proteo-
glycan depletion was found at 14 days after 
intra-articular injection of adenoviral vector 
coding for IL-18. In contrast to role of 
TNFα in the attraction of pro-inﬂammatory 
cells, provoked by IL-18 overexpression, we 
noted no differences in cartilage proteo-
glycan depletion between wild-type and 
TNFα-deﬁcient mice (Figure 3D). Of high 
interest, IL-1α,β gene-deﬁcient mice were 
almost completely protected against carti-
lage proteoglycan loss, induced by extended 
IL-18 exposure in vivo (Figure 3C). 
IL-18 induces delayed cartilage 
degradation in vitro. 
To obtain more insight in the mechanism 
of IL-18 mediated cartilage damage we 
investigated the effect of IL-18 on both chon-
drocyte proteoglycan synthesis and cartilage 
matrix degradation. Therefore, we exposed 
patellar cartilage explants with minimal 
adjacent synovial tissue to IL-18 in an in vitro 
culture system. Figure 4A shows that IL-18 
did not induce signiﬁcant inhibition of chon-
drocyte proteoglycan synthesis in vitro after a 
72 hours culture period, even at a concentra-
tion of 100 ng/ml IL-18. In contrast to IL-18, 
IL-1β strongly inhibits chondrocyte proteo-
glycan synthesis (50% inhibition compared 
to IGF-1 control) already after 24 hours of 
culture. Previous reports indicated that IL-18 
induces catabolic responses in chondrocytes 
[15], but we found no suppressive effect on 
chondrocyte metabolic function, determined 
as chondrocyte proteoglycan synthesis. In 
additional studies, we examined the catabolic 
effect of IL-18 on in vitro cartilage degrada-
tion. 35Sulphate pre-labeled patellar cartilage 
explants were cultured up to 72 hours with 
either IL-18 or IL-1β. Figure 4B shows late 
cartilage degradation after exposure to both 
10 and 100 ng/ml IL-18. We found that 
nearly 40% of the pre-labeled cartilage was 
released after 72 hours culture period. Inter-
estingly, no cartilage proteoglycan-loss was 
observed after 24 or 48 hours exposure with 
IL-18. In contrast to IL-18, IL-1β already 
induced cartilage degradation after 24 hours 
of stimulation (Figure 4B). Interestingly, the 
degree of cartilage proteoglycan-release was 
comparable at 72 hours between IL-18 (100 
ng/ml) and IL-1β (10 ng/ml).  
IL-18-driven cartilage degradation 
in vitro is IL-1β dependent.  
To investigate whether IL-1α or IL-1β was 
involved in the IL-18-driven cartilage degra-
dation, we blocked IL-1 receptor signaling 
and de novo production of IL-1β. To this end 
we added either IL-1Ra or an interleukin-1 
converting enzyme (ICE) inhibitor to the in 
vitro cultures. Figure 5A shows that addition 
of 1 µg/ml of human IL-1Ra completely 
blocked the IL-18-driven cartilage proteo-
glycan loss as found after 72 hours of culture. 
Inhibition of IL-1β-induced cartilage 
proteoglycan degradation in vitro by IL-1Ra 
conﬁrmed the efﬁcacy of used concentra-
tion of IL-1Ra. Using the ICE inhibitor we 
demonstrated that newly processed IL-1β was 
responsible for the observed IL-18-driven 
cartilage degradation in vitro (Figure 5B). 
To exclude that TNFα, induced by IL-18 
exposure was involved in the observed 
proteoglycan degradation we used carti-
lage explants from TNFα-deﬁcient mice. 
Figure 5C indicates that TNFα was not a 
crucial cytokine in the IL-18-induced carti-
lage protoeglycan loss. We found no differ-
ence in IL-18 mediated cartilage degradation 
45
C
ha
pt
er
 1
C
ha
pt
er
 2
IL-18 drives joint pathology
between the wild-type and TNFα-deﬁcient 
mice after 72 hours of IL-18 exposure. Using 
patellae from IL-1β knockout mice conﬁrmed 
the ﬁndings with the ICE inhibitor, that IL-
18-induced cartilage degradation is mediated 
by IL-1β generation (Figure 5C). 
Discussion
The present study was performed to 
investigate the direct role of IL-18 in joint 
inﬂammation and/or cartilage damage. To 
this end we overexpressed murine IL-18 
locally and analyzed joint inﬂammation and 
cartilage damage. The role of either IL-1 
or TNF in IL-18-driven joint inﬂamma-
tion was studied by using mice deﬁcient for 
either IL-1 or TNF. The in vivo observations 
were conﬁrmed by in vitro cartilage degrada-
tion studies. Therefore, we exposed murine 
cartilage explants to IL-18 and analyzed the 
catabolic effect of IL-18. Using IL-1 inhibi-
tors and/or cartilage explants from IL-1β− or 
TNF-deﬁcient mice we clearly demonstrated 
that IL-1β was the pivotal second mediator in 
IL-18-driven cartilage destruction.  
Prolonged overexpression of IL-18 in 
naive murine knee joint, using an adenovi-
rus coding for murine IL-18, resulted in mild 
joint inﬂammation and cartilage proteogly-
can loss (Figure 1, 2 and 3). Recent reports 
indicated a role of IL-18 in the pathogen-
esis of several human inﬂammatory diseases. 
Elevated IL-18 levels can be found in psoriasis, 
inﬂammatory bowel disease and sacroidoses 
[45]. Several preclinical studies have shown 
that co-administration of IL-18 enhanced 
the inﬂammatory response to antigens, such 
as collagen type II [26,46]. This is the ﬁrst 
study that showed that IL-18 overexpression 
causes joint inﬂammation that accumulates 
Figure 4. Prolonged exposure to IL-18 induced cartilage degradation 
in vitro.  
Patellar cartilage explants were isolated from naïve knee joints of C57/Bl6 mice 
and cultured for 24 to 72 hours in RPMI 1640 medium supplemented with re-
combinant hIGF-1 (250ng/ml) with or without mIL-18. Thereafter chondrocyte 
proteoglycan synthesis was determined by 35S-sulphate incorporation (A). 
For details see M&M section. For cartilage degradation studies (B), cartilage 
explants were prelabelled with 35S-sulphate. Data expressed the mean±SD of 
six patellae per group. The experiments were repeated twice with similar out-
come. *P<0.01, Mann-Whitney U-test compared to IGF-1 control group.  
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factors (e.g. IL-8 and LTB4) that may explain 
the partly TNF-independent cell inﬂux 
[19,28,48]. Interestingly, overexpression of 
IL-18 in a naive knee joint leads to cartilage 
damage, determined as loss of matrix proteo-
glycans. The loss of matrix proteoglycans 
was IL-1-dependent since IL-18 overexpres-
sion in IL-1α,β-deﬁcient mice did not result 
in cartilage damage. It is well known that 
IL-1 is the crucial cytokine that promotes 
cartilage destruction via induction of several 
catabolic mediators in synovial lining cells 
as well as in chondrocytes. IL-1 was origi-
nally identiﬁed as catabolin since it could 
induce cartilage destruction [49,50]. Block-
in time (Figure 1A and 2). In line with previ-
ous ﬁndings, IL-18 attracts predominantly 
neutrophils into the joint tissues, although at 
later stages (day 14) for the most part mono-
cytes/macrophages were seen in the synovial 
lining (data not shown). By using TNF-deﬁ-
cient mice we found that IL-18-driven joint 
inﬂammation was partly TNF-dependent. 
Joint swelling was completely absent and the 
inﬂux of inﬂammatory cells was reduced in 
TNF gene-deﬁcient mice. We have shown 
previously that TNF is the pivotal cytokine 
that drives swelling in acute SCW-induced 
joint inﬂammation [40,42,47]. IL-18 itself 
can induce chemokines and chemoattractant 
Figure 5. In vitro cartilage 
degradation by IL-18 is 
mediated by IL-1.
 Patellar cartilage explants 
were prelabelled as indicated 
in M&M section. Thereafter, 
cartilage explants were cul-
tured for 72 hours with IGF-1 
containing medium with ei-
ther IL-18 (10 or 100 ng/ml) or 
IL-1β (10 ng/ml). To block IL-1 
we added either recombinant 
mIL-1Ra (A, 10 µg/ml) or ICE-
inhibitor (B, 2.5 µM) to the 
culture medium. To conﬁrm 
the ICE data and examine 
the role of TNF in IL-18-driven 
proteoglycan loss we use pa-
tellar explants from both IL-
1β and TNFα-deﬁcient mice 
(C). For detail see ﬁgure  4. 
*P<0.01, Mann-Whitney U-
test compared to C57/Bl6 x 
129Sv wild-type mice control 
group.
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ing studies with antibodies or IL-1 receptor 
antagonist (IL-1Ra) in models of arthritis 
clearly showed that IL-1 drives cartilage and 
bone destruction [43,51]. Recently, it was 
demonstrated that intra-articular injection of 
IL-1Ra in patients with painful knee osteo-
arthritis had a dramatic therapeutic response, 
indicating once more the pivotal role of IL-1 
in cartilage catabolism [52].
Here we showed that prolonged exposure 
to IL-18 in vitro, upto 72 hours, did not result 
in inhibition of chondrocyte proteoglycan 
synthesis. Even at high concentrations (100 
ng/ml) no suppressive effects of IL-18 were 
noted (Figure 2B). In contrast, IL-1β induced 
substantial inhibition of chondrocyte meta-
bolic function already at 24 hours and at low 
concentrations (1 ng/ml). Because it is known 
that nitric oxide (NO) is the causative agent 
for suppression of chondrocyte proteoglycan 
synthesis [51] we analyzed NO production 
of cartilage explants after IL-18 exposure. In 
contrast to IL-1, we found low levels of NO 
in supernatants after 48 or 72 hours of culture 
with 10 ng/ml or 100 ng/ml IL-18 (data not 
shown). This is in line with a previous study 
indicating that IL-18 could produce NO in 
chondrocytes [15], although the levels of 
NO were higher in cultured chondrocytes 
then in cartilage explants. Despite of the 
enhanced NO levels in IL-18-exposed carti-
lage explants, no inhibition of chondrocyte 
proteoglycan synthesis was found. This indi-
cates that although the signaling pathway 
of IL-18 and IL-1 are similar, IL-18 seems 
to generate a protective mechanism against 
NO-mediated suppression of chondrocyte 
metabolic function. It is demonstrated that 
heme oxygenase-1 (HO-1) plays a crucial 
role in NO production, since this enzyme 
catalyzes heme protein, which is a co-factor 
for the NOS-2 enzyme.  More recently, it 
was shown that IL-1 and IL-17 downregu-
late HO-1 activity, which may explain the 
increased NO production by chondrocytes 
and the induction of inhibition of chondro-
cyte proteoglycan synthesis [53]. IL-18 regu-
lates induction of HO-1 expression via both 
Erk/MAPK and PI3K/Akt pathways which 
can be activated by IL-18 receptor signal-
ing [54,55]. At the moment, investigations 
are performed to unravel the IL-18-induced 
protection on chondrocyte anabolic metabo-
lism.  
IL-18 induces degradation of cartilage 
matrix molecules after extended exposure 
(Figure 4B). Olee et al  showed that IL-18 
could stimulate release of proteoglycans from 
human articular cartilage [15]. Whether this 
was due to increased degradation or enhanced 
synthesis of proteoglycans was not investi-
gated. Although IL-18 exposure of cartilage 
resulted in rapidly increased mRNA levels of 
several catabolic mediators, such as MMP-3 
and MMP-9, no degradation of proteogly-
cans was noted upto 48h of culture. Here we 
report that production of a second messenger 
molecule was responsible for the delayed 
cartilage destruction by IL-18. Blockade 
of IL-1β or the activation of pro-IL-1β was 
sufﬁcient to protect the cartilage explants 
from proteoglycan release (Figure 5A/B). It 
is known that IL-18 initiates production of 
several cytokines, including IL-1 and TNF, 
in monocytes and neutrophils [56,26]. In 
addition, very recently it was shown that 
IL-18 stimulates monocyte IL-1 and TNF 
production, induced by contact to activated 
T-cells isolated from rheumatoid arthritis 
synovium [57]. Although IL-18 can induce 
TNF mRNA production in chondrocytes 
(data not shown), TNF is not involved in 
IL-18-mediated cartilage proteoglycan loss 
in vitro (Figure 5C). 
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In conclusion, this study indicates that 
IL-18 promotes cartilage proteoglycan loss, 
both in vitro and in vivo, mediated by IL-1 
generation. Although IL-18 can induce both 
IL-1 and nitric oxide (NO) production in 
chondrocytes it is not competent to gener-
ate inhibition of chondrocyte proteoglycan 
synthesis. Local overexpression of IL-18 
resulted in a delayed inﬂux of inﬂammatory 
cells that is partly TNF-dependent. These 
data implicate that IL-18 can contribute to 
joint inﬂammation and cartilage destruction 
by separate pathways. Targeting of IL-18 
during inﬂammatory joint diseases, such as 
rheumatoid arthritis, may provide a novel 
therapy because IL-18 promotes develop-
ment of immunity and contributes to carti-
lage destruction via IL-1 production. 
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In this study we investigated whether the soluble form of IL-1 Receptor accessory protein (sIL-1RAcP), whose physiological function remains to be established, can serve as a speciﬁc inhibitor of IL-1 signaling in vitro and evaluate its applicability in collagen-induced arthritis (CIA). 
 Methods: sIL-1RAcP was cloned from murine liver complementary DNA and expressed either by the 
use of either an adenoviral vector (Ad RGD sIL-1RAcP) or a stable-transfected NIH 3T3 ﬁbroblast cell 
line. The ability of aﬃnity-puriﬁed sIL-1RAcP to inhibit IL-1 signaling was tested on NF-κB luciferase 
reporter ﬁbroblasts and quantiﬁed by luminometer. To investigate therapeutic eﬃcacy, sIL-1RAcP 
was both locally (knee joint) and systemically overexpressed in collagen-immunized male DBA/1 
mice. Severity of arthritis was monitored visually, and the pathological process in the joints was 
examined histologically. Serum was obtained from mice to quantify IL-6 and anti-bovine type II 
collagen antibody levels (anti-BCII). Results: Incubation of the NF-κB reporter ﬁbroblast with 
puriﬁed sIL-1RAcP protein showed a marked reduction of IL-1-induced, but not TNF-induced NF-κB 
activation. This showed a novel role for sIL-1RAcP as a speciﬁc inhibitor of IL-1 signaling. Local trans-
plantation of sIL-1RacP producing NIH-3T3 ﬁbroblasts into the knee before onset of CIA had little to 
no eﬀect on general disease severity in these mice. Histological evaluation of the knee joints receiv-
ing sIL-1RAcP cell transplantation showed a marked reduction in both joint inﬂammation, and bone 
and cartilage erosion. Local treatment with sIL-1RAcP had no profound eﬀect on serum levels of IL-6 
and anti-BCII antibodies, which is indicative of the ongoing presence of arthritis in distal joints. In 
contrast to local treatment, systemic treatment with AdRGDsIL-1RAcP markedly ameliorated CIA in 
all joints. Conclusion: In this study we demonstrated that soluble IL-1RAcP is a biologically active 
and innovative inhibitor of IL-1, and treatment of mice with sIL-1RAcP had a profound prophylactic 
eﬀect on collagen-induced arthritis. 
The pleiotropic cytokine Interleukin-1 
(IL-1) and its receptors are crucial in control-
ling the immunological and inﬂammatory 
response. Several members of the IL-1 
superfamily are currently known, including 
the agonists IL-1α, IL-1β and the recep-
tor antagonist IL-1Ra. These ligands bind 
with high speciﬁcity to the IL-1 receptors 
type I and II (IL-1RI and IL-1RII, respec-
tively), which are receptors that belong to 
the Interleukin-1 receptor family. Both 
receptors possess an extracellular region 
consisting out of three immunoglobulin-like 
domains. The IL-1RI mediates the biologi-
cal effects of IL-1 whereas IL-1RII is not 
capable of transducing IL-1 signaling. The 
type II IL-1 receptor acts as a decoy receptor 
or ligand sink and competes with the type I 
IL-1 receptor for IL-1 [1,2]. More insight in 
IL-1 signaling was gained with the discov-
ery of the co-receptor molecule crucial for 
IL-1 signaling, known as the IL-1 Receptor 
Accessory Protein (IL-1RAcP) [3-5]. On 
IL-1 binding to IL-1RI this co-receptor is 
recruited to form a high afﬁnity receptor 
complex, which initiates the intracellular 
signaling cascade [6]. Intracellularly, this 
dimeric receptor complex recruits the adapt-
er protein MyD88 to the TIR domains pres-
ent in both the IL-1RI and the IL-1RAcP 
[7]. Subsequently IL-1 receptor-associated 
kinases 1 and 2 (IRAK-1 and 2) are rapidly 
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translocated to the active receptor complex, 
followed by further progression of the signal 
cascade with recruitment of the down-
stream adapter tumor necrosis factor (TNF) 
receptor-associated factor 6 (TRAF-6) [8,9]. 
Eventually, this IL-1 initiated intracellular 
signaling cascade leads to degradation of the 
IκB kinase complex and activation of the 
MAP kinase family, which ultimately leads 
to NFκB and activator protein (AP)-1 trans-
location to the nucleus initiating activation 
of transcription of numerous IL-1-responsive 
genes. 
In hepatocytes of mice an alternative 
mRNA splice variant of the IL-1RAcP has 
been described. This sIL-1RAcP lacks the 
transmembrane and intracellular regions 
of the native form, which are crucial in 
IL-1 signaling [3]. Recently, the human IL-
1RAcP gene that encodes for the two alter-
native splice forms has been characterized 
and the human sIL-1RAcP has been cloned 
[10]. So far, the biological function of sIL-
1RAcP remains to be determined, but a role 
for sIL-1RAcP as an endogenous inhibitor of 
IL-1 is likely.
In rheumatoid arthritis (RA) IL-1 is 
involved as an inﬂammatory cytokine in 
many pathological processes that affect bone 
and cartilage and ultimately result in loss 
of articular function. From experimental 
animal models, IL-1 inhibition with the 
use of IL-1Ra has been proven to be an 
effective strategy [11-13]. Several successful 
approaches, both local and systemic, have 
been applied using the collagen-induced 
arthritis (CIA) animal model, which is highly 
dependent on IL-1 [13-16]. The use of the 
CIA experimental model is therefore suit-
able to test functionality of IL-1 inhibitors. 
From this and other experimental arthritis 
models, it has become clear that IL-1Ra 
administration, both locally and systemically, 
has a protective effect on cartilage and bone 
turnover and reduces the inﬂammatory cell 
inﬁltration normally seen in experimental 
arthritis. However, to achieve this complete 
inhibition of IL-1, a 100 to 1000-fold excess 
of IL-1Ra is needed. This ratio requires that 
high dosages of the IL-1 antagonist have to 
be applied, on a regular dosage regimen to 
obtain sustained levels of the protein [11,15]. 
The aim of this present study was to eluci-
date the biological function of sIL-1RAcP 
and evaluate possible therapeutic application 
of this molecule. To this end we constructed 
both a stable-transfected cell line and an 
adenoviral vector containing the murine 
sIL-1RAcP construct (AdRGDsIL-1RAcP). 
Both Local and systemic treatment with sIL-
1RAcP was achieved through either intra-
articular (i.a.) or intravenous (i.v.) injection 
of the adenoviral vector before clinical 
manifestation of the CIA.  Results from 
these experiments show the function of the 
sIL-1RAcP as inhibitor of IL-1 signaling in 
vitro. Herein we demonstrate that both local 
and systemic expression of the sIL-1RAcP 
during CIA offers a novel and effective 
approach to modulate experimental arthritis. 
Materials and Methods
Animals
Male 10- to 12-weeks old DBA-1/bom 
mice obtained from Bomholdgärd (Ry, 
Denmark). C57/Bl6 mice were bred and 
housed in top-ﬁlter cages at our animal 
facility. Mice injected with adenoviral 
vectors during experiments were housed 
in low-pressure isolator cages. The animals 
were fed a standard diet with water and food 
ad libitum. All in vivo studies complied with 
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national legislation, were approved by local 
authorities of the Care and Use of Animals 
Committee and were consistent with related 
codes of practice.
Construction of Adenoviral vector
The ﬁrst step in construction of a ﬁrst 
generation E1/E3 deleted serotype-5 adeno-
virus was the cloning of the gene of interest. 
The sIL-1RAcP was cloned from comple-
mentary DNA obtained from murine liver. 
Viral vectors were E1A, B and E3 deleted, 
and were produced according to the method 
described by Chartier et al [17]. Brieﬂy, the 
sIL-1RAcP cDNA was inserted into the E1 
deleted region of the serotype 5-adenoviral 
plasmid and was regulated by a cytomega-
lovirus (CMV) promoter. All constructed 
viruses contained the RGD (Arg-Gly-Asp) 
aminoacid motif, which was added to the H1 
loop of the adenoviral ﬁber knob [18]. Puri-
ﬁed recombinant adenoviral vector DNA 
was linearized through digestion with PacI 
and transfected into 293 viral packaging 
cells using Lipofectamin 2000 (Invitrogen, 
Carlsbad, CA, USA). AdRGDsIL-1RAcP 
and AdRGD luciferase were puriﬁed using 
2x CsCl gradient puriﬁcation and stored in 
small aliquots at -80ºC. The viral titer of 
the puriﬁed viral vectors was determined on 
911 indicator cells by immunohistochemical 
detection of viral capsid protein 20 hours 
after transfection [19].
 Construction of sIL-1RAcP 
producing cell line
The murine ﬁbroblast NIH 3T3 cell line 
was used for construction of a stable and high 
sIL-1RAcP producing cell line. To enable 
puriﬁcation, the protein was tagged using 
a C-terminal FLAG epitope. FLAG tagged 
sIL-1RAcP was inserted into the eukaryotic 
expression vector pcDNA3.1/Zeo (Invitro-
gen) under regulation of the CMV promoter. 
NIH 3T3 ﬁbroblasts were transfected using 
Lipofectamin 2000 (Invitrogen) and selected 
on stable integration with Zeocin (Invitro-
gen, Carlsbad, CA, USA). The NIH 3T3 
sIL-1RAcP producing cell line was cultured 
in Dulbecco’s modiﬁed Eagle medium 
(DMEM) containing 10% fetal calf serum 
(FCS) and 100 U/ml penicillin and strep-
tomycin (Invitrogen). Cells were cultured 
in humidiﬁed atmosphere (5% CO2/37 
oC) 
and culture supernatant was harvested every 
96 hours. Before puriﬁcation conditioned 
supernatants were centrifuged for 10 minutes 
at 15,000g, sterile ﬁltered (0.2 µm ﬁlters; 
Schleicher & Schuell, Dassel, Germany) and 
if not used for immediate puriﬁcation, stored 
at -20 oC.
Purification of sIL-1RAcP
sIL-1RAcP was puriﬁed at 4oC from 
centrifuged and sterile-ﬁltered conditioned 
supernatants through afﬁnity chromatogra-
phy using anti-FLAG M2 afﬁnity gel beads 
(SIGMA, St. Louis, MO, USA). The afﬁn-
ity bound protein was obtained by competi-
tive elution with a solution containing 100 
mg/ml 3xFLAG peptide (SIGMA) in 50 
mM Tris-HCl, 150 mM NaCl (pH 7.4). 
Concentration of the puriﬁed protein frac-
tion was achieved using molecular weight 
cut-off ﬁlters of 10 kDa (Amicon; Millipore, 
Bedford, MA, USA). The concentrated 
protein was stored in silicon coated reac-
tion tubes and stored at 4oC till later usage. 
Quantiﬁcation of the puriﬁed protein was 
achieved using Coomassie Protein assay 
reagent according to manufacturer’s proto-
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col (Pierce, Rockford, IL, USA). Bovine 
Serum Albumin was used as the standard. 
Average production of sIL-1RAcP by stable 
transfected NIH 3T3 ﬁbroblasts was ~ 500 
ng/24h/1x106 cells.
Characterization of purified sIL-1RAcP 
Protein purity was analyzed using sodium 
dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE). 
SDS-PAGE: Protein samples (10 µl) of 
puriﬁed and concentrated sIL-1RAcP were 
incubated for 5 minutes at 99oC under 
reducing conditions and analyzed on 10% 
acrylamide gel. Separated proteins were 
visualized by silver staining.
Deglycosilation: Puriﬁed protein samples 
were denatured for 4 minutes at 90oC in 
20 µl 0.2 M 2-mercaptoethanol containing 
0.2% SDS. Denaturated protein samples were 
added to deglycosilation mixture containing 
0.5 M Tris-HCl (pH 8.6), H2O, 10% Triton 
X-100, and 250 mU/ml N-Glycosidase F 
(Roche, Bioscience, Palo Alto, CA, USA). 
Reaction was performed overnight at 37oC. 
The enzyme was deactivated by adding 10% 
SDS, followed by incubation at 90oC for 5 
minutes. Deglycosilated protein samples 
were separated on SDS-PAGE gels and were 
visualized using silver staining.  
Construction of IL-1 responsive NFκB 
Reporter cell line
The IL-1 responsive murine ﬁbroblast 
NIH 3T3 cell line (American Type Culture 
Collection, Rockville, MD, USA) was used 
for construction of an IL-1 sensitive reporter 
cell line. Brieﬂy, a promoter containing a 
5xNFκB binding site cloned upstream of 
the Luciferase gene was extracted from the 
pGl3b reporter vector, which was a kind 
gift from Prof. Dr. W. Falk (Department of 
Internal Medicine, University of Regensburg, 
Germany). The obtained NFκB reporter 
construct was ligated into a promoterless 
eukaryotic expression vector pcDNA3.1A 
(Invitrogen, Carlsbad, CA, USA). Cells were 
transfected cells using Lipofectamin 2000 
(Invitrogen) and selected on stable integra-
tion with Neomycin-G418 and responsive-
ness to IL-1.
Luciferase bio-assay
The ability of sIL-1RAcP to inhibit IL-1 
signaling was tested on IL-1 responsive NIH 
3T3 NFκB reporter cells. One day prior to 
experiments reporter cells were seeded in 
Krystal 2000 96 wells plates (Thermo Labsys-
tems, Brussels, Belgium) at a concentration 
of 2-4x104 cells/well. Cells were cultured at 
5%CO2/37
oC. Test set-up consisted either 
out of pre-incubation for 24h with the sIL-
1RAcP followed by addition of different 
concentrations murine recombinant IL-1α 
(1 or 10 ng/ml). Six hours after IL-1α addi-
tion NFκB activation was measured through 
determination of intracellular Luciferase 
production. Non speciﬁc effects of the sIL-
1RAcP on NFκB signaling were tested using 
TNFα at different concentrations (1 and 10 
ng/ml).  Luciferase activity was quantiﬁed 
using Bright-Glo luciferase assay system 
(Promega, Madison, WI, USA) followed by 
luminometric detection according to manu-
facturer’s protocol (Polarstar galaxy, BMG, 
Offenburg, Germany). 
Induction of CIA
Bovine collagen type II (BCII) was 
dissolved in 0.05 M acetic acid to a concentra-
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tion of 2 mg/ml and was emulsiﬁed in equal 
volumes of CFA (2 mg/ml of M. tuberculosis 
strain H37Ra; Difco laboratories, Detroit, 
MI, USA). The mice were immunized intra 
dermally at the base of the tail with 100 µl 
of emulsion (100 µg of BCII). On day 21, 
mice were given an i.p. booster injection of 
100 µg of BCII dissolved in phosphate buff-
ered saline (PBS).The mice without clinical 
manifestation of arthritis were selected and 
used for experiments. 
To study the effects of sIL-1RAcP on 
local inﬂammation in CIA, mice without 
clinical manifestation of the disease were 
intra-articular injected with 1x106 NIH 
3T3 sIL-1RAcP ﬁbroblasts which produce 
~500 ng/24h/1x106 cells. For control injec-
tion 1x106 normal NIH 3T3 ﬁbroblasts were 
injected intra-articularly. 
To evaluate systemic effects of sIL-1RAcP 
on the development of CIA, we applied 
adenoviral delivery of the sIL-1RAcP to 
immunized mice. To achieve systemic 
overexpression of sIL-1RAcP we injected 
3x108 pfu AdRGDsIL-1RAcP intravenous 
in immunized mice without clinical signs of 
CIA. 
Normally ﬁrst signs of arthritis onset 
occur around day 22–24, in particular in 
the ankles. Peri-articular development of 
arthritis in the hind paw and ankle joint was 
macroscopically monitored till day 32 (in 
case of i.a. treatment) or till day 38 (in case 
of i.v. treatment), at which time the experi-
ment was terminated and the mice were 
killed. During this period clinical severity of 
the arthritis was scored by two independent 
observers in a blinded manner on a scale 
ranging from 0-2 for each limb. Cumula-
tive scoring depending on redness, swelling 
and in later stadium ankylosis was expressed 
as follows; 0 = no changes, 0.25 = 1 to 2 
toes red or swollen, 0.5 = 3 to 5 toes red 
or swollen, swollen ankle, swollen footpad 
and/or severe swelling and ankylosis. At day 
32 the experiment was terminated and the 
mice were bled. Serum was obtained and 
stored for further analysis. Knee joints were 
dissected and scored for macroscopical swell-
ing on a scale ranging from 0 to 2. 
Histology 
Whole dissected knee joints were ﬁxed 
in phosphate buffered 4% paraformaldehyde, 
followed by decalciﬁcation with 5% formic 
acid, and were then embedded in parafﬁn 
wax. Serial tissue sections of 7 µm were 
stained with safranin-O or heamatoxylin 
and eosin (HE) prior to microscopical analy-
sis. Loss of bone and non calciﬁed cartilage, 
which is characteristic for CIA, was scored 
on a 0 to 3 scale ranging from no effects to 
complete loss of bone structure or non calci-
ﬁed cartilage layer. The degree of proteo-
glycan (PG) depletion was determined by 
measurement of glycosaminoglycan content 
of the non-calciﬁed cartilage layer, which 
was scored in safranin-O-stained sections 
also on a scale from 0 to 3 ranging from no 
depletion to severe depletion. These histo-
pathological changes were scored in blinded 
manner by two observers. 
Murine sIL-1RAcP Elisa
Nunc Maxisorp microtiter plates were 
coated with rat anti-murine IL-1RAcP 
IgG1 monoclonal antibody M215 (Immunex 
Corporation, Seattle, WA) and incubated 
overnight at 2-8°C.  The coated wells 
were washed with PBS-Tween prior to 
use.  Samples and reagents were dispensed 
into the wells in the following order, 
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each separated by an incubation period 
and wash step: 1) serum samples and 
murine sIL-1RAcP.FLAG His concen-
tration standards diluted in PBS-Tween 
with 0.1% BSA (PBSAT);  2) rabbit anti-
murine IL-1RAcP antiserum (Immunex 
Corporation, Seattle, WA) diluted in 
PBSAT; and 3) peroxidase-labeled goat 
anti-rabbit IgG ( Jackson Immunoresearch 
Laboratories, West Grove, PA) diluted in 
PBSAT.  Color was developed with TMB 
peroxidase substrate.  The reaction was 
quenched with acid and optical densities 
(ODs) were determined at a wavelength 
of 450 nm.  The dose-response curve, 
constructed of concentration standards in 
the range of 0.125-8 ng/ml, was ﬁtted to 
a four-parameter logistic model.  Sample 
concentrations were interpolated from 
the ﬁtted curve and corrected for dilution 
factor.
Determination of specific IgG-titers 
against collagen type II
IgG1, IgG2a and total IgG anti-colla-
gen antibody titers against bovine CII 
were determined through ELISA. Brieﬂy, 
96-well plates were coated with 10 µg of 
bovine CII, followed by blockage of non-
speciﬁc binding sites. Serial dilutions of 
the mouse sera were added, followed by 
incubation with isotype speciﬁc goat anti-
mouse peroxidase (Southern Biotechnology 
Associates, Birmingham, AL, USA) and 
substrate (5-aminosalicylic acid; Sigma). 
Plates were read at an OD of 492 nm. 
Measurement of IL-6 serum levels 
Concentrations of IL-6 in serum was 
determined using the B9 bioassay as 
described previously [20]. Brieﬂy, serial 
dilutions of Serum samples were made in 
culture medium in order to quantify IL-6 
levels. B9 cells (5x103) were added to serum 
sample dilutions and incubated for 3 days (at 
37ºC/5%CO2). Four hours before harvest-
ing the cells, 0.25 µCi of 3H-Thymidine 
was added. The amount of incorporated 3H-
Thymidine was quantiﬁed using a Micro 
Beta-plate reader (Perkin-Elmer, The 
Netherlands).
Statistical analysis
Signiﬁcance of differences was determined 
using student’s t-test or Mann-Whitney U test, 
unless stated otherwise (GraphPad Prism, San 
Diego, CA, USA). P values of  less than or 
equal to 0.05 were regarded as signiﬁcant.
Results
Characterization of purified sIL-1RAcP
sIL-1RAcP was cloned from murine 
liver cDNA and stable expressed by NIH-
3T3 ﬁbroblasts using pcDNA3.1/Zeo 
vector. The protein was puriﬁed from 
conditioned culture supernatants using 
afﬁnity chromatography as described in 
Materials and Methods. Separation on SDS-
PAGE revealed a clear and highly puriﬁed 
protein migrating at 60 kDa (Figure 1, 
lane 3). Deglycosilation of sIL-1RAcP, 
resulted in additional protein bands at ~45 
and ~40 kDa, resembling partially and 
total deglycosilated sIL-1RacP (Figure 1, 
lane 2). Quantiﬁcation of puriﬁed protein 
showed an average production of sIL-
1RAcP by the stable transfected NIH 3T3 
ﬁbroblasts of ~500 ng/24h/1x106 cells.
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Figure 2.  sIL-1RAcP inhibits IL-1 signaling in vitro
Preincubation for 24 hours with diﬀerent concentration (0.1, 1 and 10 µg/ml) 
of sIL-1RAcP signiﬁcantly inhibited IL-1 signaling by IL-1 responsive NFκB re-
porter ﬁbroblasts. IL-1 response of reporter ﬁbroblasts is quantiﬁed in Relative 
Light Units (RLU). Data are presented as means + SD of a total of four experi-
ments (n=24). *, P<0.001 Data are analysed using a One-way ANOVA, with 
Bonferroni post-test.
Figure 1. Characterization of puri-
ﬁed sIL-1RAcP
Molecular weight and purity was de-
termined by using 10% SDS-PAGE gel 
electrophoresis followed by silver stain-
ing. Lane 1 represents the broad range 
protein standard. Puriﬁed sIL-1RAcP 
migrated at ~60 kDa (Lane 3). Partial 
deglycosilation of the puriﬁed protein 
sample resulted in two additional bands, 
migrating at about ~45 and ~40 kDa. 
* An additional band migrating at ~33 
kDa resembles the digestive enzyme N-
Glycosidase F.
sIL-1RAcP Inhibits IL-1 induced 
NFκB activation 
To test the IL-1-inhibitory potential 
of sIL-1RAcP, different concentrations of 
the protein were tested on IL-1-responsive 
NFκB luciferase reporter ﬁbroblasts in the 
presence or absence of variable concentra-
tions of IL-1α. 
Preincubation of the soluble receptor (0.1, 
1 and 10 µg/ml) with the luciferase reporter 
ﬁbroblasts for 24 hours followed by IL-1α 
(0, 1 and 10 ng/ml) stimulation for 6 hours 
revealed a sIL-1RAcP-induced dose-de-
pendent inhibition of the IL-1 signal. The 
inhibition of IL-1α was signiﬁcant at both 
concentrations of IL-1 used (1 and 10 ng/ml) 
(P<0.001) (Figure 2). No effects of prein-
cubation of the sIL-1RAcP were observed 
on cell viability (>98%) or TNFα mediated 
signaling (data not shown). 
Intra-articular overexpression of 
sIL-1RAcP protects against erosive 
joint destruction in CIA.
After demonstrating that sIL-1RAcP 
is a functional inhibitor of IL-1 mediated 
signaling we tested its in vivo efﬁcacy in the 
murine CIA. Macroscopic evaluation of the 
knee joints receiving sIL-1RAcP cell trans-
fer showed a signiﬁcant reduction in  the 
gross appearance of inﬂammation at day 32 
of CIA compared with the joints receiving 
control NIH 3T3 ﬁbroblasts (38% reduction, 
P<0.001) (Figure 3A). Histology conﬁrmed 
the reduction of inﬂammation in joints 
receiving sIL-1RAcP cell transplantation. 
Furthermore, sIL-1RAcP treatment mark-
edly reduced joint pathology as observed 
by diminished proteoglycan depletion 
and reduced bone- and cartilage erosion 
(Figure 3B and C). 
Interestingly, no clear effect on incidence 
(see insert, Figure 4) and severity of CIA 
was observed in the distal ankle joints of 
mice that received sIL-1RAcP cell transfer 
(Figure 4). Unchanged levels of circulat-
ing IL-6 and anti-collagen type II IgG Abs 
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Figure 3. Protection against erosive joint destruction of collagen-induced arthritis (CIA) by loal treatment with sIL-1RAcP in the knee joint
In contrast to the distal joints (see Figure 4), localized protection against CIA was observed in the treated knee joints. (A) This localized protection could be observed 
on gross appearance of inﬂammation of the sIL-1RAcP (white bars) treated vs. control treated (black bars) knee joints after dissection. (B) Histologically, this observa-
tion was conﬁrmed and additional protection on Proteoglycan (PG) depletion and bone- and cartilage erosion was observed . (C)  Saﬀranin-O-fast green-stained 
serial tissue section of CIA knee joints receiving either control cell transfer or sIL-1RAcP cell transfer were compared with normal knee joints of naive mice receiving no 
treatment.   JC=Joint Cavity, C=Cartilage, M=meniscus, S=Synovium. Date are mean + SEM of two experiments with a total of 25 mice per group.  *, P<0.05 using 
Mann-Whitney U test.
Figure 4. Lack of protection against CIA following local treatment 
with sIL-1RAcP in distal ankle joints
Cell transfer of NIH 3T3 sIL-1RacP-producing ﬁbroblasts into the knee joint cav-
ity showed no eﬀect on either severity of CIA in the distal joints or incidence  of 
CIA (see insert) in the distal ankle joints of CIA animals treated with NIH3T3 sIL-
1RAcP producing ﬁbroblasts (white bars) versus the control treatment group 
receiving NIH3T3 ﬁbroblasts (black bars). Knee joints received cell transfer at 
day 22. Development of arthritis was monitored in the paws of treated animals 
till day 32 at which the animals were killed. Data are Mean + SEM of two ex-
periments with a total n=25 per group.
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further emphasized a localized effect by sIL-
1RAcP cell transplantation (data not shown). 
Systemic overexpression of sIL-
1RAcP results in amelioration of CIA
To achieve systemic overexpression of 
the sIL-1RAcP, mice received 3x108 pfu 
Ad RGD sIL-1RAcP or the control vector 
Ad RGD Luciferase through intravenous 
injection 22 days after BCII immunization. 
The kinetics of sIL-1RAcP expression were 
determined in serum obtained from mice at 
different time points after receiving the sIL-
1RAcP adenoviral vector. Enhanced levels 
of sIL-1RAcP could be detected in serum 
at day 1 after viral injection. Levels peaked 
at day 7, and returnedto threshold at day 14 
(Figure 5). The development of the CIA was 
monitored from time of vector injection 
until day 38. 
Throughout this period, Ad RGD sIL-
1RAcP showed a clear protection against 
development of CIA in all paws of the immu-
nized mice. Severity of CIA (Figure 6) as well 
as incidence (see insert, Figure 6) was signiﬁ-
cantly reduced from day 30 till day 38. Dissect-
ed knee joints of Ad RGD sIL-1RAcP-treated 
animals revealed a clear reduction in macro-
scopically observed inﬂammation, which 
was conﬁrmed microscopically (Figure 7A, 
page 70). Furthermore, histology of the knee 
joints from animals treated with sIL-1RAcP 
revealed a clear protection of against PG deple-
tion, bone and cartilage erosion as compared 
with the control vector (Figure 7B and C). 
Figure 5. Detectable levels of sIL-1RAcP in serum following systemic 
adenoviral overexpression. 
Systemic overexpression of the sIL-1RAcP was achieved through intra venous 
injection of 3x108 pfu Ad RGD sIL-1RAcP at day 0. At diﬀerent time points af-
ter viral injection (day 1, 3, 7 and 14) mice were sacriﬁced and serum samples 
were obtained (n=4 for each time point). These data show elevated levels of 
sIL-1RAcP at day 1, peaking at day 3 and 7 and returning to threshold at day 14. 
Data are presented as average serum levels + SD of sIL-1RAcP, corrected for 
baseline values of sIL-1RAcP. 
Figure 6.  Protection against CIA by systemic treatment with sIL-
1RAcP.
Systemic overexpression of sIL-1RAcP, induced by intra orbital injection of 
3x108 pfu Ad RGD sIL-1RAcP drastically reduced both incidence (see insert) and 
severity of the CIA. Incidence and severity of CIA were monitored on both front 
and hind paws of sIL-1RAcP treated animals versus AdRGD Luciferase control 
treatment group. Furthermore development of CIA severity and incidence in 
uninfected mice is shown (No virus). Incidence is presented as percentage of 
CIA aﬀected paws. Severity is presented as a cumulative arthritis index of both 
front and hind paws, which were individually scored (0-2) creating a maximum 
score of 8 when all paws where aﬀected. Data are presented as Means + SEM of 
two experiments with a total n=24. *,P<0.05 using Mann-Whitney U test.  
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Discussion 
Several groups have shown the feasibility 
of IL-1 inhibition in experimental arthritis 
models, thus proving the importance of IL-1 
in onset and development of experimental 
arthritis. Some of these strategies today, 
such as administration of IL-1Ra have been 
conﬁrmed to be effective in humans and are 
now used in large scale in clinical settings 
[21,22]. Many studis from the past decades 
focused on IL-1 signaling and underlined the 
importance of the IL-1RAcP in IL-1-medi-
ated signaling [6,23-25]. Because of the 
importance of the IL-1RAcP in IL-1 signal-
ing and the discovery of a soluble form of 
the IL-1RAcP we created a stable transfected 
cell line and an adenoviral vector expressing 
sIL-1RAcP. With intervention strategies we 
explored the role for sIL-1RAcP in vitro and 
in an experimental arthritis setting. With 
this study, we are the ﬁrst to demonstrate that 
sIL-1RAcP is an inhibitor of IL-1 signaling 
in vitro and can serve as novel inhibitor of 
experimental arthritis. 
After characterization of sIL-1RAcP and 
demonstrating protein purity, sIL-1RAcP 
was tested for its ability to inhibit IL-1 
activity on IL-1 responsive NFκB luciferase 
reporter cells.  Puriﬁed sIL-1RAcP showed 
a signiﬁcant and concentration-dependent 
inhibition of IL-1 mediated signaling. This 
inhibition was speciﬁc for IL-1, whereas no 
inhibitory activity was observed on TNFα 
induced NFκB activation.
The local treatment, in which sIL-1RAcP 
producing ﬁbroblasts were intra-articu-
larly injected into the knee joints, showed a 
marked and signiﬁcant reduction in the path-
ological condition of the joint, as observed 
by modulation of cartilage erosion, bone 
erosion and inﬂammation. This effect was 
only local, being observed in the sIL-1RAcP 
treated knee joints, while no protective 
effects were observed on the ipsilateral 
paws. This is in contrast to the effects of 
systemic treatment with sIL-1RAcP, which 
clearly protected both knee joints and ipsilat-
eral paws. This observed difference between 
local and systemic application of the protein 
could be the result of the characteristics of 
the protein. The sIL-1RAcP is a relatively 
large and glycosilated protein, which will for 
certain affect distribution of the protein into 
different compartments of the body [26]. In 
contrast, the smaller IL-1Ra, which can be 
easily applied intraarticular, shows beneﬁcial 
effects on ipsilateral paws [14]. In the pres-
ent study, however, systemic application of 
sIL-1RAcP showed signiﬁcant reduction 
in severity of the arthritis, protecting up 
to 60% of all the joints (Figure 6), making 
systemic administration of sIL-1RAcP a 
promising new strategy in treating experi-
mental arthritis. 
The mechanism by which sIL-1RAcP 
speciﬁcally inhibits IL-1 signaling remains 
to be established. It could be either by direct 
interference on the functional formation of 
the IL-1 receptor complex or by interaction 
of sIL-1RAcP with the IL-1RII. 
With regard to the ﬁrst model, sIL-1RAcP 
competes with endogenous membrane 
bound IL-1RAcP for the formation of a 
functional receptor complex consisting out 
of the IL-1RI, IL-1 and IL-1RAcP. This 
competitive antagonism between the soluble 
form and the membrane bound form of the 
IL-1RAcP results in a receptor complex 
consisting out of the IL-1RI, IL-1, and the 
sIL-1RAcP, which is unable to transduce 
IL-1 signaling. 
In order to achieve IL-1 inhibition 
using sIL-1RAcP, Jensen et al showed that 
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sIL-1RAcP had to be anchored to the 
membrane [10]. This conﬁrms the obser-
vation by Huang et al that C-terminally 
truncated IL-1RAcP is dominant negative 
in IL-1 signaling [27].  In vitro experi-
ments performed by Jensen et al using cells 
overexpressing non-membrane anchored 
sIL-1RAcP, no IL-1 inhibition could be 
observed.  Those authors suggested that this 
was the result of a dilution of sIL-1RAcP 
below its biological activity threshold and 
speculated that in order to achieve detect-
able IL-1 inhibition, high concentrations 
of sIL-1RAcP were required at cell surface 
level. This may explain why, in our in 
vitro setting, excessive concentrations of 
sIL-1RAcP were required in order to 
achieve functional competition. 
With regard to the second model, 
sIL-1RAcP might interact with the soluble 
or membrane-bound IL-1RII forming a high 
afﬁnity trap competing for IL-1 with the 
IL-1R1/IL-1RAcP receptor complex. In this 
model IL-1 inhibition is dependent on the 
amount of functional IL-1RII/sIL-1RAcP 
complexes formed. The possibility of 
interaction between the membrane-bound 
IL-1RAcP with the IL-1RII has already 
been described [28,29]. In a recent report 
[30] the interaction between sIL-1RII and 
the sIL-1RAcP, as proposed in the second 
model, was described. The study showed 
that sIL-1RAcP was able to interact with 
the sIL-1RII, which increased its afﬁnity 
for IL-1α and β, thus forming an IL-1 scav-
enging receptor [30]. In this latter model, 
the difference between local and systemic 
application of the sIL-1RAcP, as observed 
in our study, could be the result of a discrep-
ancy in intra-articular and systemic expres-
sion of IL-1RII. Whether the amelioration 
of the CIA results from interaction of the 
sIL-1RAcP with the IL-1RII or from inter-
action with systemic circulating soluble IL-
1RII, needs to be further studied. 
There are several protein characteristics, 
which could make sIL-1RAcP an interest-
ing inhibitor of IL-1 with properties that are 
distinct from IL-1Ra. First of all, sIL-1RAcP 
can selectively inhibit IL-1 signaling, possi-
bly by competing with membrane bound 
IL-1RAcP for receptor complex formation 
with the IL-1RI. This process is IL-1 depen-
dent. 
Second, IL-1Ra can occupy all available 
IL-1RI and not IL-1RII [31], which is inde-
pendent of IL-1 or IL-1RAcP. Although this 
inhibitor is highly speciﬁc for IL-1RI, func-
tional IL-1 inhibition using IL-1Ra does not 
discriminate between target and non-target 
cells, with the consequence that high dosages 
of IL-1Ra are required to achieve saturation 
[11,15]. In contrast, sIL-1RAcP can only 
induce a functional inhibition in the pres-
ence of IL-1 bound to the IL-1RI, while 
sIL-1RAcP itself cannot bind IL-1 [23]. 
This characteristic makes sIL-1RAcP an 
IL-1 speciﬁc and target cell discriminating 
inhibitor. 
Third, IL-1RAcP can interact with 
membrane bound IL-1RII in which it can 
form an IL-1 speciﬁc membrane-bound 
trap [29]. With this observation one could 
imagine the possibility of an interaction 
of membrane bound IL-1RII with soluble 
IL-1RAcP. 
Finally, sIL-1RAcP can also interact with 
the soluble or shed IL-1RII. This interac-
tion will result in formation of soluble IL-1 
scavenger receptor [30]. Since IL-1Ra and 
sIL-1RAcP act on different levels and thus 
do not interfere with each other’s inhibitory 
activity, combination of both inhibitors will 
likely result in more effective inhibition of 
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IL-1 effects. 
With this study we have demonstrated 
the IL-1 inhibitory capacity of sIL-1RAcP 
in vitro and show the applicability of sIL-
1RAcP at local and systemic level. This 
natural occurring soluble form of the 
IL-1RAcP has a profound effect on inci-
dence and severity of CIA and opens up 
new opportunities for modulation of IL-1 
signaling in vivo.
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Figure 7.  Protection against erosive joint destruction of CIA by systemic treatment with sIL-1RAcP.
Knee joints of animals receiving either Ad RGD sIL-1RAcP or the control vector AD RGD luciferase were dissected at day 38 and processed for histological examination. 
(A) Overall protection could be observed on gross appearance of inﬂammation of the knee joints of the sIL-1RAcP-treated (white bars) vs. control-treated (black bars) 
animals after dissection (n=36 knee joints per group). (B) Histologically, this observation was conﬁrmed and additional protection  on Proteoglycan (PG) depletion and 
bone- and cartilage erosion was observed. (C) Saﬀranin-O-fast green-stained serial tissue section of knee joints of animals with CIA receiving either control adenoviral 
vector or sIL-1RAcP adenoviral vector were compared with normal knee joints of naive mice receiving mo treatment.   JC=Joint Cavity, C=Cartilage, M=meniscus, 
S=Synovium. Date are presented as means + SEM of two experiments with a total n=36 knee joints per group. *, p<0.05 **, p<0.01 using Mann-Whitney U test.
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Eﬀects of sIL-1RAcP and IL-1Ra in CIA
The aim of this study was to unravel the mode of IL-1 inhibition of sIL-1RAcP by comparison to IL-1 Receptor antagonist (IL-1Ra) in arthritis. 
 Methods: Adenoviral vectors encoding either sIL-1RAcP or IL-1Ra were administered systemically 
before onset of CIA in DBA/1 mice. Anti bovine collagen type II (BCII)IgG and IL-6 was quantiﬁed 
in serum. Proliferative response of spleen T-cells was determined in the presence of sIL-1RAcP or 
IL-1Ra. The eﬀect on IL-1 inhibition of recombinant sIL-1RAcP and IL-1Ra was further examined in 
vitro, using NFκB luciferase reporter cell lines. Q-PCR was used to determine the relative mRNA 
expression of the IL-1 receptors. Results: Adenoviral overexpression of both sIL-1RAcP and IL-1Ra 
resulted in amelioration of the collagen-induced arthritis. Both IL-1 antagonists reduced the circu-
lating levels of antigen speciﬁc IgG2a antibodies, but only IL-1Ra was able to inhibit lymphocyte 
proliferation. By using puriﬁed lymphocyte populations derived from NFκB reporter mice, we 
showed that sIL-1RAcP inhibits IL-1-induced NFκB activity in B-cells but not T-cells, whereas IL-1Ra 
inhibited IL-1 on both cell types. A study in a panel of NFκB luciferase reporter cells showed that 
the sIL-1RAcP inhibits IL-1 signaling on cells expressing either low levels of membrane IL-1RAcP or 
high levels of IL-1RII. Conclusion: We show that the sIL-1RAcP ameliorated experimental arthritis 
without aﬀecting T-cell immunity, in contrast to IL-1Ra. Data is provided in support for receptor 
competition by sIL-1RAcP, as an explanation for the diﬀerent mode of IL-1 antagonism in compari-
son to IL-1Ra.
The pro-inﬂammatory cytokine Inter-
leukin-1(IL-1) is an important mediator 
controlling local and systemic effects on a 
wide variety of target cells, thereby regulat-
ing immunity and inﬂammation [1]. IL-1 
binds to the type I IL-1 Receptor (IL-1RI) 
(80 kDa) [2,3], which results in the recruit-
ment of the IL-1 receptor accessory protein 
(IL-1RAcP) [4-8]. IL-1RAcP itself does not 
recognize the ligand itself but stabilizes the 
IL-1 binding to the IL-1RI [4,7]. Further-
more, IL-1RAcP is a crucial co-receptor in 
this complex by enabling recruitment and 
binding of intracellular adaptor proteins, 
such as MyD88 and kinases like IL-1R asso-
ciated kinases, ultimately leading to NFκB 
activation [9-14]. 
Another member of the IL-1 recep-
tor family is the type II IL-1 receptor 
(IL-1RII)(68 kDa) [15], which upon bind-
ing of IL-1 also associates with IL-1RAcP 
however this does not lead to signal trans-
duction as this receptor lacks the intracellular 
TIR domain that is crucial for MyD88 bind-
ing [16-18]. Therefore the type II receptor 
is a decoy receptor as has been described for 
its trans-membrane- and soluble form [19]. 
Another inhibitor of IL-1 signaling is the IL-1 
Receptor antagonist (IL-1Ra) that competes 
with IL-1 for occupation of the IL-1RI. 
It is generally accepted that occupation 
of only 1% of the IL-1RI by IL-1 already 
leads to full-blown cell-activation and as 
a consequence relatively high amounts of 
IL-1Ra (100 to 1000-fold molar excess) are 
required to fully block IL-1. Fortunately, 
IL-1Ra poorly binds to IL-1RII [19] and 
both IL-1Ra and sIL-1RII are cooperative in 
IL-1 inhibition. We and others demonstrated 
that administration of IL-1Ra protein or the 
IL-1Ra gene ameliorates disease in several 
models of experimentalarthritis, with a 
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profound protective effect on cartilage- and 
bone destruction [20,21].
Recently an alternative splice transcript 
of the membrane IL-1RAcP, encoding a 
smaller and soluble protein comprising the 
three extracellular Ig domains and a unique 
C-terminal domain, has been described 
[22,23]. This soluble IL-1RAcP (sIL-1RAcP) 
is mainly produced by the liver and circu-
lates systemically. We showed that systemic 
overexpression of sIL-1RAcP by adenoviral 
gene transfer in mice markedly ameliorates 
collagen-induced arthritis (CIA) [24,25]. A 
possible explanation is that sIL-1RAcP can 
interact with soluble IL-1RII, thus forming 
a high afﬁnity IL-1 scavenger [26]. Although 
the mechanism and efﬁcacy of IL-1 inhibi-
tion might be different, it is expected that 
under optimal conditions both IL-1Ra and 
sIL-1RAcP may exert similar biological 
effects.
The aim of this present study was compare 
the inhibitory effect of sIL-1RAcP and IL-
1Ra in CIA and to unravel their mode of 
action. Systemic overexpression of either sIL-
1RAcP or IL-1Ra using adenoviral vectors 
before onset of CIA resulted both in amelio-
ration of CIA, underlining their potential 
as IL-1 inhibitors in vivo. Treatment of both 
inhibitors resulted in a clear reduction of 
circulating levels of antigen speciﬁc IgG2a 
and IL-6 levels. However, sIL-1RAcP treat-
ment did not affect T-cell function whereas 
IL-1Ra inhibited both antigen– and mito-
gen– induced lymphocyte proliferation. Next 
we studied the effect of both inhibitors on 
enriched T and B-cells obtained from naive 
NFκB luciferase reporter mice. Recombinant 
sIL-1RAcP protein was unable to block IL-1 
signaling on T-cells, while IL-1Ra inhibited 
IL-1 induced NFκB activation in both T- 
and B-cells. A study in an array of reporter 
cell types that differ in their expression of 
the IL-1 receptors; IL- 1RI, IL-1RII and the 
co-receptor IL-1RAcP, provided a possible 
explanation for the cell type speciﬁc inhibi-
tory effect of sIL-1RAcP, that of receptor 
competition with the membrane IL-1RAcP.
Methods
Animals
Male 10- to 12-weeks old DBA-1/bom 
mice obtained from Bomholdgärd (Ry, 
Denmark). C57/BL6 mice were obtained 
from Charles River, Sulzfeld, Germany and 
during the experiments housed in low-pres-
sure isolator cages. The animals were fed a 
standard diet with water and food ad libitum. 
All in vivo studies complied with national 
legislation and were approved by local 
authorities of the Care and Use of Animals 
with related codes of practice.
Construction of adenoviral vector
The sIL-1RAcP or IL-1Ra gene was 
obtained from murine liver cDNA and 
cloned into the ﬁrst generation E1/E3 
deleted serotype-5 adenoviral vectors and 
produced according to the method described 
by Chartier et al [27]. All constructed viruses 
contained the RGD aminoacid motif (Arg-
Gly-Asp), which was incorporated to the H1 
loop of the adenoviral ﬁber knob [28,29]. 
Puriﬁed recombinant adenoviral vector 
DNA was linearized through digestion with 
PacI and transfected into 293 viral packaging 
cells using Lipofectamin 2000 (Invitrogen,
Carlsbad, CA, USA). Ad sIL-1RAcP Ad 
IL-1Ra and Ad luciferase were puriﬁed using 
2x CsCl gradient puriﬁcation and stored in 
small aliquots at -80ºC. Viral titer of the 
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puriﬁed viral vectors was determined on 
911 indicator cells by immunohistochemical 
detection of viral capsid protein 20 hours 
after transfection [30].
Production and purification of 
sIL-1RAcP recombinant protein
C-terminal FLAG-tagged sIL-1RAcP 
recombinant protein was obtained from 
a stable transduced NIH 3T3 cell line and 
puriﬁed as described previously [24]. Brief-
ly, sIL-1RAcP was puriﬁed at 4oC from 
conditioned supernatants through afﬁnity 
chromatography using anti-FLAG M2 afﬁn-
ity gel beads (SIGMA chemical Co, USA), 
followed by competitive elution with a solu-
tion containing 100 µg/ml 3xFLAG peptide 
(SIGMA chemical Co, USA) in 50mM Tris-
HCl, 150 mM NaCl (pH 7.4). The protein 
was concentrated using MW cutoff ﬁlters of 
10 kDa (Amicon, Millipore, Bedford, MA, 
USA) and stored in silicon coated reaction 
tubes at 4oC till later usage. Puriﬁed protein 
was quantiﬁed achieved using Coomassie 
Protein assay Reagent according to manufac-
turers’ protocol (Pierce, Rockford, IL, USA), 
and the average production of sIL-1RAcP by 
stable transfected NIH 3T3 ﬁbroblasts was 
about 500 ng/24h/1x106 cells. Inhibition 
studies using IL-1Ra and sIL-1RAcP. The 
IL-1 responsive murine ﬁbroblast NIH 3T3 
cell line, EL.4 NOB-1 thymocytic cell line 
(ATCC) and the H4 chondrocyte cell line 
[31] stable transfected with a NFκB luciferase 
reporter construct were used. Reporter cells 
were seeded in Krystal 2000 96 wells plates 
(Thermo Labsystems, Brussels, Belgium) 
at a concentration of 2-4x104 cells/well, 
and cultured for one day at 5% CO2/37
oC. 
Therefore cells were incubated for 24 hours 
with either sIL-1RAcP or IL-1Ra (Amgen, 
Boulder, CO, USA) followed by addition of 
different concentrations of murine recombi-
nant IL-1 (1 or 10 ng/ml). Six hours after IL-
1 addition the intracellular luciferase activity 
was quantiﬁed using Bright-Glo luciferase 
assay system (Promega, Madison, WI, USA) 
followed by luminometric detection accord-
ing to manufactures protocol (Polarstar 
galaxy, BMG, Offenburg, Germany).
Induction of CIA
Bovine collagen type II was dissolved in 
0.05 M acetic acid to a concentration of 2 
mg/ml and was emulsiﬁed in equal volumes 
of CFA (2 mg/ml of M. tuberculosis strain 
H37Ra; Difco laboratories, Detroit, MI, 
USA). The mice were immunized intra 
dermal at the base of the tail with 100 µl of 
emulsion (100 µg of bovine collagen type II). 
On day 21, mice without clinical manifesta-
tion of arthritis received an i.p. booster injec-
tion of 100 µg of collagen type II dissolved in 
phosphate buffered saline (PBS). 
To evaluate systemic effects of sIL-1RAcP 
and IL-1Ra on development of CIA, we 
applied adenoviral delivery of the transgenes 
to immunized mice. We injected 3x108 pfu 
of adenoviral vector intravenously in immu-
nized mice without clinical signs of CIA, at 
the onset of arthritis (day 22–24). Peri-arti 
cular arthritic development of the hind paw 
and ankle joint was macroscopically moni-
tored till day 38 at which the experiment 
was terminated and the mice were sacriﬁced. 
Arthritis was scored by two independent 
observers in a blinded manner on a scale 
ranging from 0-2 for each limb, based on 
redness, swelling and in later stadium anky-
losis was  as follows; 0 - no changes; 0.25 – 1 
to 2 toes red or swollen; 0.5 – 3 to 5 toes red 
or swollen; 0.5 – swollen ankle; 0.5 – swollen 
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footpad; 0.5 – severe swelling and ankylosis. 
Maximal score for each mouse ranged from 
0 to 8 depending on the cumulative score of 
all four paws. Serum was obtained and stored 
for further analysis.
Determination of specific IgG-titers 
against collagen type II IgG2a 
anti-collagen
 Abs titers against bovine CII was deter-
mined through ELISA. Brieﬂy, 96-well 
plates were coated with 10 µg of bovine CII, 
followed by blockage of non-speciﬁc binding 
sites. Serial dilutions of the mouse sera were 
added, followed by incubation with isotype-
speciﬁc goat anti-mouse peroxidase (South-
ern Biotechnology Associates, Birmingham, 
AL) and substrate (5-aminosalicylic acid; 
Sigma). Absorbency was determined at 492 
nm.
Lymphocyte stimulation assay
Splenocytes were obtained from mice 
systemically treated with sIL-1RAcP, IL-
1Ra or injection with the control adenoviral 
vector Ad CMV Luciferase. Mice previously 
immunized against bovine collagen type II, 
were injected with the adenoviral vectors. 
Spleens from mice, which already developed 
CIA, were used for lymphocyte proliferation 
assay in the presence or absence of recom-
binant mouse IL-1Ra (10 µg/ml). Three 
days after receiving the viral load, mice were 
sacriﬁced and spleens were dissected. Spleens 
were disintegrated and erythrocytes were 
removed by osmotic shock. Remaining cell 
fraction was washed twice and incubated in 
RPMI at 37ºC/5%CO2 for one hour in order 
to remove the splenic adherent cells (SAC) 
fraction. Non-adherent lymphocytic cells 
were used for the lymphocyte stimulation 
assay. Lymphocyte stimulation was deter-
mined against the T-lymphocyte stimulating 
concanavalin A (ConA) and the immuniza-
tion antigen bovine collagen type II (heated 
for 10 minutes at 80ºC). 1x105 thymocytes 
were added to the stimuli and incubated for 
3 days (37ºC/5% CO2). Six hours before 
harvesting the cells, 0.25 µCi of 3H-Thymi-
dine was added. The amount of incorporated 
3H-Thymidine was quantiﬁed using a Micro 
Beta-plate reader (Perkin-Elmer, The Neth-
erlands). 
Isolation of NFκB reporter T- and 
B-lymphocytes 
Spleen lymphocytes were obtained from 
3xNFκB luciferase reporter mice [32]. 
Spleens were disintegrated and erythrocytes 
were removed by osmotic shock. Remaining 
cell fraction was washed twice and incubated 
in RPMI at 37ºC/5% CO2 for one hour in 
order to remove the splenic adherent cells 
(SAC) fraction. Non-adherent lymphocytic 
cells were used for puriﬁcation of T- and B-
cell fraction. T-lymphocytes were obtained 
through negative selection using MACS 
mouse pan T-cell sorting and puriﬁcation 
kit (Miltenyi biotech, Bergisch Gladbach, 
Germany). Unlabeled T-cell fraction was 
collected as efﬂuent by placing separation 
columns in a strong magnetic ﬁeld. Purity 
of isolated T-cells was >96%. Columns were 
repeatedly washed using PBS containing 
0.5% BSA/2 mM EDTA. In order to obtain 
the fraction containing the splenic B-cell, 
columns were removed from the magnetic 
ﬁeld and labeled cell fraction was ﬂushed out 
using PBS 0.5% BSA/2 mM EDTA. Both 
unlabeled T-cell fraction as labeled enriched 
B-cell fraction were washed in PBS 0.5% 
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BSA/2 mM EDTA, centrifuged at 1100 rpm 
for 5 minutes and taken up in RPMI contain-
ing 5% Fetal calf serum and gentamycin. For 
the NFκB activity assay 1x105 T- or B-cells 
were seeded in Krystal 2000 96-wells plates 
(Thermo Labsystems, Brussels, Belgium) in the 
presence of IL-1Ra (1 µg/ml) or sIL-1RAcP 
(1 µg/ml) for 24 hours, followed by a 6 hours 
incubation using 10 ng/ml of IL-1α. NFκB 
activation was quantiﬁed through determina-
tion of intracellular Luciferase production, as 
described previously.
Measurement of IL-6 serum levels
Concentrations of IL-6 in serum was 
determined using the B9-bioassay as described 
before [33]. Brieﬂy, serial dilutions of Serum 
samples were made in culture medium in order 
to quantify IL-6 levels. 5x103 B9 cells were 
added to serum sample dilutions and incu-
bated for 3 days (37ºC/5% CO2). Four hours 
before harvesting the cells were incubated in 
the presence of 0.25 µCi of 3H-Thymidine.
RNA isolation and Quantitative 
PCR analysis. 
Tissue samples from different organs were 
obtained in naive DBA/1 mice and snap frozen 
in liquid nitrogen. Total RNA was extracted 
from these samples using TRIzol reagent, as 
described by Chomcynski and Sacchi [34]. 
NIH 3T3 NFκB reporter ﬁbroblasts, H4 
NFκB reporter chondrocytes or EL.4NOB-1 
NFκB reporter thymocytes were cultured for 
24 hours after which the cells were washed 
with saline and total RNA was extracted using 
TRIzol. Quantitative real time PCR was 
performed using the ABI/Prism 7000 sequence 
detection system (Applied Biosystems, Foster 
City, CA, USA). PCR protocol consisted 
out of; 2 minutes at 50°C and 10 minutes at 
95°C, followed by 40 cycles of 15 seconds at 
95°C and 1 minutes at 60°C. All PCR were 
performed using SYBR green master mix 
(Applied biosystems), 10 ng of cDNA and a 
primer concentration of 300 nmol/L in a total 
reaction volume of 25 µl. Quantiﬁcation of the 
PCR signals was achieved by comparing the 
cycle threshold value (Ct) of the gene of inter-
est of each sample with the Ct value of their 
reference gene GAPDH. 
Primer sequences for gene expression 
analysis are for mouse GAPDH (Fw; 5’-
ggcaaattcaaggcaca-3’, Rv; 5’-gttagggggtctc-
gctcctg-3’), mIL-1RI (Fw; 5’-cgaggtccagtgg-
tataagacctgta-3’, Rv; 5’-tcagccacattcctcaccaa-3’) 
mIL-1RII (Fw; 5’-gcaggctattacagatgtgttatgaca-
3’, Rv; 5’-ggatgggttccgtggttgt-3’) and mIL-
1RAcP (Fw; 5’-ttggatacaaggtgtgcatcttc-3’, Rv; 
5’-gctgagggtctcatctgtgaca-3’).
Statistical analysis
Non-linear regression analysis was 
performed using GraphPad Prism 4.0 software 
(GraphPad Software Inc.,San Diego, Ca.). 
The dose response curves were analyzed and 
ﬁtted according to a sigmoidal dose response 
model (with variable slope). Signiﬁcance of 
differences was determined using student’s 
t-test or Mann-Whitney U test (GraphPad 
Prism, San Diego CA, USA). P values of 0.05 
or less were regarded as signiﬁcant.
Results
Adenoviral mediated 
overexpression of sIL-1RAcP and 
IL-1Ra ameliorates CIA
Both adenoviral vectors were validated 
and gene transfer resulted in high produc-
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tion of sIL-1RAcP and IL-1Ra as described 
previously [24;35] For sIL-1RAcP systemic 
overexpression resulted circulating amounts 
of sIL-1RAcP up to 900 ng/ml three days 
after injection of the adenoviral vector [24]. 
Prophylactic treatment through systemic 
overexpression of both sIL-1RAcP and IL-
1Ra resulted in a marked reduction of the 
disease severity in both front and hind paws 
which was signiﬁcant at day 30 till day 38 
(Figure 1A). Although sIL-1RAcP treat-
ment reduced severity of arthritis, progres-
sion was still evident. This was in contrast 
to systemic IL-1Ra gene transfer, which 
arrested development of CIA.
sIL-1RAcP treatment reduced 
circulating levels of anti-BCII IgG’s 
and IL-6
Systemic overexpression of sIL-1RAcP in 
mice after immunization resulted in a signif-
icant reduction of circulating levels IgG2a 
antibodies directed against BCII seven days 
Figure 1. Eﬀects of sIL-1RAcP and IL-1Ra gene therapy in CIA
A; Systemic overexpression of either sIL-1RAcP or IL-1Ra resulted in a clear 
reduction of the collagen-induced arthritis, which was signiﬁcant at day 30 
till 38 for both treatments.  Mice were systemically injected with 3x108 pfu 
of the adenoviral vector at day 22 and severity was scored as described in 
material and methods. Data are means±SE of four individual experiments 
using at least 10 mice per treatment group per experiment. B; Both sIL-1RAcP 
and IL-1Ra treatment reduced circulating levels of anti bovine collagen type 
II IgG2a. Data were obtained from mice suﬀering from CIA at seven days af-
ter adenoviral injection with sIL-1RAcP or IL-1Ra. Data are absorbances (OD 
492 nm) of BCII antibodies in individual serum measurements of six mice 
per group. Mean absorbencies are indicated per group. C; Three days after 
systemic injection of either the control Ad Luciferase, Ad sIL-1RAcP , or Ad 
IL-1Ra spleen lymphocytic proliferative activity was determined. Systemic 
treatment of mice suﬀering from CIA using IL-1Ra showed a clear reduction 
of both lymphocyte proliferative activity towards the immunization antigen 
BCII and the mitogen ConA. No eﬀect on lymphocyte proliferative activity was observed in the sIL-1RAcP treated animals. Data are mean stimulation index±SE of spleen 
derived lymphocytes of individually treated mice (n=3 per group) measured in quadruple. * P<0.05; ** P<0.01, using student’s t-test (A and C) or Mann-Whitney U 
test (B).
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valin A. Recombinant IL-1Ra (10 µg/ml) 
signiﬁcantly inhibited the Con A induced 
lymphocyte proliferation in vitro with 
47% and 53% at concentrations of ConA 
of respectively 1.25 and 0.6 µg/ml. This 
revealed the importance of IL-1 in lympho-
cyte function and conﬁrmed our in vivo data 
of IL-1Ra as a functional antagonist of T-
cell proliferative activity. Interestingly, and 
in contrast to IL-1Ra, a high dose of sIL-
1RAcP (10 µg/ml) was not able to inhibit 
lymphocyte activity. 
sIL-1RAcP inhibits IL-1 signaling 
on B-cells not T-cells
The different effect of sIL-1RAcP treat-
ment on immunity, in which sIL-1RAcP 
mainly inhibited humoral immunity, with-
out affecting T-cell function, could be 
reﬂected by a discrepancy of sIL-1RAcP 
inhibition of IL-1 signaling on T- and B-
cells. To demonstrate that in vivo effects 
of sIL-1RAcP were the result of a direct 
effect of sIL-1RAcP induced modulation 
of IL-1 signaling on B-cells, we tested 
the IL-1 responsiveness of T- and B-cells 
in the presence or absence of sIL-1RAcP 
using IL-1Ra as a control. Puriﬁed T- and 
B-cell populations derived from transgenic 
mice, expressing a 3xNFκB reporter gene 
showed to be sensitive to IL-1Ra treatment, 
which resulted in a reduced NFκB activity 
upon IL-1 stimulation (Figure 2). Interest-
ingly, incubation with a similar dose of sIL-
1RAcP in the presence of IL-1 did not affect 
NFκB activation in puriﬁed T-cell popula-
tions, whereas the enriched B-cell fraction 
showed to be sensitive towards sIL-1RAcP 
treatment (Figure 2). 
thereafter (Figure 1B). 
Therapeutic intervention using IL-1Ra 
also resulted in a signiﬁcant reduction 
of circulating IgG2a BCII antibodies 
(Figure 1B). Reduced levels of the B-cell 
activating cytokine IL-6 preceded the 
observed reduction of circulating anti BCII 
IgG levels, which was evident three days 
after either sIL-1RAcP or IL-1Ra adenovi-
ral injection. IL-6 levels were determined in 
serum of at least three treated animals per 
group (mean±SE), which were respectively 
control treated 527±47 pg/ml; sIL-1RAcP 
188±31 pg/ml, (P<0.05 versus control); IL-
1Ra 217±23 pg/ml, (P<0.05 versus control).
sIL-1RAcP does not affect 
lymphocyte activity, in contrast to 
IL-1Ra
Splenocytes were isolated from bovine 
collagen II immunized mice three days 
after systemic injection with either Ad 
sIL-1RAcP, Ad IL-1Ra or the control 
vector Ad luciferase. Lymphocytes obtained 
from IL-1Ra treated animals showed a 
signiﬁcantly reduced overall proliferative 
response towards the immunization anti-
gen BCII and the mitogen conA. Although 
both IL-1Ra and sIL-1RAcP ameliorated 
CIA, sIL-1RAcP treatment did not reduce 
lymphocyte proliferative activity, in contrast 
to IL-1Ra treatment (Figure 1C). 
To conﬁrm that sIL-1RAcP, contrary 
to IL-1Ra was unable to inhibit lympho-
cyte proliferation we performed an in vitro 
experiment using spleen derived T lympho-
cytes from untreated CIA DBA/1 mice. 
These lymphocytes were cultured in the 
presence or absence of either recombinant 
IL-1Ra or sIL-1RAcP protein and stimu-
lated with the pan T-cell activator concana-
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Availability of the membrane IL-1RAcP 
accounts for the effectiveness of the 
sIL-1RAcP to inhibit IL-1 signaling 
T- and B-cell populations expressed all 
three IL-1 receptor sub-types. Interest-
ingly, B-cells highly expressed the IL-1RII, 
revealing 21 times more IL-1RII mRNA 
compared to the IL-1RI, while T-cells 
expressed 5 times more IL-1RII compared 
to the IL-1RI (Figure 2A). The levels of 
expression of the different types of IL-1 
receptors may contribute antagonistic activ-
ity of sIL-1RAcP. Therefore we wanted to 
further substantiate the mechanism of action 
in vitro using NFκB reporter cell lines. For 
these experiments the reporter cell lines 
were characterized on their expression of the 
IL-1RI, IL-1RII and IL-1RAcP. 
Detection of the IL-1 receptor compo-
nents on cell lines using immunohistochem-
istry or FACS analysis was futile due to low 
surface expression of all three IL-1  receptor 
components, which hampered their detec-
tion. Therefore we used the more sensitive 
QPCR for analysis of mRNA expression. 
On H4-chondrocytes, which compared 
to B-cells also highly express the IL-1RII 
(Figure 3A), sIL-1RAcP efﬁciently inhibited 
IL-1 signaling. A concentration of 1000 ng/
ml sIL-1RAcP inhibited the IL-1 (10 ng/ml) 
response with 47%, whereas the maximal 
observed inhibition was ranging from 100 ng 
to 10.000 ng/ml were tested, with a maximal 
observed inhibition of 88% at a concentra-
tion of 10.000 ng/ml sIL-1RAcP (Figure 
3C). On EL4.NOB-1 Thymoma cell line 
which expressed very low, to nearly detect-
able amounts of the IL-1RII (Figure 4A) sIL-
1RAcP was even at the highest tested concen-
tration of 10.000 ng/ml unable to inhibit 
IL-1 induced NFκB activity (Figure 4C). In 
contrast to the EL4.NOB-1 thymocyte and 
the H4 chondrocyte, the NIH 3T3 cell line 
showed no mRNA expression of IL-1RII and 
low expression of the membrane IL-1RAcP 
(Figure 5A). Yet, these cells clearly revealed 
Figure 2. sIL-1RAcP reduces NFκB activity in puriﬁed B-cells
Purified spleen T- and B-cells from BCII immunized DBA/1 mice were ana-
lyzed on their relative expression of mRNA encoding for the IL-1RI, IL-1RII 
and the IL-1RAcP. Relative expression shown in figure A was determined 
by quantitative PCR. In between parenthesis is the relative expression 
compared to the IL-1 R type I. Ct values were corrected for the housekeep-
ing gene GAPDH and expressed as 2e-∆CT (x10-4). Quantitative analysis was 
performed after 35 PCR cycli. The data are mean expression of two samples 
and SD was less than 0.5 cycle for each primer set. Figure B shows the IL-1 
responsiveness of isolated T-cells from spleens of 3xNFκB reporter mice in-
cubated in the presence of IL-1Ra. A marked reduction of IL-1 induced NFκB 
activation could be observed in T-cells incubated with 1000 ng/ml IL-1Ra, 
which could not be observed in sIL-1RAcP treated T-cells. In contrast to T-
cells, splenic B-cells were both sensitive towards IL-1 inhibition by IL-1Ra 
and sIL-1RAcP, which resulted in a marked reduction of IL-1 induced NFκB 
activity in these cells. Data are presented as relative light units±SD of at 
least four measurements per group.
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to be susceptible towards IL-1 inhibition by 
sIL-1RAcP, in a dose-dependent fashion, 
revealing a 48% inhibition of the IL-1 acti-
vation at a concentration of 1000 ng/ml in 
the presence of 10 ng/ml IL-1. On all three 
reporter cell lines a 1000-times excess of IL-
1Ra (1000ng/ml IL-1Ra in the presence of 1 
ng/ml IL-1α) was able to completely inhibit 
IL-1 induced NFκB activity.
Discussion
Membrane IL-1RAcP is a crucial 
component of the IL-1 signaling complex, 
stabilizing the IL-1/IL-1RI complex and 
mediating IL-1 signaling [7,16,17,36]. The 
recently discovered natural occurring alter-
native splice transcript of the membrane 
IL-1RAcP, is comprised out of the three 
extracellular Ig-like domains [4,22,23]. Due 
to the conservation of the ligand binding 
domains of the sIL-1RAcP, this molecule 
may still share the receptor complex stabiliz-
ing function, thereby acting as an inhibitor 
of IL-1 signaling through formation of an 
IL-1 trap. This action of sIL-1RAcP could 
therefore be distinct from IL-1Ra mediated 
inhibition of IL-1 signaling, since binding 
of IL-1Ra to the IL-1RI does not lead to 
recruitment of the IL-1RAcP [4,37,38]. In 
this study we compared the effect of both 
inhibitors in collagen-induced arthritis.
Adenoviral mediated transfer of 
sIL-1RAcP or IL-1Ra gene intravenously 
resulted in a clear-cut protective effect on 
bone and cartilage in the murine CIA as was 
shown previously [20,21,24,25]. Accord-
ingly, we expected similar effects of both 
inhibitors on the parameters of immunity 
and inﬂammation. Indeed, both inhibitors 
Figure 3. sIL-1RAcP inhibits IL-1 induced NFκB activity in cells express-
ing IL-1R type II
H4 NFκB reporter chondrocytes expressing the IL-1R type II show (A) are sus-
ceptible for IL-1 inhibition by both IL-1Ra (B) and sIL-1RAcP (C). Diﬀerent con-
centrations of either IL-1Ra or sIL-1RAcP were incubated for twenty-four hours, 
followed by six hours of incubation with IL-1 in dose-response (B) or 10 ng/ml 
(C) on NFκB luciferase H4 chondrocytes. Relative expression was determined 
by quantitative PCR. In between parenthesis is the relative expression com-
pared to the IL-1 R type I. Ct values were corrected for the housekeeping gene 
GAPDH and expressed as 2e-∆CT (x10-4). Quantitative analysis was performed 
after 35 PCR cycli. The data are mean expression of two samples and SD was 
less than 0.5 cycle for each primer set. IL-1 induced NFκB response was quanti-
ﬁed as Relative Light Units (RLU). The data are representative of two experi-
ments with similar result and presented as mean±SD of triplicate measure-
ments for IL-1Ra dose-response curves and mean±SD (n=6) per concentration 
antagonist for sIL-1RAcP. * P<0.05 / ** P<0.01 using students’ t-test
86
C
ha
pt
er
 1
C
ha
pt
er
 4
Eﬀects of sIL-1RAcP and IL-1Ra in CIA
Figure 5. sIL-1RAcP inhibits IL-1 induced NFκB activity in cells ex-
pressing relatively low IL-1RAcP and no IL-1R type II 
NIH 3T3 NFκB reporter ﬁbroblast cells showed no detectable expression 
of the IL-1R type II after 40 cycles of PCR, and a relative low expression of 
the IL-1RAcP (A). These reporter cells were susceptible for IL-1 inhibition by 
both IL-1Ra (B) and sIL-1RAcP (C). Diﬀerent concentrations of either IL-1Ra 
or sIL-1RAcP were incubated for twenty-four hours, followed by six hours of 
incubation with IL-1 in doseresponse (B) or 10 ng/ml (C) on NFB luciferase 
EL4.NOB-1 thymocytes. Relative expression was determined by quantitative 
PCR. In between parenthesis is the relative expression compared to the IL-1 
R type I. Ct values were corrected for the housekeeping gene GAPDH and ex-
pressed as 2e-∆CT (x10-4). Quantitative analysis was performed after 35 PCR 
cycli. The data are mean expression of two samples and SD was less than 
0.5 cycle for each primer set. IL-1 induced NFκB response was quantiﬁed as 
Relative Light Units (RLU). The data are representative of two experiments 
with similar result and presented as mean±SD of  triplicate measurements 
for IL-1Ra dose-response curves and mean±SD (n=6) per concentration an-
tagonist for sIL-1RAcP. ** P<0.01 using students’ t-test
Figure 4. sIL-1RAcP does not inhibit IL-1 induced NFκB activity in cells 
expressing high IL-1RAcP andrelatively no IL-1R type II
EL4.NOB-1 NFκB reporter thymoma cells showed practically no expression 
of the IL-1R type II, while a relative high expression of the IL-1RAcP could 
be observed (A). These reporter cells were susceptible for IL-1 inhibition by 
IL-1Ra (B) but not sIL-1RAcP (C). Diﬀerent concentrations of either IL-1Ra or 
sIL-1RAcP were incubated for twenty-four hours, followed by six hours of 
incubation with IL-1 in dose-response (B) or 10 ng/ml (C) on NFκB lucifer-
ase EL4.NOB-1 thymocytes. Relative expression was determined by quanti-
tative PCR. In between parenthesis is the relative expression compared to 
the IL-1 R type I. Ct values were corrected for the housekeeping gene GAPDH 
and expressed as 2e-∆CT (x10-4). Quantitative analysis was performed after 
35 PCR cycli. The data are mean expression of two samples and SD was 
less than 0.5 cycle for each primer set. IL-1 induced NFκB response was 
quantiﬁed as Relative Light Units (RLU). The data are representative of two 
experiments with similar result and presented as mean±SD of triplicate 
measurements for IL-1Ra dose-response curves and mean±SD (n=6) per 
concentration antagonist for sIL-1RAcP.
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reduced circulating levels of antigen speciﬁc 
IgG and IL-6, a well-known B-cell activating 
and maturating cytokine [39]. This observa-
tion is in line with IL-1 being an adjuvant 
for antibody production [40,41]. In contrast, 
IL-1Ra gene transfer in mice inhibited both 
mitogen- and antigen-induced lymphocyte 
proliferation, whereas sIL-1RAcP gene 
transfer has no effect on this parameter. It is 
known that IL-1 plays an important role in 
the activation of T-lymphocytes in CIA [42]. 
Furthermore, the proliferative activity of 
T-cells is enhanced in IL-1Ra-/- mice, while 
decreased in IL-1α/β-/- mice underlining the 
importance of IL-1 in T-cell activation and 
proliferation [43,44]. However, this unex-
pected discrepancy on T-cell modulation 
could be due differences in pharmacokinet-
ics of both IL-1 inhibitors. Therefore, we 
tested both inhibitors in vitro using recombi-
nant protein. Splenocytes from mice suffer-
ing from CIA were obtained and incubated 
with either sIL-1RAcP or IL-1Ra. Recom-
binant IL-1Ra reduced mitogen speciﬁc 
T-cell proliferation in contrast to sIL-1RAcP, 
which did not affect the T-cell proliferative 
response. Likewise, in experiments using 
enriched T- and B-cell populations from 
NFκB reporter mice, sIL-1RAcP inhibited 
IL-1 induced NFκB activity in B-cells but 
had no effect on IL-1 signaling in T-cells. 
Notably, IL-1Ra inhibited IL-1 induced 
NFκB activity in both T- and B-lympho-
cytes. These results conﬁrmed the selective 
mode of action of sIL-1RAcP compared 
to IL-1Ra as observed in vivo. A possible 
explanation is that sIL-1RAcP acts as an IL-1 
antagonist by of competing for the association 
with the IL-1RI with membrane IL-1RAcP. 
Therefore, differential expression of the IL-1 
receptor components between cell types 
could determine the antagonistic activity of 
sIL-1RAcP. This was further emphasized by 
the fact that T- and B-cell populations are 
known to differ in their receptor expression 
[15,45]. B-cells derived from BCII immu-
nized mice revealed abundant expression of 
the IL-1RII, in contrast to puriﬁed T-cells.
To elucidate the mechanism behind 
the cell-speciﬁc antagonistic activity of 
sIL-1RAcP we compared three NFκB lucif-
erase reporter cell lines that differ in their IL-
1 receptor composition (IL-1R expression in 
relation to antagonist activity is summarized 
in table I). We demonstrated that sIL-1RAcP 
was able to inhibit IL-1 induced NFκB acti-
vation in cell lines that either express low 
levels of membrane IL-1RAcP or high levels 
of IL-1RII. It has already been shown that 
membrane anchored sIL-1RAcP functions as 
a co-receptor competitive IL-1 inhibitor [23]. 
These same authors were however unable to 
observe IL-1 inhibition using sIL-1RAcP on 
HepG2 cells, which they explained to be the 
result of a low sIL-1RAcP concentration at 
membrane level. Alternatively, the inability 
of sIL-1RAcP to inhibit IL-1 signaling on 
HepG2 cells could be a consequence of the 
high expression of membrane IL-1RAcP 
[46] in comparison to the low expression on 
NIH3T3 ﬁbroblasts on which we were able 
to induce sIL-1RAcP mediated IL-1 antago-
nism.
Taken together, our results show that the 
underlying mechanism of cell-speciﬁcity is 
most probably dependent on the availability 
of the membrane IL-1RAcP for IL-1 signal-
ing. As already mentioned, sIL-1RAcP can 
interact with the soluble IL-1RII, thus form-
ing an IL-1 scavenging molecule [26]. Hence, 
the formation of this IL-1 trap together with 
the observed inhibition of IL-1 at the cell 
membrane are both mechanisms of IL-1 
antagonism, which could operate simultane-
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ously in vivo. We observed IL-1 antagonism 
by sIL-1RAcP on cells, highly expressing 
the IL-1RII (B-cells and H4 chondrocytes). 
Since we can not exclude the formation of 
a membrane bound IL-1 decoy receptor 
comprised out the IL-1RII and sIL-1RAcP, 
this could still be an optional mechanism 
of IL-1 antagonism on cells expressing high 
levels of IL-1RII. However, the IL-1RII 
can also indirectly determine the availability 
of the IL-1RAcP. The amount of IL-1RII 
expression on the membrane determines the 
sensitivity of the cell towards IL-1 and the 
membrane IL-1RAcP is able to interact with 
the IL-1RII [18,47]. Therefore, abundant 
expression of the IL-1RII will not only lead 
to scavenging of IL-1, but will also reduce 
the available IL-1RAcP to form a signaling 
complex with the type I receptor, shifting 
the balance in favor of the sIL-1RAcP for 
receptor competition with the IL-1RAcP 
for receptor complex formation with the IL-
1RI.
This study provides evidence for an 
additional antagonistic mechanism by 
which sIL-1RAcP could directly inhibit 
IL-1 signaling at cell membrane level. 
Due to the distinct action of sIL-1RAcP 
compared with IL-1Ra, both function-
ally and mechanistically, combining both 
Table 1. Summary of mRNA expression analysis of IL-1R type I, type II and the IL-1RAcP on cells in relationto their sensitivity towards IL-1 antagonism 
by either IL-1RA or sIL-1RAcP
Expression of the IL-1 Receptor components was determined on puriﬁed spleen T- and B-cells from BCII immunized DBA/1 mice and the NIH 3T3 ﬁbroblast, EL4.NOB-1 
thymocyte and the H4 chondrocyte by QPCR. Because of the discrepancy on receptor component expression on T- and B-cells compared to the reporter cell lines a 
diﬀerent a classiﬁcation was used. T/B cell classiﬁcation (2e-∆CT (x10e-4) <10 = - ; 10-100 = +/- ; 100-300 = + ; 300-1000 = ++; 1000-3000 = +++ ). Classiﬁcation 
for receptor expression on reporter cells (2e- ∆CT (x10e-4) <0.1 = - ; 0.1-1 = +/- ; 1-3 = + ; 3-10= ++; 10-30> = +++ ; N.D= not detectable after 40 cycles of  PCR.) 
* IL-1 inhibition determined at a concentration of 1000 ng/ml antagonist over 10 ng/ml agonist. a) IL-1 inhibition determined at a concentration of 100 ng/ml IL-1Ra 
over 1 ng/ml IL-1α.
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antagonists offers additive therapeutic 
effects [25]. With the sIL-1RAcP we can 
now discriminate between the role of IL-1 
in T- and B-cell driven processes, and this 
may have therapeutic opportunities in 
disease in which B-cell derailment plays a 
prominent role.
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Combination of sIL-1RAcP with IL-1Ra
In this study we investigated the IL-1 antagonistic potential of soluble IL-1RAcP and evaluate the possible therapeutic application in experimental arthritis either alone or in combination with IL-1Ra 
Previously we showed that puriﬁed sIL-1RAcP was able to inhibit up to 60% of the IL-1 induced NFκB 
activation in vitro. Furthermore, systemic adenoviral delivery of sIL-1RAcP ameliorated collagen-
induced arthritis (CIA) in mice and histology showed signiﬁcant reduction in both joint inﬂammation 
and destruction. In this study we show that addition of sIL-1RAcP to sub-optimal concentrations of 
IL-1RA almost completely blocked IL-1 signaling in vitro. Adenoviral delivery of both inhibitors during 
CIA was eﬃcacious in pilot studies. These results show that sIL-1RAcP is an active inhibitor of IL-1, 
functional in experimental arthritis. Furthermore, we show that IL-1 inhibition by sIL-1RAcP can act 
in addition to IL-1 inhibition by IL-1RA. This additive inhibition of IL-1 by sIL-1RAcP in combination 
with IL-1Ra was non-competitive, creating new opportunities for combination strategies.
Several members of the IL-1 superfamily are 
known today, including the agonists IL-1α, IL-
1β and the IL-1 receptor antagonist (IL-1Ra). A 
co-receptor molecule crucial for IL-1 signaling 
was described, named the IL-1Receptor Acces-
sory Protein (IL-1RAcP) [1]. Upon binding 
of IL-1 to the IL-1R type I this co-receptor 
is recruited to form a high afﬁnity recep-
tor complex, which initiates the intracellular 
signaling cascade [2]. Recently, a soluble form 
of IL-1RAcP has been described which lacks 
the transmembrane and intracellular regions 
crucial for IL-1 signaling [3]. This soluble 
IL-1RAcP has been postulated to be a novel 
contributor to the antagonism of IL-1 [4].
IL-1 plays an important role in arthritis 
affecting bone and cartilage. From IL-1 inhibi-
tion studies in experimental arthritis it appeared 
that in order to achieve complete inhibition of 
IL-1 a 100 to 1000-fold excess of IL-1Ra is 
required [5]. The aim of the present study was 
to demonstrate the potential of sIL-1RAcP as a 
novel antagonist of IL-1 and evaluate possible 
therapeutic application in experimental arthritis 
either alone or in combination with IL-1Ra. 
Materials and Methods
Luciferase bio-assay 
The ability of sIL-1RAcP to inhibit IL-
1 signaling was tested on IL-1 responsive 
NIH 3T3 NFκB luciferase reporter cells. 
One day prior to experiments reporter cells 
were seeded at a concentration of 2-4x104 
cells/96-well. Experimental design; cells 
were pre-incubated for 24 hours with the 
sIL-1RAcP (0.1, 1 and 10 µg/ml) in the pres-
ence or absence of IL-1Ra (0.3 or 1 µg/ml) 
followed by addition of different concentra-
tions murine recombinant IL-1α (1 or 10 
ng/ml). Six hours later, IL-1 induced NFκB 
activation was determined as intra-cellular 
luciferase expression. All in vitro tests were 
performed with recombinant sIL-1RAcP 
and IL-1Ra.
 Adenoviral Vectors 
The sIL-1RAcP and IL-1Ra adenoviral 
vectors were E1A, B and E3 deleted and 
produced according to the method described 
by Chartier et al [6]. The transgenes were 
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under regulation of a CMV promoter. 
Induction of collagen-induced 
arthritis(CIA) 
DBA/1 mice were immunised at day 0 
and 21 [4]. Combination studies (Table 1) 
were started during onset of arthritis (around 
day 22-24). To evaluate systemic effects of 
sIL-1RAcP and IL-1Ra on development of 
CIA, we applied adenoviral delivery of both 
transgenes. In both experimental designs 
Ad luciferase was used as control treatment 
(Table 1). All mice received equal viral load 
of 3.3x108 pfu. 
Peri-articular development of arthritis in 
the hind paw and ankle joint was macroscopi-
cally scored by two independent observers in 
a blinded manner using a scale ranging from 
0-2 for each limb, resulting in a cumulative 
maximal score of 8. 
Statistical analysis 
Signiﬁcance of differences was determined 
using Student’s t-test or Mann-Whitney U 
test. P values of 0.05 or less were regarded as 
signiﬁcant.
Results and Discussion
Preincubation of the sIL-1RAcP followed 
by IL-1α stimulation revealed a signiﬁcant 
dose-dependent inhibition of IL-1. No effect 
of sIL-1RAcP was observed on TNFα medi-
ated signaling, thus proving IL-1 speciﬁc-
ity. Systemic overexpression of sIL-1RAcP 
through adenoviral delivery of the transgene 
in mice resulted in a marked amelioration of 
CIA, which is an IL-1 dependent model [7]. 
This amelioration was observed as an over-
all protection of the joints against erosive 
destruction [8]. After proving functionality 
of sIL-1RAcP as an inhibitor of IL-1 and a 
functional modulator of CIA we compared 
the potency of this novel inhibitor towards 
IL-1Ra. Therefore we characterised the 
inhibitory capacity of each protein at equi-
molar ratio, of 0.3 µg/ml for IL-1Ra and 
1 µg/ml for sIL-1RAcP. Both IL-1Ra and 
sIL-1RAcP incubation in the presence of 1 
ng/ml IL-1 resulted in a signiﬁcant inhibi-
tion of the IL-1 response, with similar IL-1 
Figure 1. Equimolar dosages of IL-1Ra and sIL-1RAcP results in similar 
IL-1 inhibitory potencies.
NIH 3T3 NFκB  luciferase reporter cells were  pre-incubated with sIL-1RAcP 
(1 µg/ml) or IL-1Ra (0.3 µg/ml) for 24 hours, followed  by addition of  IL-1α 
(1 ng/ml). Six hours thereafter IL-1 induced NFκB- activity was determined 
through luminometric quantiﬁcation of intracellular luciferase activity (RLU). 
Data are  presented as mean±SD of six individual assays per agonist/antago-
nist. *P<0.05 using students’ t-test.
Table 1. Experimental design of combination treatment in vivo
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inhibitory potencies (Figure 1). 
Co-incubation of a standard dose of IL-
1Ra (0.3 µg/ml) with varying dosages of sIL-
1RAcP revealed a signiﬁcant and an additive 
inhibition of IL-1 signaling. This additive 
effect of IL-1Ra was prominent at 1 µg/ml 
sIL-1RAcP and resulted in a 80% inhibition 
of IL-1 (Figure 2). 
After showing in vitro efﬁcacy of combin-
ing both IL-1Ra and sIL-1RAcP in IL-1 
inhibition, we validated combination treat-
ment in the CIA. Both systemic overexpres-
sion of IL-1Ra and sIL-1RAcP resulted in a 
marked reduction of CIA severity. Moreover, 
combination of Ad IL-1Ra with Ad sIL-
1RAcP further ameliorated CIA, which was 
signiﬁcant from day 28 till day 36 (Figure 
3), illustrating additive effects in vivo.  To 
unravel the mechanism of action by which 
sIL-1RAcP modulates CIA we evaluated 
the effects of sIL-1RAcP on immunological 
parameters of T- and B- cell function. Due to 
the importance of IL-1 in T-cell functioning 
we tested the effect of sIL-1RAcP on antigen 
(collagen type II) speciﬁc T-cell proliferation. 
In contrast to IL-1Ra, sIL-1RAcP was unable 
to inhibit antigen speciﬁc proliferation of T-
cells measured by 3H-thymidine incorpora-
tion. This result indicated that sIL-1RAcP 
did not directly affect T-cell function, which 
revealed an action distinct from IL-1Ra. To 
assess the effect of sIL-1RAcP on B-cell 
function, which is also an important factor 
in induction of CIA we determined collagen 
Figure 2. Co-incubation of IL-1Ra with varying dosages of sIL-1RAcP 
results in a signiﬁcant additive inhibition of IL-1
NIH 3T3 NFκB  luciferase reporter cells were  pre-incubated with varying dos-
ages of sIL-1RAcP  (0.1, 1  or 10 µg/ml) in the presence or absence of  IL-1Ra 
(0.3 µg/ml) for 24 hours, followed  by addition of  IL-1α  (1 ng/ml). Six hours 
thereafter IL-1 induced NFκB  activity was determined through luminometric 
quantiﬁcation of intracellular luciferase activity (RLU).   Data are  presented 
as mean±SD of six individual assays per agonist/antagonist. *P<0.05 using 
students’ t-test.
Figure 3. Signiﬁcant amelioration 
of CIA after systemic adenoviral 
mediated overexpression of IL-1Ra 
with sIL-1RAcP 
Systemic injection of 3x108  pfu Ad 
sIL-1RAcP in combination with 3x107 
pfu Ad IL-1Ra resulted in signiﬁcant 
amelioration of the CIA, in both front 
and hind paws of treated mice. Data 
are mean±SD using at least 10 mice 
per treatment group. *P<0.05 control 
versus combination using Mann-Whit-
ney U test
102
C
ha
pt
er
 1
C
ha
pt
er
 5
Combination of sIL-1RAcP with IL-1Ra
speciﬁc antibody titers (anti-BCII-IgG) in 
the serum of sIL-1RAcP treated animals at 
time of sacriﬁce.  Results from these experi-
ments showed a marked reduction in total 
anti-BCII-IgG (including isotype 1 and 2a) 
in sIL-1RAcP treated animals, while IL-1Ra 
treatment showed no clear effect on anti-
BCII-IgG titers. Taken together, from these 
later experiments it appears that sIL-1RAcP 
is able to affect B-cell function, but not 
T-cell function. This in contrast to IL-1Ra, 
which predominantly affects T-cell function. 
In vitro and in vivo studies revealed addi-
tive and non-competitive action between 
sIL-1RAcP and IL-1Ra. Both inhibitors 
have a different mode of action; IL-1Ra 
inhibits IL-1 action by competing with IL-1 
for the IL-1R type I [9], thus acting on all 
IL-1R type I. sIL-1RAcP competes with 
membrane bound IL-1RAcP for interaction 
with IL-1 bound to the IL-1RI. IL-1RAcP 
itself cannot bind IL-1 or IL-1Ra, therefore 
both inhibitors can act independently from 
each other in a non-competitive manner [1] 
(Figure 4).
 The differences between IL-1Ra and sIL-
1RAcP as observed on T and B-cell function, 
suggests an even more complex mechanism 
of in vivo interference, which might be due to 
differences in expression levels of IL-1 recep-
tor subtypes on different cells.
With this study we identiﬁed that 
sIL-1RAcP is an inhibitor of IL-1 signal-
ing, functional in experimental arthritis and 
as equipotent as IL-1Ra. Furthermore, we 
show that combination of both inhibitors 
results in clear-cut additional inhibition of 
IL-1 signaling and severity of CIA. More 
interestingly, we describe a novel inhibitor 
of IL-1, which is functionally distinct from 
IL-1Ra.
Figure 4.  Suggested mechanism of IL-1 antagonsim by sIL-1RAcP and IL-1Ra.
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Interleukin-18 (IL-18) is a pleiotropic 
member of the IL-1 cytokine family, which 
was originally described as IFNγ-inducing 
factor 1. Synergistically with IL-12, IL-18 
exhibits a strong Th1-promoting activity 
[2,3]. Production of this pro-inﬂammatory 
cytokine induces IFNγ, TNFα and IL-1β 
secretion and enhances cytotoxic activity of 
NK cells [4-6]. A broad range of immuno-
regulatory cells, including activated macro-
phages and dendritic cells but also stromal 
like cells such as keratinocytes and osteoblasts 
can produce IL-18 [7-9]. Similar to IL-1, 
IL-18 is present in cells as a precursor protein, 
which has to be cleaved to an 18 kDa mature 
glycoprotein by Interleukin-1β convert-
ing enzyme (ICE, caspase-1). Initiation of 
intracellular signaling by secreted IL-18 
starts with the formation of a high afﬁn-
ity receptor complex, comprising out of the 
IL-18 binding α-receptor chain (IL-18Rα) 
and the β-chain (IL-18Rβ), which itself can 
not bind IL-18 [10,11]. Dimerization of both 
receptor units upon IL-18 binding results in 
activation of intracellular signal transduc-
tion pathways induced by recruitment of the 
adapter protein MyD88 towards the receptor 
complex, followed by binding of Interleukin 
receptor activated kinase (IRAK) and TNF 
receptor associated factor-6 (TRAF-6). The 
formation of this activation complex of the 
IL-18 signal cascade ﬁnally leads to down-
stream NFκB-mediated activation of tran-
scription [2]  
Recently, a novel physiological inhibi-
tor of IL-18 signaling has been discovered. 
This inhibitor, called Interleukin-18 binding 
protein (IL-18BP) is a protein with the abili-
ty to bind and neutralize IL-18 [12]. IL-18BP 
is a non-membrane bound protein, which 
Elevated concentrations of Interleukin-18 (IL-18) are found in both serum and synovial ﬂuid of patients suﬀering from Rheumatoid Arthritis (RA) and this cytokine has recently been implicated in the development of experimental arthritis.  In this present study, we developed an IL-18 neutral-
izing intervention and examined its eﬃcacy for local intra-articular treatment of experimental 
arthritis. 
 To this end we constructed an adenoviral vector containing the murine IL-18 Binding Protein 
isoform c gene (AdCMVIL-18BPc). The constructed adenoviral vector was validated on replication 
deﬁciency, transfection eﬃcacy and ability to express biological functional IL-18BPc. Intra-articu-
lar overexpression of IL-18BPc signiﬁcantly reduced incidence of collagen-induced arthritis (CIA) 
in treated kneejoints. Aﬀected kneejoints of IL-18BPc treated mice showed less severe arthritis, 
characterised by reduction of inﬂammation and destruction of bone and cartilage. Local intra-
articular IL-1BPc treatment in both knees provided additional protection against CIA incidence 
and severity in distal paws. Measurement of serum levels of speciﬁc collagen type II antibodies 
revealed a moderate reduction of circulating IgG2a anti-BCII antibodies, while IgG1 anti-BCII 
antibodies remained at similar level. The present study underlines the involvement of IL-18 as an 
important pro-inﬂammatory cytokine in onset of experimental arthritis. Furthermore, it shows 
that endogenous IL-18 can be blocked eﬃciently through local adenoviral overexpression of IL-
18BPc, indicating that treatment with IL-18BPc might contribute to joint protection in RA.
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has only a single Ig-domain and shows little 
resemblance with the IL-1 receptor family. 
Elevated levels of IL-18BP are found in serum 
of patients suffering from septic shock and 
IL-18BP is expressed in response to IFNγ 
[13]. Several isoforms have been discovered 
resulting from alternative mRNA splicing of 
which IL-18BPa and IL-18BPc exhibit the 
highest afﬁnity towards IL-18 [14]. These 
isoforms are able to neutralize >95% of the 
biological activity of IL-18 at a 1:1 molar ratio. 
The immune modulating role of IL-18BP 
is furthermore underlined by reports of the 
presence of viral forms of IL-18BP, which 
have been located in DNA of poxvirus family 
[15].
As a pro-inﬂammatory cytokine, IL-18 
has been associated with the development of 
several inﬂammatory diseases including RA 
[6]. IL-18 is highly expressed in RA synovium 
and correlates with inﬂammation [16].  Signiﬁ-
cantly elevated concentrations are found in both 
serum [17] and synovial ﬂuid of RA patients 
[18,19], and can be rapidly reduced by anti-
TNFα treatment [20]. Furthermore, the inﬂu-
ential role of IL-18 in experimental arthritis 
was obtained from studies with IL-18-/- mice, 
which showed impaired development of CIA 
[21]. The importance of IL-18 in experimental 
arthritis was furthermore shown in the acute 
streptococcal cell wall (SCW) arthritis animal 
model. Systemic blockage of endogenous IL-18 
through neutralizing signiﬁcantly reduced 
joint inﬂammation probably by reduction of 
local TNFα and IL-1β levels [22]. Systemic 
treatment of CIA with recombinant human 
IL-18BP showed amelioration of arthritis [23]. 
However, IL-18 is involved in both innate and 
acquired immunity during host defence against 
foreign pathogens and systemic neutralization 
could lead to severe impairment of the immune 
response [24]. Therefore, in some situations 
it appears preferable to choose local instead 
of systemic treatment. Studies by Bakker et 
al already showed functionality of local intra-
articular therapy for arthritis using IL-1 recep-
tor antagonist [25,26].
The aim of this present study is to develop a 
therapeutic approach to treat arthritis through 
local neutralization of IL-18. To this end we 
constructed an adenoviral vector containing 
the murine IL-18BP isoform c gene. Local 
treatment with IL-18BP was achieved through 
intra-articular (i.a.) injection of the adenovi-
ral vector before clinical manifestation of the 
CIA.  Here we report that IL-18 is a pivotal 
cytokine during onset of CIA, and that local 
intra-articular treatment with an adenoviral 
vector containing the IL-18BPc gene is a novel 
approach to modulate experimental arthritis. 
Materials and Methods
Animals
Male 10- to 12-weeks old DBA-1/bom 
mice obtained from Bomholdgärd (Ry, 
Denmark). C57/Bl6 mice were bred and 
housed in top-ﬁlter cages at the animal facility. 
Mice injected with adenoviral vectors during 
experiments were housed in low-pressure 
isolator cages. The animals were fed a stan-
dard diet with water and food ad libitum. All in 
vivo studies complied with national legislation 
and were approved by local authorities of the 
Care and Use of Animals with related codes 
of practice.
Construction of IL-18BPc 
Adenoviral vector
The ﬁrst step in construction of a ﬁrst 
generation E1/E3 deleted serotype-5 adeno-
virus was the cloning of the gene of interest. 
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IL-18BPc was copied from isolated murine 
liver cDNA, using a nested primer strategy. 
The 5’ inner primer was modiﬁed to contain 
XhoI restriction site at the 5’ end. The 3’ inner 
primer contained a XbaI site in the 3’ end. 
Recombinant virus was produced according 
to the method described by Vogelstein et al 
[35]. Brieﬂy, a single banded PCR product 
was obtained and subsequently digested 
with XhoI and XbaI before ligation into the 
pShuttle (Stratagene) containing the cyto-
megalovirus (CMV) promoter. Homologous 
recombination of AdEasy-1 viral back-bone 
with the pShuttleCMV containing the IL-
18BPc construct was preformed in BJ 5183 
bacteria after electroporation (BIOrad gene 
pulser). Positive clones were selected and 
recombinant viral vector plasmid was ampli-
ﬁed using JM109 bacteria. Puriﬁed recombi-
nant adenoviral vector DNA was linearised 
through digestion with PacI and transfected 
into 911 viral packaging cells using Lipo-
fectamin 2000 (Invitrogen, Carlsbad, CA, 
USA). Viruses were puriﬁed using 2x CsCl 
gradient puriﬁcation and stored in small 
aliquots at -80ºC.  Replication deﬁciency of 
the virus was determined by PCR and tested 
on HeLa cells. 
Construction of IL-18 responsive 
NFκB Reporter cell line
The IL-18 responsive murine thymoma 
derived T-cell line EL-4D6/76 was used for 
construction of an IL-18 sensitive reporter 
cell line. Brieﬂy, a promoter containing a 
5xNFκB binding site cloned upstream of the 
Luciferase gene was extracted from the pGl3b 
reporter vector, which was a kind gift from 
Prof. Dr. W. Falk (Department of Internal 
Medicine, University of Regensburg, Germa-
ny). The obtained NFκB reporter construct 
was ligated into a promoter-less eukaryotic 
expression vector pcDNA3.1A (Invitrogen, 
Carlsbad, CA, USA). Cells were transfected 
cells using Lipofectamin 2000 (Invitrogen, 
Carlsbad, CA, USA) and selected on stable 
integration with neomycin-G418
Detection of mIL-18BPc through 
immunocytochemistry
To test virus functionality, 2x105 NIH 3T3 
ﬁbroblasts were seeded and transfected for 2 
hours under serum-free culture conditions 
with different MOI’s of AdCMVIL-18BPc 
or the control vector. Following transfec-
tion cells were washed and cultured for 30 
hours in DMEM containing 10% FCS and 
antibiotics. Conditioned supernatants were 
used for in IL-18 inhibition assay (See IL-18 
bio-assay). For intracellular detection of IL-
18BPc, cells were ﬁxed with -20ºC metha-
nol for 15 minutes, followed by 15 minutes 
incubation phosphate buffered saline (PBS) 
containing 0.1% Triton X-100.   After ﬁxa-
tion, cells were incubated for 1 hour at room 
temperature with PBS containing mouse IL-
18BPc speciﬁc polyclonal goat IgG (R&D 
systems Europe, Abingdon, UK). Cells were 
washed 5 times with PBS and incubated for 
1 hour with the second HRP conjugated 
Ab. Intracellular expressed IL-18BPc was 
detected using DAB staining reaction.
Detection of mIL-18BPc by 
immunoblotting
Cell-free 30 hours conditioned superna-
tants of mIL-18BPc transfected cells, lucif-
erase transfected or non transfected controls 
were precipitated using trichloroacetic acid 
(TCA). Brieﬂy, an equal volume of 20% 
TCA was added to the supernatant. After 
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30 minutes incubation at 0ºC, samples were 
centrifuged for 15 minutes at 4ºC (13,000g). 
Pellets were washed in 5% TCA, followed 
by centrifugation. Finally the obtained pellet 
was washed with acetone and resuspended 
in protein sample buffer. TCA precipitated 
proteins were separated using 10% SDS-
PAGE. After blotting IL-18BPc was detected 
using mouse IL-18BPc-speciﬁc polyclonal 
goat IgG (R&D systems Europe, Abingdon, 
UK).
IL-18 bio-assay
The effect of adenoviral overexpression 
of mIL-18BPc on IL-18 was tested using 
IL-18 responsive EL-4D6/76 NFκB reporter 
cells. 2-4x104 reporter cells were incubated 
for 6 hours in the presence of conditioned 
supernatants containing IL-18BPc or control 
supernatants of transfected cells. IL-18 
induced production of luciferase was quanti-
ﬁed using Bright-Glo luciferase assay system 
(Promega, Madison, WI, USA) followed by 
luminometric detection according to manu-
factures protocol (Polarstar galaxy, BMG, 
Offenburg, Germany).
Induction of CIA
Bovine collagen type II was dissolved in 
0.05 M acetic acid to a concentration of 2 mg/
ml and was emulsiﬁed in equal volumes of 
CFA (2 mg/ml of M. tuberculosis strain H37Ra; 
Difco laboratories, Detroid, MI, USA). The 
mice were immunised intra dermal at the 
base of the tail with 100 µl of emulsion (100 
µg of bovine collagen type II). On day 21, 
mice were given an i.p. booster injection of 
100 µg of collagen type II dissolved in phos-
phate buffered saline (PBS). The mice with-
out clinical manifestation of arthritis were 
selected and intra-articular injected with 
1x107 pfu AdCMVIL-18BPc or  the control 
adenoviral vector (ADCMVLuc) into both 
knees. Normally, ﬁrst signs of arthritis onset 
occur around day 22–24, in particular in the 
ankles. Peri-articular arthritic development 
of the hind paw and ankle joint was macro-
scopically monitored till day 27, at which the 
experiment was terminated and the mice 
were scariﬁed. During this period clinical 
severity of the arthritis was scored by two 
independent observers in a blinded manner 
on a scale ranging from 0-2 for each limb. 
Cumulative scoring depending on redness, 
swelling and in later stadium ankylosis was as 
follows; 0 - no changes; 0.25 – 1 to 2 toes red 
or swollen; 0.5 – 3 to 5 toes red or swollen; 
0.5 – swollen ankle; 0.5 – swollen footpad; 
0.5 – severe swelling and ankylosis. At day 27 
the experiment was terminated and the mice 
were bled. Knees were dissected and scored 
for macroscopical swelling on a scale ranging 
from 0 to 2. 
SCW Preparation and  Induction of 
SCW arthritis
Streptococcus pyogenes T12 organisms were 
cultured overnight in Todd-Hewitt broth. 
Cell walls were prepared as described previ-
ously [36]. The resulting 10,000g superna-
tant was used in experiments and contained 
11% muramic acid. Before induction of SCW 
arthritis mice were intra-articularly injected 
with 1x107 pfu AdCMVIL-18BPc or the 
control AdLuc virus. One day after transfec-
tion of the synovial lining, acute bilateral 
arthritis was induced by intra-articular injec-
tion of 25 µg of SCW (Rhamnose content) 
dissolved in 5 µl of PBS into the knee joints 
of C57/Bl6 mice.
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Histology 
Whole dissected knee joints were ﬁxed 
in phosphate buffered 4% paraformaldehyde, 
followed by decalciﬁcation with 5% formic 
acid and embedded in parafﬁn wax. Serial 
tissue sections of 7 µm were stained with safra-
nin-O or Heamatoxylin/Eosin (HE) prior to 
microscopical analysis. Loss of bone and non-
calciﬁed cartilage, which is characteristic for 
CIA, was scored on a 0 to 3 scale ranging from 
no effects to complete loss of bone structure 
or non-calciﬁed cartilage layer. The degree of 
proteoglycan (PG) depletion was determined 
by measurement of Glycosaminoglycan content 
of the non-calciﬁed cartilage layer, which was 
scored in safranin-O-stained sections also on 
a scale from 0 to 3 ranging from no depletion 
to severe depletion. These histopathological 
changes were scored in blinded manner by two 
observers. Synovial thickening was quantiﬁed 
using computer analysed microscopic measure-
ment (Leica Qwin; Leica, germany).
Determination of specific IgG-titers 
against collagen type II
IgG1, IgG2a and total IgG anti-colla-
gen antibody titers against bovine CII were 
determined through ELISA. Brieﬂy, 96-well 
plates were coated with 10 µg of bovine CII, 
followed by blockage of non-speciﬁc binding 
sites. Serial dilutions of the mouse sera were 
added, followed by incubation with isotype-
speciﬁc goat anti-mouse peroxidase (Southern 
Biotechnology Associates, Birmingham, AL) 
and substrate (5-aminosalicylic acid; Sigma). 
Plates were read at 492 nm. 
Measurement of IL-6 serum levels 
Concentrations of IL-6 in serum was 
determined using the B9 bioassay as described 
before [37]. Brieﬂy, serial dilutions of Serum 
samples were made in culture medium in 
order to quantify IL-6 levels. 5x103 B9 cells 
were added to serum sample dilutions and 
incubated for 3 days (37ºC/5%CO2). Four 
hours before harvesting the cells, 0.25 µCi 
of 3H-Thymidine was added. The amount 
of incorporated 3H-Thymidine was quanti-
ﬁed using a Micro Beta-plate reader (Perkin-
Elmer, The Netherlands).
Determination of IFNγ and TNFα
Concentrations of IFNγ and TNFα were 
determined in patellae washouts. Patellae 
were isolated from the knee, leaving adja-
cent synovial tissue surrounding the patel-
lae. Patellae were cultured in RPMI 1640 
medium at room temperature for 1 hour 
(200 µl/patella). IFNγ was determined using 
ELISA (Organon Technica NV, Boxtel, The 
Netherlands). TNFα levels were determined 
by non-equilibrium radioimmunoassay 
(RIA) [38]. Detection limits for IFNγ was 
~30 pg/ml and ~40 pg/ml for TNFα.
Statistical analysis
Signiﬁcance of differences was deter-
mined using student’s t-test or Mann-Whit-
ney U test (GraphPad Prism, San Diego CA, 
USA). P values of 0.05 or less were regarded 
as signiﬁcant.
Results
Validation of adenoviral IL-18BPc 
vector
To test the functionality of the adeno-
viral vector, NIH 3T3 ﬁbroblasts were 
114
C
ha
pt
er
 1
C
ha
pt
er
 6
Exogenous IL-18BPc ameliorates CIA
transfected with AdCMVIL-18BPc. 
Transfected NIH 3T3 f ibroblasts 
showed clear intracellular expression of 
mIL-18BPc, which was not observed 
in non transfected or AdCMVLucifer-
ase control-transfected cells (Figure 1). 
Conditioned culture supernatants of 
transfected cells were collected 30 hours 
post transfection. Precipitation of secret-
ed proteins of transfected cells, followed 
by immunoblotting revealed a sharp band 
at 40 kDa, indicating the production of 
secreted IL-18BPc by transfected cells 
(Figure 1C, lane 3). Normal or control 
transfected cells did not constitutively 
produce IL-18BPc  (Figure 1C, lanes 1 
and 2).   
Adenoviral overexpressed IL-18BPc 
neutralizes IL-18 activity in vitro
To determine the biologic activity of secreted 
mIL-18BPc, conditioned culture supernatants 
were tested on IL-18 sensitive luciferase report-
er cells.  Conditioned culture supernatants of 
cells transfected with a MOI of 10 resulted in 
signiﬁcant neutralization of 10 and 1 ng/ml IL-
18, respectively 33% and 53% (P=0.004) inhibi-
tion of bioactive IL-18. To test dose dependent 
inhibition of IL-18 by IL-18BPc, conditioned 
supernatants of cells transfected at a higher 
MOI of 100 were tested. IL-18BPc in the pres-
ence of 10 ng/ml IL-18 neutralized almost 86% 
of the IL-18 the bioactivity (P=0.0002), while 
it was able to completely neutralize bioactivity 
of 1 ng/ml IL-18 (P=0.02) (Figure 1D). 
Figure 1. Adenoviral gene transfer 
with AdCMVIL-18BPc leads to expres-
sion and secretion of biological active 
mIL-18BPc. 
NIH 3T3 ﬁbroblasts were transfected at 
a MOI of 50 for 2 hours with either Ad-
CMVLuc serving as control transfection 
(A) or AdCMVIL-18BPc (B). At 30 hours 
post-transfection cells were ﬁxed and the 
expression of IL-18BPc protein was deter-
mined through immunological detection. 
Secreted IL-18BPc was detected by immu-
noblotting in TCA precipitated conditioned 
culture supernatants of AdCMVIL-18BPc 
transfected cells as a protein of approx. 
40 kDa (C, lane 3). Lanes 1 and 2 represent 
respectively, TCA precipitated conditioned 
culture supernatants of either non transfected or AdCMVLuc control transfected cells. Biological functionality of secreted IL-18BPc was tested using conditioned culture 
supernatants of IL-18BPc transfected cells at MOI of 100 or 10 (D). The data are presented as mean±SD of triplicate experiments. *, P<0.05; **/*** P<0.01 compared 
with control transfection using Student’s t-test.
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Effect of neutralization of IL-18 
through IL-18BPc on local cytokine 
levels
Inhibition of IL-18 through IL-18BPc was 
tested in the acute streptococcal cell-wall 
arthritis model. Two days prior to i.a. chal-
lenge with SCW the synovial lining was trans-
fected with AdCMVIL-18BPc or the control 
AdCMVLuciferase vector. Transfection of the 
synovial lining with IL-18BPc resulted in a 
signiﬁcant inhibition of TNFα production at 
90 minutes after intra-articular SCW chal-
lenge. Levels of IFNγ in supernatants of SCW 
challenged patellae resulted in marked but not 
signiﬁcant reduction of IFNγ production at 24 
hours after SCW challenge (Table 1). 
Overexpression of IL-18BPc results 
in decreased severity of CIA
To elucidate the local role of IL-18 in 
the onset of CIA, knee joints of immunised 
DBA/1 mice were injected with 1x107 pfu 
AdCMVIL-18BPc, before clinical manifes-
tation of the disease. Macroscopic evalua-
tion of dissected knee joints showed a clear 
reduction of joint swelling by viral IL-18BPc 
treatment (Figure 2A). Further histological 
examination showed that IL-18BPc over-
expression reduced inﬂux of polymorpho-
nuclear cells and hypertrophy of the synovial 
lining as illustrated by a decrease in synovial 
     90 min SCW i.a. 24h SCW i.a
     TNFα  IFNγ
Treatment     pg/ml      N pg/ml  N
Control     530±57      5 177±76  5
IL-18BPc     78±25*      5 50±19 (ns)  5
Table 1. IL-18 neutralization through IL-18BPc after SCW challenge 
reduces local cytokine levels of TNFα a
a Synovial tissue levels of TNFα and IFNγ after treatment with AdCMVIL-18BPc 
or the control treatment. Viral vectors were injected into the knee joint cavity 
2 days prior to SCW challenge. For each time-point 5 mice were used. Patellae 
and adjacent tissue were cultured and cytokine levels determined as described 
in Materials and methods. Data are presented as mean±SEM. *P<0.01, com-
pared to control treatment by Mann-Whitney U test.
Figure 2. IL-18BPc treated knee joints are protected against colla-
gen-induced arthritis.
Macroscopic evaluation of dissected knee joints of aﬀected animals treated 
with IL-18BPc at endpoint of CIA  (A) showed markedly less inﬂammation 
compared to control treatment. Severity of joint swelling was scored through 
macroscopic evaluation on a scale ranging from 0 to maximum of 2. (B) syno-
vial thickening was quantiﬁed as described Materials and Methods. *, P<0.01 
compared to control treatment. Data are presented as means±SEM (A) or indi-
vidual synovial thickening measurements of each knee joint (B). Bar indicates 
mean synovial thickening determined in 22 dissected knee joints per group. 
Data are representative of two experiments with similar results and are anal-
ysed using the Mann-Whitney U test.
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thickening (Figure 2B). 
Furthermore, histological scoring of 
proteoglycan depletion of the cartilage 
matrix, cartilage erosion and bone erosion 
in the treated knee joints showed that 
intra-articular overexpression of IL-18BPc 
protected the joint signiﬁcantly against these 
parameters of arthritic pathology (Figure 3). 
Intra-articular overexpression of 
IL-18BPc in the knee joint reduces 
incidence and severity in distal paws
 Development of the experimental arthritis 
was followed in the paws after injection of the 
adenoviral vector at day 21 till time of sacri-
ﬁce at day 27. Overexpression of IL-18BPc 
in both knee joints had a distal protective 
effect on the CIA development in the drain-
ing paws. At day 27, only 25% of the paws 
in IL-18BPc treated animals developed signs 
of arthritis, while in control treated animals 
72% of the paws were affected (Figure 4A). 
Figure 4B shows the average clinical score in 
the affected paws during time course of the 
CIA. Treatment with IL-18BPc signiﬁcantly 
ameliorated the CIA severity in the affected 
paws from day 24. Although IL-18BPc treat-
ment compared to control treatment reduced 
severity in the affected paws, IL-18BPc was 
not able to fully arrest progression of the 
disease in some animals. 
IL-18BPc reduces serum levels of IL-6 
As a marker of disease activity, IL-6 levels 
were determined at the time of sacriﬁce 
in serum of IL-18BPc treated animals and 
control treated animals. High levels of IL-6 
(2780±245 pg/ml) could be detected in 
serum of control treated animals, while serum 
levels of IL-6 were signiﬁcantly reduced in 
IL-18BPc treated mice (993±162 pg/ml) 
(Figure 5). 
Figure 3. IL-18BPc 
treatment reduces CIA 
induced joint destruc-
tion.
IL-18BPc treated mice 
developed signiﬁcantly 
less erosive joint de-
struction compared to 
control treated animals. 
Treated knee joints were 
dissected at day 27 and 
processed for histologi-
cal analysis. Safranin-O-
stained tissue sections of 
control treatment (B) and IL-18BPc treatment (C) reveal marked protection against CIA induced joint destruction (P; patellae, JC; Joint cavity, F; Femur). (A) Appear-
ance of cartilage PG depletion, bone erosion and cartilage erosion was scored on a 0-3 scale. Pathological changes were scored by two observers in a blinded manner. 
* P<0.01, **P<0.001 in treated versus control treated animals. Data are representative of two experiments with similar results and are presented as means±SEM of 
22 dissected knee joints/group. Data are analysed using the Mann-Whitney U test. 
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the relation between IgG isotypes balance 
and Th1/Th2 balance we determined colla-
gen type II speciﬁc IgG titers in sera at time of 
sacriﬁce. As shown in ﬁgure 6, intra-articu-
lar treatment with IL-18BPc had no effect on 
circulating levels of collagen II speciﬁc IgG1 
levels, while it reduced collagen II speciﬁc 
circulating IgG2a antibody levels. 
Discussion
This study was performed to develop and 
determine the efﬁcacy of local IL-18BPc 
Figure 4. Reduced disease severity in distal paws through Intra-ar-
ticular overexpression of IL-18BPc.
Treatment with IL-18BPc reduced incidence (A) and severity (B) of CIA in mice 
compared to the control treatment. DBA/1 mice with CIA were treated through 
intra-articular injection of 1x107 pfu AdCMVIL-18BPc or the control vector after 
receiving the booster at day 21 as described in Materials and Methods. Inci-
dence was calculated as cumulative incidence of positive distal paws (clinical 
score>0.25 was considered positive). Diﬀerence between incidence curves was 
determined by χ2-contingency analysis. CIA was scored by two observers in a 
blinded manner. CIA severity in animals is presented as Mean clinical scores of 
aﬀected hind paws and analysed with the Mann-Whitney U test.  *P<0.05 in 
treated versus control group. Data are means±SEM (n=11).
Effect of IL-18BPc on serum levels 
of anti-collagen type II antibodies
Because of the involvement of IL-18 in 
T-cell polarization towards a Th1 subset and 
Figure 5. Reduced 
levels of IL-6 in sera 
of IL-18BPc treated 
animals
Levels of the acute 
phase marker IL-6 
were determined in 
sera of mice, sacriﬁced 
at day 27 after immunization. Diﬀerences between IL-6 levels of IL-18BPc treat-
ed animals (n=11) and control treated animals (n=10) were determined using 
the Mann-Whitney U test. *,P<0.01 in treated vs. control. Data are presented 
as individual serum measurements; mean absorbances indicated per group.
gene therapy in CIA. Several recent stud-
ies have reported the importance of IL-18 
in experimental arthritis [21] and described 
possible therapeutic potential of IL-18 
neutralization [22,23]. In the later papers 
the effect of systemic neutralization has been 
reported through application of an IL-18 
neutralizing antibody strategy or injection of 
large amounts of recombinant IL-18BP. This 
present study is the ﬁrst study to report efﬁ-
cient i.a. intervention with IL-18 signaling 
in CIA through application of recombinant 
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adenoviruses containing the murine form of 
the IL-18BPc. 
To achieve local expression of the inhibitor 
we chose for an adenoviral expression system 
in which the construct was under the control 
of the cytomegalo virus (CMV) promoter. In 
vitro testing of the newly constructed adeno-
viral vector on transfection efﬁcacy and 
expression by ﬁbroblasts showed high intra-
cellular levels and secretion of the IL-18BPc. 
Furthermore, supernatants of AdCMVIL-
18BPc transfected cells showed high IL-18 
neutralizing activity, thus proving secretion 
of a biologically active inhibitor of IL-18. 
From these in vitro experiments we estimated 
that the IL-18 neutralizing capacity of the 
i.a. injected AdCMV IL-18BPc (1x107 pfu) 
is about 5 ng IL-18 at a 1:1 stoichiom-
etry (Figure 1D), theoretically leading to a 
concentration of 500 ng mIL-18BPc per ml 
synovial ﬂuid in the murine joint. It is tech-
nically not possible to measure the amount 
of mIL-18BPc produced, but we expect that 
the level will be far above the level of IL-18 
found in synovial ﬂuid of RA patients [19]. 
To test the in vivo functionality of AdCMV 
IL-18BPc we used the acute SCW challenge 
arthritis model.  IL-18 has been shown to 
be involved in acute SCW challenge and the 
cytokine is able to induce several cytokines 
in different subsets of cells, including TNFα 
and IFNγ from macrophages and T-cells 
[22,27,28]. Evaluation of direct effects of 
IL-18 neutralization by adenoviral induced 
expression of IL-18BP during acute SCW 
inﬂammation revealed reduced levels of local 
produced TNFα in washouts of synovial 
tissue. After validation of IL-18 neutraliza-
tion through the IL-18BPc virus, these results 
clearly show the direct involvement of IL-18 
as a pro-inﬂammatory cytokine during the 
early phase of an arthritic process.
The observed pro-inﬂammatory proﬁle 
of IL-18 was ﬁrst described in studies 
by Gracie et al [18] and Wei et al [21], in 
which they demonstrated the pivotal role of 
IL-18 in the development of inﬂammatory 
arthritis. Other studies by Joosten et al 
[22,23] veriﬁed the importance of IL-18 
in experimental arthritis through systemic 
neutralization of IL-18. Besides this systemic 
role of IL-18, it has been demonstrated that 
IL-18 is also produced in high amounts by 
the synovial lining of RA patients [16,18]. 
Because of these high levels of IL-18 in 
local inﬂammatory processes intra-articular 
neutralization of IL-18 by adenoviral overex-
pressed IL-18BPc during onset of CIA could 
be effective. While control treated mice 
developed a progressive inﬂammatory artic-
ular disease, intra-articular overexpression of 
IL-18BPc before clinical manifestation of the 
CIA resulted in amelioration of the arthritis. 
Clinical effects of IL-18BPc treatment were 
observed as markedly lower incidence and 
Figure 6. IL-18BPc treatment does not aﬀect serum levels of anti-col-
lagen II antibody concentrations
Anti-collagen type II levels of the isotypes IgG1, IgG2a and the total IgG were 
measured in serum of IL-18BPc treated animals and compared with control 
treated animals at time of sacriﬁce. Data is presented as absorbance (OD 
492 nm) of CII antibodies in individual serum measurements (six mice per 
group). Mean absorbances are indicated per group
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reduced severity of erosive joint destruction 
of the CIA in dissected knee joints.  
Interestingly, an additional effect on the 
poly-arthritic CIA model was observed. Intra-
articular treatment of the knee joints also 
reduced the severity of the CIA in the distal 
paws of IL-18BPc treated animals. Obser-
vation of this protection of adjacent joints 
opens new prospects for local treatment of 
experimental arthritis. Similar observations 
have been made after intra-articular treat-
ment of CIA with IL-1 receptor antagonist, 
which also results in amelioration of the CIA 
in the distal paws of treated mice [25,26]. 
Whether these effects are the result of a direct 
local inhibition of cytokine spillover and 
antigen release by reduced inﬂammation or 
caused by leakage of IL-18BPc to distal joints 
remains to be established. When comparing 
incidence versus severity in the distal paws of 
IL-18BP treated animals, IL-18 signiﬁcantly 
reduced incidence while increase in severity 
of affected hind paws could not be halted. 
This observation suggests an important role 
for IL-18 in onset of arthritis, while its role 
in progression of disease remains to be estab-
lished.
IL-18 is considered to be a pivotal cyto-
kine regarding T-cell activation, resulting in 
production of IFNγ and polarisation of Th1 
responses. Impressive synergy of IL-18 on 
IFNγ production by T-cells can be observed 
in the presence of IL-12 [3,29,30]. In animal 
studies CIA mice injected with IL-12 alone, 
developed earlier onset and more severe 
progression of the arthritis [31].  However, 
a resembling synergy between IL-12 and 
IL-18 was observed through co-injection 
of these cytokines in CIA mice, which 
enhanced incidence and disease severity 
above those of IL-12 alone [31]. Results from 
our study show that local inhibition of IL-18 
results in a signiﬁcant lower incidence and 
severity of the arthritis. However, increase in 
severity of affected hind paws could not be 
halted. Because of the resemblance in func-
tion between IL-18 and IL-12, this IL-18 
independent progression of severity could be 
the resultant of IL-12 function. Therefore, 
therapeutic strategies should be developed to 
locally block both IL-18 and IL-12, which 
could prove to be effective in the future.
Wei et al also showed that induction of 
CIA in IL-18 KO mice had no effect on 
IgG1 titres directed towards collagen type II, 
but showed signiﬁcant reduction in IgG2a 
titres [21]. This reduction in IgG2a antibod-
ies, which is normally produced during Th1 
mediated responses, underlines the involve-
ment of IL-18 in induction of polarization 
towards a Th1 mediated CIA. Interestingly, 
after local treatment of experimental arthritis 
we also observed no differences in serum titers 
of IgG1 antibodies directed towards colla-
gen type II between control and IL-18BPc 
treated animals, while IgG2a antibodies 
showed a marked, but due to large variation, 
not signiﬁcant reduction.  These data suggest 
possible inﬂuence of locally produced IL-18 
in modulation of the systemic Th1 response. 
We also found a systemic reduction of circu-
lating levels of IL-6 after local treatment with 
IL-18BPc. From the same study by Wei et al 
[21] similar reduction in circulating levels 
of IL-6 was observed in sera obtained at 37 
days after induction of CIA in IL-18 KO 
mice compared to wild-type DBA/1 mice. 
Because of the effects of local treatment with 
IL-18BPc on the described systemic param-
eters IL-6 and IgG2a antibodies, a possible 
mechanism could be that the observed 
systemic effects of local IL-18 neutralization 
depend on reduced release of IL-18 and other 
cytokines from inﬂamed joints. 
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In recent years, several systemic cytokine 
inhibiting therapies in RA have been intro-
duced of which the anti-TNFα treatment is 
the best studied. However, as it has become 
clear that systemic inhibition of TNFα can 
induce some adverse effects. These effects 
can vary from mild opportunistic diseases 
to tuberculosis or even Multiple sclerosis 
[32-34]. Although the effective treatment of 
RA through anti-TNFα therapy, it appears 
from these studies that deprivation of this 
cytokine in some cases can result in severe 
impairment of the immune response. It is 
not unthinkable that systemic cytokine 
blocking therapies will eventually result in 
systemic impairment of innate and acquired 
immunity, while local therapies can be less 
interfering with systemic processes. Because 
systemic IL-18BP treatment can also results 
in scavenging of IL-18, ultimately leading to 
deprivation, it is warranted to develop local 
treatments which can minimise interference 
on a systemic level. Because of the involve-
ment of IL-18 in pathogenesis of other 
inﬂammatory diseases like type I diabetes 
mellitus [6], local expression in affected 
organs of IL-18BPc may be the way to go.
The rapid induction of IL-18 during 
inﬂammatory processes and its pro-
inﬂammatory character make IL-18 a logical 
target in many inﬂammatory disorders. With 
this study, we have conﬁrmed the local pro-
inﬂammatory role of IL-18 in experimental 
arthritis. More interestingly, we now present 
a novel and local gene therapeutic approach 
that neutralizes endogenous IL-18, which 
may provide a future joint protective therapy 
in RA.
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sIL-18Rβ, a regulator of IL-18 signaling  
In the inﬂammatory process preceding degenerative arthritis, Interleukin-18 (IL-18) plays an important role. IL-18 is known to regulate immune responses by stimulating Th1 maturation. The objective of this study was to determine the role of a recently described soluble form of the IL-18 
Receptor accessory protein (IL-18Rβ) in mice. 
 Short IL-18Rβ mRNA was highly expressed in tissue of lymphoid origin, and no expression could 
be observed in immune privileged organs like testis, eye and brain, suggesting a prominent role 
in immune regulation.  Short IL-18Rβ appeared to be disease regulated in mice suﬀering from 
collagen induced arthritis (CIA), whereas the full-length IL-18Rβ was not regulated. Splenocytes 
of sIL-18Rβ treated immunized mice produced signiﬁcantly less IFNγ and IL-10 compared to control 
treated animals. Adenoviral overexpression of the sIL-18Rβ before clinical manifestation of CIA 
signiﬁcantly aggravated arthritis, which was accompanied by a reduction of circulating IL-10, IFNγ 
and a signiﬁcant increased anti-bovine collagen II IgG1. In this study we describe the expression and 
regulation of a novel short soluble IL-18Rβ in mice. Furthermore, we show that this sIL-18Rβ is an 
important regulator of T-cell function in mice suﬀering from collagen-induced arthritis.
Rheumatoid Arthritis is a chronic joint 
disease, characterized by degeneration of 
cartilage and bone, which eventually results 
in the loss of articular function. In the 
onset and maintenance of the inﬂammation 
preceding the degenerative process, pro-in-
ﬂammatory cytokines like Interleukin-18 
(IL-18) play an important role [1]. IL-18, 
formerly known as IFNγ-inducing factor, 
belongs to the IL-1 family of cytokines and 
is a key molecule in regulating innate and 
adaptive immune responses by stimulating 
Th1 maturation. 
 For IL-18, the signaling recep-
tor is comprised out of the IL-18 binding 
IL-18R (IL-18Rα) and the IL-18Rβ, which 
functions as an accessory protein stabilizing 
the receptor complex and enabling signal 
transduction [2]. Recently a short alterna-
tive splice variant of the IL-18Rβ has been 
described in rat brain [3]. In this study we 
describe the expression and regulation of a 
novel short soluble IL-18Rβ (sIL-18Rβ) in 
mice. Furthermore, our study showed that 
this sIL-18Rβ is an important regulator of 
T-cell function by modulating IL-18 actions 
in mice suffering from collagen-induced 
arthritis (CIA).
Materials and Methods
RNA isolation and Quantitative 
PCR analysis
Tissue samples from organs were obtained 
from bovine collagen II (BCII) immunized 
DBA/1 mice. Total RNA was extracted using 
TRIzol reagent. Short IL-18Rβ expression 
was either determined by endpoint PCR or 
by quantitative PCR, using the Fw primer 
5’-atggcctgttgtatcaagacagtct-3’ and Rv 5’-
ttacaccagttttagcaaatccatcc-3’. Other primer 
sets used were, IL-18Rα; Fw primer 5’-
atgagggaacgtacatttctcaagtc-3’ Rv; 5’-tctta-
caagtgatatgcagagatttgttaac-3’ and IL-18Rβ; 
Fw; 5’-agatgacctggtacaaggatggaa-3’ and Rv; 
5’-cagctcggactgtccaggaa-3’. Quantiﬁcation 
of the PCR signals was achieved by compar-
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ing the cycle threshold value (Ct) of the 
gene of interest of each sample with the Ct 
value of their reference gene GAPDH (Fw; 
5’-ggcaaattcaacggcaca-3’ and Rv; 5’-gttagt-
ggggtctcgctcctg-3’).
Cytokine measurement
The levels of murine IL-4, IFNγ and 
IL-10 were determined in plasma and sple-
nocyte culture supernatants of sIL-18Rβ and 
control treated animals using the Luminex 
multi-analyte technology. The sensitivity 
was approximately 1 pg/ml.
Adenoviral Vectors 
The sIL-18Rβ (Ad sIL-18Rβ) and the 
control Luciferase adenoviral vector (Ad 
Luc) were E1A, B and E3 deleted and 
produced according to the method described 
by Chartier et al [4]. The transgenes were 
under regulation of a CMV promoter. 
Induction of collagen-induced 
arthritis(CIA) 
DBA/1 mice were immunised at day 0 
and 21, as previously described [5]. Adenovi-
ral vectors were injected systemically before 
onset of arthritis, one day after receiving the 
booster injection at day 21. All mice received 
equal viral load of 3x108 pfu. Peri-articular 
development of arthritis in the hind paw 
and ankle joint was macroscopically scored 
by two independent observers in a blinded 
manner using a scale ranging from 0-2 for 
each limb, resulting in a cumulative maxi-
mal score of 8 per mouse. 
Results and Discussion
Comparison of amino acid sequence of 
rat sIL-18Rβ  (GenBank: AJ550893) with 
the mouse sIL-18Rβ (GenBank: AK053176) 
revealed great homology between both 
species. Both proteins contained an Ig-like 
Figure 1. Short IL-18Rβ is 
abundantly expressed in 
tissue of lympoid origin
The short variant of the mem-
brane IL-18Rβ (sIL-18Rβ) was 
abundantly expressed in tissue 
of lymphoid origin. No expres-
sion of sIL-18Rβ is observed in 
immune privilege organs, such 
as testis, brain and eyes (A). 
Figure B shows the regulation 
of the full-length membrane 
IL-18Rβ and the short IL-18Rβ 
mRNA in thymus, lymph node 
and spleen of mice with or 
without CIA, as quantiﬁed us-
ing QPCR.
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domain and unique C-terminal tail, with 
the rat isoform being 62 amino acids shorter 
in length [3].
Expression analysis of the IL-18 recep-
tor components in a tissue cDNA library 
prepared from DBA/1 mice revealed abun-
dant expression of both IL-18Rα and the 
accessory chain IL-18Rβ (Figure 1A). In 
contrast to the full-length receptor, the short 
form of the IL-18Rβ was mainly expressed 
in tissue of lymphoid origin, such as lymph 
nodes, thymus and spleen. Expression could 
also be observed in lung tissue, from which 
the sequence was originally described [6]. No 
expression of sIL-18Rβ could be observed in 
the so-called immune privileged organs, in 
which immune cell invasion is strictly regu-
lated such as testis, brain and eyes, and in 
tissue of the ﬁrst line of defense, like ileum, 
lung and skin, suggesting a prominent role in 
immunoregulation. 
sIL-18Rβ revealed increased expression in 
organs of primary and secondary lymphoid 
origin and the sIL-18Rβ expression in mice 
suffering from CIA was up regulated in the 
thymus, and down regulated in secondary 
lymphoid tissue like lymph node and spleen, 
whereas the membrane IL-18Rβ revealed 
not to be disease regulated (Figure 1B).  
In order unravel the physiological func-
tion of sIL-18Rβ, we created an adenovi-
ral vector containing the sIL-18Rβ gene. 
Because IL-18 is crucial in onset of CIA [7], 
we injected AdsIL-18Rβ i.v. just before onset 
of CIA. Systemic injection of Ad sIL-18Rβ 
resulted in an increased mRNA expression 
of the transgene, predominantly in the liver. 
At four days after adenoviral injection, sple-
nocytes of sIL-18Rβ treated animals mark-
edly produced less IL-10 (-61%, P<0.05) and 
IFNγ (-95%, P<0.05), compared to control 
treated animals, after stimulation with IL-18 
or a pan T-cell activator Concanavalin A 
(ConA) (Table 1). Since IL-18 is a potent 
inducer of IFNγ in T-cells [8], sIL-18Rβ 
could function as an antagonist of IL-18 
signaling on Th1 cells. Interestingly, systemic 
overexpression of sIL-18Rβ before onset of 
          IL-4  IL-10  IFNγ
Treatment      pg/ml    pg/ml   pg/ml
Control IL-18 1.6±0.5  3.9±0.6  949.4±72.3
 ConA 4.7±2.1  49.2±14.1  139.9±83.4
 - 2.4±0.3  N.D.  N.D.
sIL-18Rβ IL-18 1.8±1.2  2.4±3.5  51.4±6.9*
 ConA 4.2±1.4  19.2±11.9*  76.8±20.8
 - 1.7±1.2  N.D.  N.D.
Table 1. Splenocyte derived production of T-cell cytokines after systemic treatment with sIL-18Rβ a
a Production of T-cell derived cytokines IL-4, IL-10 and IFNγ was quantiﬁed in pooled supernatants (n=6) of stimulated and unstimulated (-) cultured splenocytes of 
sIL-18Rβ treated animals (n=3) and control treated animals (n=3). *, P<0.05 using students’ t-test
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CIA resulted in a signiﬁcant aggravation of 
the experimental arthritis (ﬁgure 2A), which 
was accompanied by a signiﬁcant increase of 
circulating IgG1 antibodies directed against 
BCII. In plasma of sIL-18Rβ treated mice, 
both IL-10 and IFNγ levels were signiﬁ-
cantly reduced, respectively 49% and 72% 
at day four (Figure 2B). Furthermore, an 
adenoviral vector containing an alternatively 
truncated IL-18Rβ expressing extracellular 
part of the receptor was also able to aggra-
vate CIA and increased circulating anti-BCII 
IgG1.  Together with the observation of 
reduced systemic IFNγ, an increased IgG1 
production and reduced IL-10, which is a 
key effector regulatory cytokine produced 
by regulatory T-cells [9], these results could 
reﬂect a transition of a Th1 into a Th2 medi-
ated disease.
Our results describe the existence of a 
novel short soluble form of the membrane IL-
18Rβ, which is mainly expressed in tissue of 
lymphoid origin. This sIL-18Rβ expression 
appears regulated during CIA. Furthermore, 
we show that this novel soluble IL-18Rβ 
functions as a putative modulator of IL-18 
signaling, aggravating CIA, by modulating 
T-cell immunity. 
Figure 2. sIL-18Rβ aggravates CIA through 
disturbance of Th1/Th2 balance
Systemic adenoviral overexpression of sIL-
18Rβ resulted in an aggravation of CIA (A). 
(n=12 mice per group.) sIL-18Rβ reduced 
circulating IFNγ and the regulatory T-cell cy-
tokine IL-10. Plasma of 3 individual mice per 
group per time point was used. *P< 0.05 using 
students’ t-test. 
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Pro-inﬂammatory cytokines are crucial 
in maintenance and control of immunity 
and onset of inﬂammation. Several impor-
tant members of these cytokines include 
Interleukin-1 (IL-1), IL-18 and the Tumor 
Necrosis Factor (TNF)α. These speciﬁc 
cytokines have pleiotropic characters, which 
offer multiple physiological responses after 
infection, tissue damage and stress [1,2]. The 
ability to antagonize these pro-inﬂammatory 
cytokines is thus a pharmacological quest. 
The evaluation of potential antagonists of the 
above mentioned cytokines is often limited 
to the available cytokine assays. When avail-
able the assay procedure is based on an indi-
rect measurement of cytokine activity. This 
means that the readout of the assay depends 
on a secondary effect, e.g. IL-1 induced IL-2 
production in a NOB/CTLL assay [3], which 
not only results in a prolonged assay time, 
but also increases the chance of secondary 
effects interfering with the assay outcome. 
Due to our need of a functional assay system, 
which could be used for testing antagonists 
on broad panel of cytokines, we focused on 
an intracellular reporter system with more 
speciﬁcity, which would ultimately result in 
decreased assay time.
Most pro-inﬂammatory cytokines are 
able to induce NFκB. Since its discovery, 
this eukaryotic transcription factor has been 
shown to play a crucial role in the regula-
tion of many genes involved in immunity 
and inﬂammation [4-6]. NFκB is present in 
virtually every cell type and activation can 
be the result of many extracellular stimuli, 
Nuclear factor κ B (NFκB) mediated gene-expression plays a central role in normal cellular physi-ology and regulation of immune- and inﬂammatory responses. Currently NFκB is a subject of many cytokine signaling studies and is regarded as a potential therapeutic target in human 
disease.  We developed a quick and easy-to-use reporter cell assay for direct quantiﬁcation of 
NFκB activity. 
 Methods: An eukaryotic expression vector was created containing ﬁve tandemly arranged 
NFκB binding sites in front of a minimal promoter to regulate the expression of the luciferase 
gene. In order to obtain selective cytokine speciﬁcity we transduced diﬀerent cell lines derived 
from ﬁbroblasts, chondrocytes and thymocytes, with the NFκB reporter construct. Cells lines 
were selected for stable incorporation of the construct and characterized on cytokine respon-
siveness. Results: Our selected reporter cell lines, showed good responsiveness and high 
sensitivity towards NFκB inducing cytokines or Toll like receptor agonists with low intra-assay 
variance. Speciﬁc inhibition of IL-1 or IL-18 induced NFκB activation using respectively recom-
binant IL-1Ra or adenoviral overexpressed IL-18 Binding Protein (IL-18BP) revealed applicability 
of this reporter cell assay for testing cytokine inhibitors. This inhibition of NFκB activation was 
easily quantiﬁable six hours after addition of the cytokine. Furthermore, we show that these cell 
lines can be exquisitely used for therapeutic evaluation of novel targets involved in the NFκB 
signal transduction pathway using knock down RNA interference. Conclusion: These reporter 
cell-lines can be valuable and reliable pharmacological tools to study involvement of NFκB 
activation in cellular processes and to evaluate cytokine/NFκB based inhibition therapies.
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such as pro-inﬂammatory cytokines, bacte-
rial and viral components and even physi-
ological or chemical stress (Figure 1) [5,7]. 
The importance of this transcription factor 
becomes evident in many human disorders 
e.g. arthritis and asthma in which inap-
propriate regulation of NFκB is involved 
[8].  Activation of NFκB results in increased 
expression of many genes encoding for cyto-
kines, chemokines, adhesion molecules and 
receptors involved in immune recognition 
[9]. Therefore regulation of NFκB activation 
is an interesting target and speciﬁc inhibi-
tion of NFκB or its inducing cytokines could 
result in amelioration of several inﬂamma-
tion related diseases, like rheumatoid arthritis 
(RA) [10,11]. 
NFκB activity in cell cultures can be 
studied by observing increased NFκB bind-
ing to DNA using EMSAs or immunolocal-
ization of NFκB translocated to the nucleus. 
However, NFκB reporter cell lines would be 
more easy to use through quick quantiﬁca-
tion of NFκB activation in vitro. With the 
development of different stable transduced 
NFκB luciferase reporter cell lines we allow 
standardized quantiﬁcation of NFκB activ-
ity and show the applicability in time saving 
functional cytokine/NFκB inhibition assays 
in vitro.  
Materials and Methods
Construction of NFκB reporter 
plasmid
For determination of NFκB transcription 
activity, a pGL3-Basic vector containing 
ﬁve tandemly arranged NFκB binding sites 
was constructed the laboratory of Prof. Dr. 
W. Falk (dept of Internal Medicine, Univer-
sity of Regensburg, Germany). Brieﬂy, the 
NFκB binding sites were derived from the 
HIV long terminal repeat enhancer (5’-
GGGACTTTCC-3’) and cloned into the 
pCAT promoter vector. The created NFκB 
binding repeats plus minimal promoter from 
pCAT were excised from the vector using 
Figure 1. Schematic and simpliﬁed representation 
of the common signaling pathway of the cytokines 
IL-1, IL-18, TNFα,  IL-17 and bacterial compounds 
like LPS or SCW. 
Signaling of the TNFα and the Interleukins -1, -17 and –18 
or bacterial fragments is initiated upon binding of these 
ligands to their receptors. The intracellular signaling 
cascade is initiated by recruitment of adapter proteins 
(MyD88) and kinases (IRAK) to the intracellular region 
of the receptor complexes. This signaling cascade further 
progresses downstream through TRAF-2 or-6 and eventu-
ally results in activation of transcription by translocation 
of activated NFκB into the nucleus. IL-1RAcP; IL-1Receptor 
accessory protein, MyD88; Myeloid diﬀerentiation factor-88, IRAK; IL-1R-associated kinase, TRAF; TNF-receptor associated factor, IKK; IkB kinase, NIK; NFκB-inducing 
kinase.
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BglII and HindIII and inserted into the pGL3 
basic vector (pGL3-5xNFκB). 
Construction of NFκB reporter 
plasmid for eukaryotic expression.
For construction of cells stably express-
ing the NFκB reporter construct, the insert 
containing NFκB binding repeats followed 
by the minimal promoter and luciferase gene 
was excised from the pGL3-5xNFκB using 
BglII and XbaI. The obtained construct 
was used for ligation into the eukayotic 
expression plasmid pcDNA3.1. The CMV 
promoter of the pcDNA3.1 was exchanged 
with the construct using BglII and XbaI. A 
similar strategy was applied for construct-
ing the pcDNA4 V5-His, which is also an 
eukaryotic expression plasmid contain-
ing a zeocin selection cassette. The CMV 
promoter was exchanged by inserting the 
5xNFκB luciferase construct using BglII 
and XbaI. 
Preparation of stable transfected 
cell lines
For the preparation of stable transfected 
cells different celltypes were selected. NIH 
3T3 ﬁbroblasts, EL4.NOB-1 Thymocytes 
and EL4.D6/76 thymocytes were trans-
fected with the pcDNA 3.1 NFκB-Lucif-
erase, using Lipofectamin 2000 according 
to manufacturers protocol. These celltypes 
were selected on stable incorporation 
of the transgene using Neomycin G418. 
H4 chondrocytes [13] were transfected 
with pcDNA4 NFκB-Luc and cells were 
selected using Zeocin at a concentration of 
800 µg/ml. All transfected cell types were 
submitted to clonal selection by limiting 
dilution. 
Cytokine sensitivity in vitro assay
The ability of the cytokines IL-1α, 
TNFα, IL-18 and IL-17 to induce NFκB 
activation was tested on the different NFκB 
reporter cell lines. One day prior to experi-
ments reporter cells were seeded in Krystal 
2000 96-wells plates (Thermo Labsystems, 
Brussels, Belgium) at a concentration of 2-
4x104 cells/well. Cells were cultured at 5% 
CO2/37
oC. Dose response kinetics of the 
different cytokines was determined after six 
hours of cytokine incubation on the reporter 
cells. Cytokine responsiveness of the reporter 
cells was quantiﬁed by measurement of 
NFκB induced production of Luciferase. 
Luciferase activity was quantiﬁed using 
Bright-Glo luciferase assay system (Promega, 
Madison, WI, USA) followed by lumino-
metric detection according to manufactures 
protocol (Polarstar galaxy, BMG, Offenburg, 
Germany). Sensitivity of reporter cell lines 
towards different cytokines was determined 
by calculation of EC50 values (g/ml). 
In vitro antagonist assay
IL-1 sensitive EL4.NOB-1 luciferase 
reporter cells were used for the determina-
tion of the antagonistic activity of recom-
binant IL-1 Receptor antagonist (IL-1Ra). 
2-4x104 reporter cells were seeded in Krystal 
2000 96-wells plates and incubated for 6h 
with varying concentrations of IL-1 in the 
presence or absence of IL-1Ra.  
In order to determine antagonistic activ-
ity of adenoviral overexpressed IL-18 Bind-
ing protein (IL-18BP) NIH 3T3 ﬁbroblasts 
were seeded at a concentration of 2x105/ml 
and transfected for 2 hours under serum-free 
culture conditions with different Multi-
plicities of Infection (MOI’s) of AdCMVIL-
18BPc [12] or the control vector. Cell-free 
142
C
ha
pt
er
 1
C
ha
pt
er
 8
NFκB reporter cell lines 
30 hours conditioned supernatants of cells 
adenovirally overexpressing mIL-18BP was 
tested on IL-18 sensitive EL-4D6/76 lucif-
erase reporter cells. IL-1 or IL-18 induced 
production of luciferase was quantiﬁed after 
six hours using Bright-Glo luciferase assay 
system followed by luminometric detection 
according to manufactures protocol.
Luciferase siRNA
In order to achieve constitutive expres-
sion of siRNA a vector was constructed 
in which RNA expression was under the 
regulation of the murine U6 polymerase III 
promoter. This promoter was cloned from 
murine genomic DNA isolated for the tail 
and ligated into the PCRscript (promega). 
Complementary DNA corresponding to 
the ﬁreﬂy luciferase sequence (5’-tggattc-
caattcagcgggagccacctgat-gacgcgtg-atcag-
gtggctcccgctgaattggaatccattttt-3’) was 
purchased as HPLC puriﬁed oligonucle-
otide (Biolegio, Malden, the Netherlands) 
and annealed to generate dsDNA. This 
dsDNA was then ligated into the PCR-U6 
in order to achieve constitutive driven lucif-
erase hairpin RNA expression. To evaluate 
applicability of the reporter cells for testing 
siRNA construct NIH 3T3 NFκB reporter 
cells were were seeded at a density of 
5x104 cells/well in a Krystal 2000 96 wells 
microtiter plate 18-24 hours before transfec-
tion. The cells were transfected with PCR-
U6 Luc or the control plasmid (PCR-U6 
or padTrack) (1.6ng) using oligofectamine 
(Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. After trans-
duction cells were incubated for 24 hours 
at 37°C/5%CO2 and assayed for luciferase 
activity according to manufacturer’s instruc-
tion using Polarstar luminometer. 
NFκB siRNA
SiRNA targeting human (h)NFκB p65 
(GenBank: NM_021975) and an irrelevant 
gene (human activated leukocyte cell adhesion 
molecule (hALCAM); GenBank: NM_001627) 
were used as controls for sequence speciﬁcity. 
The following target sequences were chosen for 
each molecule (numbering after the start codon): 
mNFκB p65: 1363-1385, h-NFκB p65: 661-683, 
hALCAM: 178-200. Human sequence for NFκB 
p65 differed from mouse by one nucleotide. 
Both sense and anti-sense siRNA corresponding 
to the target sequences were purchased as HPLC 
puriﬁed oligonucleotide (RNA-TEC) and 
annealed to generate dsRNA. NIH3T3 NFκB 
reporter cells were were seeded at a density of 
1.5x104 cells/well in a Krystal 2000 96 wells 
microtiter plate 18-24 hours before transfection. 
The cells were transfected with dsRNA (10 nM) 
using oligofectamine (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instruction. The 
cells were stimulated with TNFα (10 ng/ml) 
24 hours after the transfection, and assayed for 
luciferase activity 6 hours after the stimulation 
according to manufacturer’s instruction using 
Polarstar ﬂuoro/luminometer.
Dose response curves and statistical 
analysis
Non-linear regression analysis was 
performed using GraphPad Prism 4.0 software 
(GraphPad Software Inc., San Diego, Ca.). The 
dose response curves were analysed and ﬁtted 
according to a sigmoidal dose response model 
(with variable slope) and the concentration at 
which 50% of the maximal cytokine response 
(EC50) was obtained was determined. Statisti-
cal differences between means were determined 
using student’s t-test or Mann-Whitney U test. 
P values of 0.05 or less were regarded as signiﬁ-
cant.
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Results
Characterization of reporter cell 
lines
Selected reporter cell lines NIH 3T3 
(ﬁbroblast), H4 (immortalized chondrocyte), 
EL4.NOB-1 and the EL-4.D6/76 were 
characterized on their cytokine responsive-
ness towards IL-1, IL-18, IL-17 and TNFα. 
The Luciferase expression was determined 
6 hours after culturing in the presence of 
cytokines, at which responsiveness was opti-
mal. Responsiveness and sensitivity towards 
above mentioned cytokines is summarized in 
table 1.
IL-1 responsiveness
The generated NFκB reporter cells were 
stimulated for 6 hours with murine recom-
binant IL-1α. Dose-response curves were 
analyzed and sensitivity was expressed by 
determination of the EC50 value. Non-linear 
regression analysis of EL4.NOB-1 revealed a 
–log EC50 value of 10.70±0.04 (19.90±0.90 
pg/ml). Further analysis of H4 chondrocyte 
and the NIH 3T3 reporter ﬁbroblast showed 
a –log EC50 value of respectively 10.47±0.02 
(34±0.96 pg/ml) and 9.85±0.04 (140±0.92 
pg/ml). The EL-4.D6/76 reporter cell 
showed no responsiveness towards IL-1 
(Figure 2A).  
IL-18 responsiveness
In order to determine the sensitivity of 
the generated NFκB reporter cells towards 
IL-18, cells were stimulated for 6 hours with 
different concentrations of murine recom-
binant IL-18. Similar to IL-1α, generated dose 
response curves were analyzed and sensitivity was 
expressed by determination of the EC50 value. 
Only the H4 chondrocyte and the EL-4.D6/76 
appeared responsive towards IL-18 and non-linear 
regression analysis revealed a –log EC50 value of 
respectively 8.70±0.04 (1940±0.91 pg/ml) and 
8.80±0.03 (1528±0.93 pg/ml) (Figure 2B).
TNFα responsiveness
Sensitivity towards TNFα was deter-
mined after 6 hours with different concen-
Table 1. Responsiveness and sensitivity towards NFκB inducing cytokines IL-1, -17, -18 and TNFα of constructed luciferase reporter cell lines. a
a Responsiveness and sensitivity of the diﬀerent reporter cell lines was determined for each individual cytokine.  Sensitivity was determined by calculation of the EC50 
values using GraphPad Prism 4.0 software package.  Responsiveness was evaluated through determination of the maximal biological response (Vmax) in Relative Light 
Units (RLU). ++; very good. +; good. +/-average. -; bad. --; not responsive/ sensitivity.
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trations of TNFα. Obtained dose response 
curves were analyzed as described previously. 
All cell types showed TNFα responsiveness. 
Highest sensitivity was observed on NIH 
3T3 reporter ﬁbroblasts and H4 reporter 
chondrocytes. Non-linear regression analysis 
of NIH 3T3 and H4 revealed a –log EC50 
value of 9.25±0.02 (558±0.96 pg/ml) and 
respectively 9.19±0.02 (641±0.94 pg/ml). 
Although EL4.NOB-1 reporter cells showed 
a proper TNFα response, cellular sensitiv-
ity was low which became evident in the 
–log EC50 value of 8.74±0.01 (1820±0.97 
pg/ml). Lowest TNFα responsiveness was 
observed on EL-4D6/76 although sensitivity 
was comparable with that of the H4 condro-
Figure 2. Characterization of cytokine response and sensitivity of diﬀerent luciferase reporter cell lines. 
The H4 chondrocyte cell line, NIH 3T3 ﬁbroblast cell line, EL4.NOB-1 and EL-4 D6/76, which are both thymocytic derived cell lines were characterized on their sensitivity 
towards a panel of NFκB inducing cytokines. Figure A represents the responsiveness of the NFκB luciferase reporter cell lines towards IL-1; B towards IL-18; C towards 
TNFα and D towards IL-17. Data are presented as dose-response curves of cytokine induced luciferase activity of triplicate measurements quantiﬁed in Relative Light 
Units (RLU)±SD. Sensitivity towards each individual cytokine is presented as EC50 value (g/ml) and summarized in the table below each graph. ND; No detectable 
response.
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cytes (Figure 2C). 
IL-17 responsiveness
Dose response curves were analyzed and 
H4 chondrocytes revealed highest sensitiv-
ity and responsiveness to IL-17 stimulus, as 
shown in ﬁgure 2D.  Non-linear regression 
analysis of H4 revealed a –log EC50 value 
of 8.72±0.13 (1914±0.74 pg/ml).  Speciﬁc 
IL-17 response was also observed on NIH 
3T3 ﬁbroblasts and EL4.NOB-1 thymocytes, 
although the sensitivity and responsiveness 
of the latter cell type is rather poor.  
Responsiveness towards bacterial 
components
Response of NIH 3T3 reporter ﬁbroblasts 
towards streptococcal cell wall components 
(SCW) and lipopolysaccharide (LPS) was 
determined in a dose dependent manner. Six 
hours of incubation with the TLR-4 agonist 
LPS at a concentration of less than 20 ng/ml 
already revealed a strong activation of NFκB 
(Figure 3A). Similar responsiveness was 
determined for the TLR-2 agonist SCW. Six 
hours of incubation with SCW components 
revealed a dose-dependent response, less 
potent in NFκB induction as compared to 
LPS (Figure 3B).
Application of reporter cell lines
The stable transfected reporter cell lines, 
which are described here, can be used for 
several speciﬁc applications.  These applica-
tions can vary from testing speciﬁc cytokine 
inhibitors and receptor antagonists to detailed 
study and elucidation of the NFκB signaling 
pathway. As already discussed, the selected 
cytokines are all able to induce NFκB activa-
tion. A schematic and simpliﬁed representa-
tion of the cytokine speciﬁc NFκB activation 
cascade is presented in ﬁgure 1. 
Inhibition assays
Inhibition of IL-1 induced NFκB 
activation by IL-1Ra
The IL-1 sensitive EL4.NOB-1 cell was 
used to test the sensitivity and speciﬁcity of 
the assay for IL-1 inhibition by IL-1Ra.  A 
concentration of 1 ng/ml recombinant IL-
1Ra was able to signiﬁcantly shift the IL-1 
Figure 3. Toll like receptor (TLR) signaling in reporter ﬁbroblasts
Responsiveness towards bacterial components was determined by exposing 
NIH 3T3 NFκB reporter ﬁbroblasts towards TLR-2 or 4 agonists. NFκB activity 
induced by LPS or SCW fragments are shown in ﬁgure A and B respectively. 
Data are presented as mean luciferase activity of triplicates, quantiﬁed in Rela-
tive Light Units (RLU)±SD. 
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dose response, and a concentration of 100 
ng/ml almost completely abolished IL-1 
signaling (Figure 4). These data conﬁrmed 
that in order to obtain complete IL-1 inhibi-
tion, a 1000-fold molar excess of IL-1Ra was 
needed.
Inhibition of IL-18 induced NFκB 
activation by IL-18BPc
In order to evaluate whether reporter 
cells could be directly used for determina-
tion of inhibitory activity present in culture 
supernatants, NIH 3T3 ﬁbroblasts were 
adenoviral transduced with IL-18 binding 
protein c (IL-18BPc). Conditioned culture 
supernatants of adenoviral transfected NIH 
3T3 ﬁbroblasts were collected and used 
for determination on their IL-18 neutral-
izing capability.   For this experiment the 
EL-4D6/76 IL-18 responsive cell line was 
used. Supernatant of cells transduced with 
AdIL-18BPc at a Multiplicity of infection 
(MOI) of 100 could completely inhibit IL-
18 response of 1 ng/ml IL-18. Incubation 
of conditioned supernatants with 10 ng/ml 
IL-18 resulted in an approximately 90% 
reduction of the IL-18 signal (Figure 5), 
as compared to the supernatant of control 
infected NIH 3T3 ﬁbroblasts cells.
Knock down of luciferase in NIH 3T3 
NFκB reporter fibroblast using siRNA 
results in decreased luciferase activity
In order to show the applicability of the 
reporter cell lines in studying intra-cellular 
signaling pathways using the RNA interfer-
Figure 4. Inhibition of IL-1 induced NFκB activation through IL-1Ra
The use of NFκB induced luciferase reporter cell lines enables eﬃcient and 
convenient testing of conventional and novel antagonists. EL4.NOB-1 lucif-
erase reporter cells were used as described in materials and methods for the 
determination of the antagonistic activity of recombinant IL-1 Receptor an-
tagonist (IL-1Ra). This ﬁgure shows a dose dependent inhibition of the IL-1 
signal using increasing dosages of IL-1Ra. Data presented as IL-1 dose response 
curves (triplicate measurement) versus increasing concentrations of IL-1Ra and 
quantiﬁed in Relative Light Units±SD.  
Figure 5. Testing IL-18BP antagonistic activity in supernatants of 
transfected cells
IL-18 sensitive EL-4.D6/76 reporter cells were applied to test IL-18 neutralizing 
activity of adenoviral overexpressed IL-18 Binding protein (IL-18BP). Culture 
supernatants of IL-18BP transfected cells at a Multiplicity of infection (MOI) of 
100 completely antagonized the IL-18 signal at 1 ng/ml. Supernatant of cells 
transfected with an adenoviral vector overexpressing Luciferase was used at 
similar MOI. Data presented as percentage of RLU±SD, n=3 per concentration 
IL-18.  *P<0.05 using students’ t-test.
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ence (RNAi), we developed short hairpin 
RNA vectors containing the murine U6 
RNA promoter which regulates expres-
sion of hairpin cDNA complementary to 
luciferase mRNA. NIH 3T3 reporter cells 
transfected with pU6 luciferase directed 
against luciferase mRNA showed a 
signiﬁcant reduction of basal levels lucif-
erase activity while the control plasmid 
(pU6mock) showed no reduction in basal 
luciferase activity (Figure 6A).
Knock down of NFκB in 
decreased luciferase expression
In order to show the applicability of 
the reporter cell lines in studying intra-
cellular signaling pathways using RNA 
silencing, we developed siRNA probes 
against several speciﬁc and non-speciﬁc 
target sequences. 3T3 NIH reporter cells 
transfected with dsRNA directed against 
murine NFκB p65 showed a reduction of 
basal levels of NFκB activity. Furthermore 
this transfection with dsRNA directed 
against mNFκB p65 showed a signiﬁcant 
inhibition of TNFα induced NFκB activ-
ity. Transfection with dsRNA directed 
against hALCAM or the human sequence 
of NFκB p65 revealed no reduction in 
basal and TNFα induced NFκB activity 
(Figure 6B). 
Discussion
Biological assays, which can be used 
for quantitative measurement of cytokine 
activity, are rather scarce and if available 
can be laborious. These assays, like for 
instance the TNF and IL-1 bioassays, take 
at least 24 hours to perform [3,13,14] but 
can be highly sensitive. Since these assays 
measure indirect effects we developed an 
assay, which depended on direct quantiﬁ-
cation of NFκB activation. Different cell 
types were transduced using a NFκB lucif-
Figure 6. Applicability of reporter cell lines in intracellular antago-
nism using RNA interference
A Speciﬁc knock-down of luciferase activity by transient transfection of NFκB 
reporter ﬁbroblasts using pU6 luciferase.  Transfection with the plasmid 
containing a complementary luciferase cDNA controlled by the murine tran-
scriptional regulatory RNA promoter resulted in a signiﬁcant knock down of 
basal luciferase activity. Control transfection with a vector containing only the 
murine U6 promoter did not aﬀect luciferase activity. B Speciﬁc gene silencing 
of NFκB using short interfering RNA (siRNA) resulted in signiﬁcant inhibition, 
which was not observed using siRNA directed against the human homologue 
or an irrelevant siRNA for ALCAM. Data presented as mean RLU (of n=6)±SD. 
*, P<0.01 using student’s t-test.
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erase reporter plasmid and selected on stable 
incorporation, giving rise to a broad family 
of reporter cell lines. The NFκB reporter 
assay as described in this paper is rapid and 
sensitive towards a broad scale of NFκB 
inducing stimuli. These cell lines can be 
efﬁciently used for screening of potential 
novel antagonists, either extra- or intracel-
lular, on their ability to speciﬁcally inhibit 
cytokine induced NFκB activity. Another 
advantage of using NFκB as readout is its 
rapid activation upon stimulation [15], 
which enables us to speed up assay time to 
6 hours. 
For speciﬁc measurement of IL-1 we 
developed a NFκB reporter cell line derived 
from the EL4.NOB-1, showing a high 
sensitivity towards IL-1 which could detect 
as little as 1 pg/ml. This is in line with the 
described sensitivity of the EL4.NOB-1 for 
IL-1 [3]. This IL-1 sensitivity makes this 
cell line ideal for the study of antagonist, 
like IL-1Ra in the IL-1 signal pathway 
(Figure 4). In order to completely inhibit 
IL-1 signaling on these EL4 NOB-1 NFκB 
reporter cells a 100 to 1000-fold excess of 
IL-1Ra was needed. This is in line with 
previous studies showing a similar excess 
of IL-1Ra, which validates the applicability 
of this reporter cell line for evaluating IL-1 
antagonistic potential [16]. By selecting the 
IL-1 insensitive EL4 subclone D6/76 we 
generated a NFκB reporter cell line, which 
is comparable to the EL4.NOB-1 reporter 
cell. This enables to discriminate between 
IL-1 dependent and independent activation 
of NFκB. 
A focus of our research is the involve-
ment of articular chondrocytes in develop-
ment of OA and RA. In order to investigate 
the responses of chondrocytes to cytokines 
or their environment, we developed a 
reporter cell line derived from immortal-
ized chondrocytes. This articular chon-
drocyte line H4 was created from chon-
drocytes obtained from articular cartilage 
and is well-characterized [17]. For tissue 
engineering, this reporter cell line could be 
of use when studying the response of chon-
drocytes seeded into an artiﬁcial matrix. 
However, these cells have a rather high 
basal NFκB activity, which can be reduced 
by culturing these cells under serum free 
conditions (Table1). 
With the characterization of the 
reporter ﬁbroblast cell line NIH 3T3 we 
have created an easy-to-use cell type that 
is very suitable for studying intracellular 
signaling. This adherent cell line, which 
has a low basal NFκB activity can be easily 
transfected making it suitable for silenc-
ing genes applying RNA interference. 
This enables high throughput screening 
of novel RNAi probes and targets in a 
mammalian test system. In our hands 
we were able to selectively inhibit NFκB 
signaling by knock down of NFκB p65 
and NFκB induced luciferase gene expres-
sion (Figure 6). 
With the developed reporter cell-lines 
we created a valuable pharmacological tool 
to study involvement of NF-κB activation 
in cellular processes and to evaluate cyto-
kine/NFκB based inhibition therapies.
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Nuclear factor κ B (NFκB) is highly activated in synovium of patients suﬀering from RA and can be induced by a wide variety of pro-inﬂammatory cytokines. Since NFκB is involved in regula-tion of inﬂammation, NFκB itself or its inducing agents are interesting therapeutical targets. 
We developed reporter cell lines in which activated NFκB controlled the ﬁreﬂy luciferase gene 
expression. These cell lines, derived from ﬁbroblasts and thymocytes, showed good cytokine 
responsiveness in vitro towards a panel of inﬂammatory cytokines e.g. IL-1 and TNF. Since NFκB 
activation can be observed in arthritic joints, we evaluated whether NFκB reporter cells could 
be used as biomonitors of “NFκB activating triggers” in vivo. Therefore, reporter cells were 
transplanted into the murine knee joints, followed by a single intra-articular (i.a.) injection of 
IL-1. IL-1 induced NFκB activity could be visualized using an in vivo imaging system. IL-1 induced 
NFκB activation was transient, lasting for only 24 hours. Furthermore, i.a. injection of IL-1 
resulted in activation of NFκB at remote sites, revealing systemic distribution of the monokine 
after injection. A more complex inﬂammatory process such as streptococcal cell wall (SCW) 
arthritis resulted in a signiﬁcant increase in NFκB activity, which remained detectable in the 
knee joint up to three days after SCW injection. SCW induced NFκB activation markedly corre-
lated with the inﬂammation.  Interestingly, SCW injection induced activation of NFκB at sites 
remote from the location of stimulus injection, which is the result of systemic cytokine spill over 
due to excessive SCW induced cytokine production. With this study we show the feasibility of 
reporter cell lines to monitor NFκB activation the murine knee joint. Furthermore, this approach 
enables the direct study of NFκB induced inﬂammation during experimental arthritis or during 
NFκB/cytokine based interventions.
Pro-inﬂammatory cytokines are crucial 
in maintenance and control of immunity and 
onset of inﬂammation. Several important pro-
inﬂammatory cytokines are Interleukin-1 
(IL-1), IL-18 and the Tumor Necrosis Factor 
α (TNFα). These speciﬁc pro-inﬂammatory 
cytokines have pleiotropic characteristics, 
which can induce multiple physiological 
responses after infection, tissue damage and 
stress. In the onset of an inﬂammatory process 
the intracellular transcription factor Nuclear 
Factor κB (NFκB) plays a key role.  NFκB is 
present in virtually every cell type and acti-
vation can be the result of many extracellular 
stimuli, other than pro-inﬂammatory cyto-
kines, such as bacterial and viral components 
and even physiological or chemical stress 
[1,2]. The importance of this transcription 
factor becomes evident in many human 
disorders e.g. arthritis and asthma in which 
inappropriate regulation of NFκB is involved 
[3].  Since its discovery, the eukaryotic tran-
scription factor NFκB has been shown to 
regulate gene expression in immunity and 
inﬂammation [1,4,5], resulting in  increased 
expression of cytokines, chemokines, adhe-
sion molecules and receptors involved in 
immune recognition [6]. Therefore regu-
lation of NFκB activation is an interesting 
target and speciﬁc inhibition of NFκB or its 
inducing cytokines could result in ameliora-
tion of several inﬂammation related diseases, 
like rheumatoid arthritis (RA) [7,8]. 
From experimental animal models of 
inﬂammatory arthritis it has become clear 
that NFkB activation plays a prominent 
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role in the pathogenesis. Localized NFκB 
activation can be observed in synovial tissue 
of animals suffering from collagen-induced 
arthritis (CIA), which gradually increases 
during development of disease [8]. Since 
NFκB is highly activated at sites of inﬂam-
mation and its activation plays a prominent 
role in arthritis, many treatments aim to 
selectively modulate NFκB activity, either 
directly by interfering with NFκB activ-
ity [9] or indirectly through modulation of 
pro-inﬂammatory cytokine signaling [10]. 
Direct interference on NFκB activation, 
using a speciﬁc NFκB inhibitor resulted in 
a signiﬁcantly reduced CIA disease severity 
due to suppressed NFκB activity in synovial 
tissue of arthritic mouse ankles [11]. 
In vivo imaging has been ﬁrst been described 
to study the pathogenic processes associated 
with salmonella infection in living animals 
[12]. By using ﬁreﬂy luciferase as reporter 
construct luminescence could be detected by 
the use of a photon sensitive CCD camera. 
This method of in vivo imaging in living 
animals has developed in recent years into a 
sensitive and successful technology to moni-
tor tumor growth [13,14] bacterial infections 
[12,15-17] and viral infections [18,19]. By 
development of transgenic reporter mice, 
this technique has been further evolved into 
a tool to study pathophysiological processes 
in vivo [20,21]. Recently transgenic NFκB 
reporter mice have been generated, which 
are suitable for real time studying of NFκB 
activity [20]. These transgenic animals have 
intrinsic luminescence in lymphoid tissue, 
like lymphnodes and thymus and show reac-
tivity to extrinsic stimuli such as TNFα or 
IL-1.  However, the use of these reporter 
mice is restricted to distinct ﬁelds of inter-
est, since the NFκB reactivity/sensitivity 
of reporter construct appears to be tissue 
speciﬁc in these transgenic mice. Further-
more, for induction of experimental arthritis 
the strain susceptibility or strain sensitivity 
towards the arthritis-inducing trigger is very 
important. Therefore, not all reporter mice 
strains are suitable in the study of experi-
mental arthritis. Hence, we developed a 
NFκB reporter system on a cellular base. 
With this study we describe and charac-
terize different new created stable transfected 
NFκB luciferase reporter cell lines. The 
generated reporter cell lines were validated 
in the murine Streptococcal Cell wall (SCW) 
induced arthritis model, which is an mono 
articular acute but transient inﬂammatory 
arthritis model, characterized by release of 
pro-inﬂammatory cytokines. The results 
presented here demonstrate the feasibility of 
localized reporter cell transfer in determining 
NFκB activation/NFκB activating triggers 
in the murine knee joint during processes of 
inﬂammatory arthritis. As NFκB is involved 
in many pathological processes, this reporter 
cell transfer could offer an easy and reproduc-
ible approach for studying NFκB activation 
and regulation in different animal models of 
experimental arthritis.
Materials and Methods
Animals
Male 10- to 12-week old Balb/c and C57/
BL6 mice were obtained from Charles River 
(Sulzfeld, Germany). Mice were housed 
in top-ﬁlter cages at the animal facility. 
The animals were fed a standard diet with 
water and food ad libitum. All in vivo studies 
complied with national legislation and were 
approved by local authorities of the Care and 
Use of Animals with related codes of prac-
tice.
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Construction of NFκB reporter 
plasmid
For determination of NFκB tran-
scription activity, a pGL3-Basic vector 
containing ﬁve tandemly arranged NFκB 
binding sites was constructed in the labora-
tory of Prof. Dr. W. Falk (dept of Inter-
nal Medicine, University of Regensburg, 
Germany). Brieﬂy, the NFκB binding sites 
were derived from the HIV long terminal 
repeat enhancer (5’-GGGACTTTCC-
3’) and cloned into the pCAT promoter 
vector. The created NFκB binding repeats 
plus minimal promoter from pCAT were 
excised from the vector using BglII and 
HindIII and inserted into the pGL3 basic 
vector (pGL3-5xNFκB). 
Construction of NFκB reporter 
plasmid for eukaryotic expression.
For construction of cells stably express-
ing the NFκB reporter construct, the insert 
containing NFκB binding repeats followed 
by the minimal promoter and luciferase 
gene was excised from the pGL3-5xNFκB 
using BglII and XbaI. The obtained 
construct was used for ligation into the 
eukayotic expression plasmid pcDNA3.1. 
The CMV promoter of the pcDNA3.1 was 
exchanged with the construct using BglII 
and XbaI. 
Preparation of stable transfected 
cell lines
For the preparation of stable transfected 
cells different celltypes were selected. NIH 
3T3 ﬁbroblasts and EL4.NOB-1 thymo-
cytes were transfected with the pcDNA 
3.1 NFκB-Luc, using Lipofectamin 2000 
according to manufacturers protocol. These 
celltypes were selected on stable incorpora-
tion of the transgene using Neomycin G418. 
All transfected cell types were submitted to 
clonal selection by limiting dilution. 
Cytokine sensitivity in vitro assay
The ability of the cytokines IL-1α, TNFα, 
IL-18 and IL-17 to induce NFκB activation 
was tested on the different NFκB reporter 
cell lines. One day prior to experiments 
reporter cells were seeded in Krystal 2000 
96 wells plates (Thermo Labsystems, Brussels, 
Belgium) at a concentration of 2-4x104 cells/
well. Cells were cultured at 5% CO2/37
oC. 
Dose response kinetics of the different cyto-
kines was determined after six hours of cyto-
kine incubation on the reporter cells. Cyto-
kine responsiveness of the reporter cells was 
quantiﬁed by measurement of NFκB induced 
production of Luciferase. Luciferase activity 
was quantiﬁed using Bright-Glo luciferase 
assay system (Promega, Madison, WI, USA) 
followed by luminometric detection accord-
ing to manufactures protocol (Polarstar galaxy, 
BMG, Offenburg, Germany). Sensitivity of 
reporter cell lines towards different cytokines 
was determined by calculation of EC50 values 
(g/ml). 
SCW preparation and induction of 
SCW arthritis
Streptococcus pyogenes T12 organisms were 
cultured overnight in Todd-Hewitt broth. 
Cell walls were prepared as described previ-
ously [22]. The resulting 10,000g superna-
tant was used in experiments and contained 
11% muramic acid. Acute unilateral arthritis 
was induced by i.a injection of 25 µg of SCW 
(Rhamnose content) dissolved in 5 µl of PBS 
into the right knee joints of C57/Bl6 mice.
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Real time monitoring of inflammation 
in vivo
Adherent NIH 3T3 reporter ﬁbroblasts 
were harvested using trypsin, washed two 
times with physiological salt solution and 
resuspended in RPMI without serum 
or antibiotics. The non-adherent EL4.
NOB-1 reporter thymocytes were also 
washed twice and resuspended in RPMI 
without additives. For this approach 
white Balb/c mice were injected with 
either EL4.NOB-1 reporter thymocytes 
(1x105 cells) or NIH 3T3 reporter ﬁbro-
blasts reporter cells (1x104 cells) i.a. into 
the right, left knee joint or sub-cutane-
ously in the ear. Mice either received an 
i.a. Injection IL-1 (10 ng) or 25 µg SCW 
fragments into the right knee joint. Prior 
to in vivo imaging mice were anesthe-
tized using isoﬂurane and injected intra-
peritoneally with 150 mg luciferin per kg 
body weight (Xenogen Corp., Alameda, 
CA, USA.) 
In vivo luciferase images were obtained 
using in vivo imaging system (Xenogen 
Corp.) and analyzed with the LivingImage 
2.11 software  (Xenogen Corp.). Lucifer-
ase images were acquired three, six and 24 
hours after either SCW or IL-1 injection. 
At each time point a background lucif-
erase measurement was obtained which 
represented mice injected with reporter 
cells, without IL-1. For visualization, 
photon emission transmitted from the 
mice was measured and the intensity 
was recorded as maximum [photons.s-1 . 
cm-1 . sr-1 (steradian)] within the region 
of interest (ROI). The ROI was selected 
manually over the signal intensity. The 
area of the ROI was kept constant and the 
photon counts were quantiﬁed within the 
ROI [photons.s-1 . cm-1].
Quantification of NFκB activity ex-vivo
For this approach C57/BL6 mice were 
injected with either EL4.NOB-1 reporter 
thymocytes (1x105 cells) or NIH 3T3 reporter 
ﬁbroblasts reporter cells (1x104 cells) i.a. into 
the right and left knee joint. Mice, which had 
been injected with the IL-1 sensitive EL.4 
NOB-1, received an IL-1 injection (10 ng) 
at one or seven days post cell transfer. Mice 
injected with NIH 3T3 reporter ﬁbroblasts 
received a single injected of 25 µg SCW frag-
ments i.a. into the right knee joint. Patella 
and large quantity of surrounding synovial 
tissue was dissected at one, three and seven 
days after SCW injection. Obtained tissue 
was taken up in dH2O and immediately snap 
frozen in liquid nitrogen. Before determina-
tion of NFκB induced luciferase expression 
tissue was lysed through three times freeze-
thaw cycles. Luciferase activity was quanti-
ﬁed using Bright-Glo luciferase assay system 
(Promega, Madison, WI, USA) followed by 
luminometric detection according to manu-
factures protocol (Polarstar galaxy, BMG, 
Offenburg, Germany). Luciferase expression 
quantiﬁed as Relative Light Units (RLU) 
were corrected for the total protein content, 
which was quantiﬁed using Coomassie 
protein assay reagent according to the manu-
factures protocol (Pierce). 
Quantification pro-inflammatory 
cytokine production after SCW 
stimulation
C57/BL6 mice were i.a. injected with 
25 µg of SCW and mice were sacriﬁced 
90 minutes, 4 hours or 24 hours thereafter. 
Patellae and surrounding synovial tissue 
were dissected from inﬂamed knee joints 
as previously described [23]. Isolated 
patellae were taken up into 200 µl RPMI 
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1640 containing 0.1% BSA and incubated 
for one hour at RT. Thereafter, superna-
tants of patellae were collected and cell 
debris was removed by centrifugation 
(5 minutes, 1000g). Cytokine levels for 
TNFα and IL-1β were determined using 
the Luminex multi-analite technology 
[24]. The Bioplex system in combination 
with multiplex cytokine kits was used. 
Cytokines content was analysed in 50 µl 
of patellae washout medium. The sensi-
tivity of the multiplex kit was ~5 pg/ml 
for TNFα and IL-1β
Measurement of joint 
inflammation
Joint inﬂammation was quantiﬁed 
using the technetium pertechnetate 
(99mTc)-uptake method [25]. This method 
quantiﬁes the accumulation of the radio-
isotope 99mTc at sites of inﬂammation by 
means of external gamma counting. The 
accumulation of the radioisotope is due to 
increased blood ﬂow and tissue swelling. 
The severity of inﬂammation is expressed 
as the ratio of 99mTc in the right (inﬂamed) 
over the left (non-inﬂamed) joint. All 
ratios exceeding 1.10 were assigned as 
inﬂammation.
Dose response curves and 
statistical analysis
Non-linear regression analysis was 
performed using GraphPad Prism 4.0 soft-
ware (GraphPad Software Inc., San Diego, 
CA, USA). The dose response curves 
were analysed and ﬁtted according to a 
sigmoidal dose response model (with vari-
able slope) and the concentration at which 
50% of the maximal cytokine response 
(EC50) was obtained was determined. 
Statistical differences between means were 
determined using student’s t-test or Mann-
Whitney U test. P values of 0.05 or less 
were regarded as signiﬁcant.
Figure 1. Characterization of cytokine response and sensitivity of two 
luciferase reporter cell lines. 
The reporter cell lines NIH 3T3 ﬁbroblast (A) and the thymoma derived cell line 
EL4.NOB-1 (B), in which luciferase gene expression was controlled by NFκB 
activity cell line and were characterized on their sensitivity towards a panel 
of NFκB inducing cytokines; IL-1, IL-18, TNFα and IL-17. 2-4x104 reporter cells 
were stimulated for 6 hours with the NFκB inducing cytokines. Dose response 
analyses of each cytokine were performed in duplo. Data are presented as 
mean luciferase activity quantiﬁed in Relative Light Units (RLU). Sensitivity 
towards each individual cytokine is determined as EC50 value (g/ml) and is 
shown in the result section. 
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Results
Characterization of reporter cell lines
The obtained reporter cell lines NIH 3T3 
(ﬁbroblast), EL4.NOB-1 were characterized 
on their cytokine responsiveness towards 
the NFκB inducing cytokines IL-1, IL-18, 
IL-17 and TNFα.  Cytokine sensitivity of 
EL.4NOB-1 NFκB thymocyte reporter cells 
was determined after stimulation for 6 hours 
with murine recombinant cytokines. Dose-
response curves were analyzed and sensitiv-
Figure 2. In vivo imaging of IL-1 induced NFκB activation in the murine 
knee joint
IL-1 sensitive EL4.NOB-1 reporter cells (1x105) were i.a. injected 1 hour prior to in-
jection of the NFκB inducing cytokine IL-1. IL-1 (10ng/ right knee joint) injection 
(red arrow) resulted in a clear, rapid transient activation of NFκB at the site of the 
monokine injection ( A). No NFκB activation was observed at three, six or twenty-
four hours in knee joints of control mice, which did not receive an injection of IL-1. 
The inserts represent the NFκB activation in the ear, which shows together with the 
contralateral joint the activation of NFκB at sites remote from the IL-1 injection. 
Figure B shows the quantiﬁcation of NFκB activity in the knee joints of mice using 
LivingImage 2.11 software, indicating the acute and transient nature of IL-1 induced 
NFκB activation. Results were visualized using the IVIS technology and emitted 
light was quantiﬁed as photons/sec/cm2. Data are presented as mean of two mice 
per group per time point. 
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ity was expressed by determination of the 
EC50 value. Non-linear regression analysis 
of EL4.NOB-1 revealed a –log EC50 value 
for IL-1 of 10.70±0.04 (19.90±0.90 pg/ml) 
(Figure 1A). Although EL4.NOB-1 reporter 
cells showed to be TNFα responsive,  sensi-
tivity was low which became evident in the 
–log EC50 value of 8.74±0.01 (1820±0.97 
pg/ml). The generated EL4.NOB-1 reporter 
cells were unresponsive towards IL-18 and 
IL-17.
The NIH 3T3 reporter ﬁbroblast showed 
a –log EC50 value for IL-1 and TNFα of 
respectively 9.85±0.04 (140±0.92 pg/ml) and 
9.25±0.02 (558±0.96 pg/ml) (Figure 1B). 
The generated NIH 3T3 were moderately 
sensitive towards IL-17, while no response 
towards IL-18 could be observed. 
Intra-articular injection of IL-1 
results in an acute but transient 
activation of NFκB.
Since EL4.NOB-1 reporter cells were 
highly sensitive towards IL-1 we used these 
cells for the in vivo imaging of IL-1 induced 
NFκB activation. Therefore, we transferred 
EL4.NOB-1 thymoctes into knee joints of 
naive Balb/c mice. NFκB activation was 
quantiﬁed as luciferase activity using the IVIS 
technology, which quantiﬁes light emitted 
from the organism. Intra-articular IL-1 injec-
tion resulted in a high luciferase signal, as can 
be observed in ﬁgure 2A. This emission was 
already present three hours after IL-1 injec-
tion, returning to basal levels after 24 hours. 
Interestingly, contralaterally deposited report-
er cells also responded towards IL-1 injected 
into the right knee joint, which reveals activa-
tion of NFκB at remote sites from the mono-
kine injection, such as the contralateral knee 
joint and the ear.  
Intra-articular transplanted reporter 
cells in vivo are retained in the knee 
joint cavity and remain sensitive 
towards IL-1 
Intra-articular deposited reporter cells were 
stimulated for 6 hours through i.a. injection 
with IL-1α after one or seven days after cell 
transfer in order to determine whether these 
cells were retained in the knee joint cavity 
and remained responsive. One day after cell 
transplant a clear and signiﬁcant IL-1 induced 
NFκB activation could be observed. The cells 
were retained in the knee joint cavity and 
sensitive towards exogenously injected IL-1 
up to seven days post cell transfer (Figure 3). 
Figure 3. Retention and responsiveness of i.a. transferred NFκB 
reporter cells.
Intra-articular injection of 10 ng IL-1 murine knee joint was able to induce 
NFκB activation up to seven days after cell transfer. 1x105 EL.4NOB-1 reporter 
cells were i.a. injected and mice received an i.a. injection of IL-1 at one or seven 
days post cell transfer. IL-1 induced NFκB activity was determined in knee 
joints of mice by quantiﬁcation of i.a. luciferase activity. Data are presented 
mean NFκB activity corrected for total protein content of the samples ± SD 
in 4 mice (eight knee joints per group) and measured in duplicate.  * P<0.05 
vs. control injected knee joints of C57/BL6, which only received the EL4.NOB-1 
reporter cells (naive).
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Single intra-articular injection of 
SCW induces an acute production 
of pro-inflammatory cytokines IL-1 
and TNFα and activation of NFκB
After showing the feasibility of reporter 
cell lines for in vivo monitoring of NFκB 
activity, we evaluated whether reporter 
cells could be used for monitoring a more 
complex inﬂammatory stimuli, such as 
SCW. Intra-articular injection of 25 µg 
SCW resulted in an acute release of pro-
inﬂammatory cytokines IL-1 and TNFα, 
which was already evident after 90 minutes, 
increasing towards four hours. Both IL-1 
and TNFα production at 24 hours after 
SCW challenge were signiﬁcantly reduced 
compared to four hours, revealing the 
acute character of SCW induced inﬂam-
mation (Figure 4).  
NFκB induced luciferase activity was 
quantiﬁed during the ﬁrst phase of acute 
SCW inﬂammation, which spanned 
up to 24 hours after SCW injection. As 
can be observed in ﬁgure 5, both EL4.
NOB-1 (Figure 5A) and NIH 3T3 (Figure 
5B) rapidly responded towards the SCW 
induced inﬂammation, which became 
evident in a marked increase in NFκB 
activation in the intra-articular deposited 
reporter cells. 
Interestingly and already evident three 
hours after SCW challenge, reporter cells 
deposited at sites remote from the SCW 
injection revealed an increase in NFκB 
activity.  Both reporter cell lines revealed 
an almost similar response towards SCW 
induced inﬂammation, although distinct 
kinetics of NFκB activity in EL4NOB-1, 
compared to NIH 3T3 ﬁbroblasts could 
be observed at 3 and 24 hours after SCW 
challenge. 
Figure 4. Streptococcal cell wall induces acute release of pro- 
inﬂammatory cytokines
Intra-articular 
injection of 25 µg 
of arthritogenic 
SCW components 
resulted in an 
acute release of the 
pro-inﬂammatory 
cytokines IL-1 and 
TNFα. Already af-
ter 1.5 hours after 
SCW injection high 
amounts of TNF can 
be detected in SCW 
challenged synovial 
washouts, with the 
maximal produc-
tion at 4 hours after 
SCW challenge. For 
IL-1 a similar kinetic 
of production could 
be observed. Data 
are presented as 
means±SD of sy-
novial washouts of patellae of three SCW challenged mice (n=6). Cytokine 
production wash determined using the Luminex multi analyte technology as 
described in materials and methods. *P<0.01 compared to control, **P<0.01 
cytokine production at 4 hours compared to 24 hours.
Reporter fibroblasts can be used 
as biomonitor of intra-articular 
NFκB activation during SCW 
arthritis.
SCW induces an acute but transient 
inﬂammation, which last up to a maxi-
mum of seven days. Therefore we quanti-
ﬁed NFκB activation at later stages during 
inﬂammatory arthritis, ranging from one 
to seven days after SCW injection. Quan-
tiﬁcation of NFκB activity was compared 
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to the conventional method of quantifying 
inﬂammation, using 99mTc (see for details 
Material and Methods section). Similar to 
previous experiments, SCW challenge 
signiﬁcantly increased NFκB activation 
at 24 hours after injection. From this time 
point NFκB activation gradually declined 
towards low NFκB activity at day 7 as can 
be observed in ﬁgure 6A. The inﬂamma-
tion, as quantiﬁed using 99mTc, is in paral-
lel with the observed NFκB activation in 
the SCW challenged joint (Figure 6B), 
revealed a signiﬁcant and positive correla-
tion between joint inﬂammation and intra-
articular NFκB activation.  
Localized inflammatory processes 
can induce NFκB activity at remote 
sites
Data obtained using the IVIS technol-
ogy, indicated that i.a. SCW injection 
increased activation of NFκB at sites 
remote from the SCW arthritis (Figure 3). 
Contralateral NFκB activity was evident at 
24 hours, returning towards basal NFκB 
activity after 3 days (Figure 7A), reveal-
ing a temporary character of contralateral 
NFκB activity. As can be observed in ﬁgure 
4, localized intra-articular SCW injection 
resulted in increased production of IL-1β 
(1826 pg/ml, four hours after SCW injec-
tion). Since the observed remote NFκB 
activity could be the result of systemic 
spill over of IL-1β, we wanted to deter-
mine whether contralateral NFkB activ-
ity was cytokine dependent. Treatment 
of mice with anti IL-1α/β IgG revealed 
that contralateral NFκB activation was 
signiﬁcantly reduced compared to control 
IgG injected animals, indicating at least a 
partial IL-1 dependency of remote NFκB 
activation (Figure 7B). 
Figure 5. Streptococcal cell wall injection results in acute NFκB acti-
vation 
Intra-articular injection of 25 µg of arthritogenic SCW components resulted 
in an acute activation of NFκB, which could already be detected using the IVIS 
technology three hours after SCW challenge. This SCW injection resulted in 
systemic NFκB activation as could be observed by detection of emitted light 
from reporter cells deposited in ears and contralateral knee joint. Control knee 
joints that only received reporter cells injection showed low basal NFκB activ-
ity compared to NFκB activity in SCW challenged mice. Figure A represents 
the EL.4NOB-1 cell transfer and ﬁgure B represents the NIH 3T3 cell transfer. 
Results were visualized using the IVIS technology and emitted light is quanti-
ﬁed as photons/sec/cm2. Data are presented as mean of two mice per group 
per time point. 
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Discussion
In this study we applied ex vivo cell 
transfer of genetically modiﬁed cell lines, 
in which luciferase gene expression is regu-
lated by NFκB activation, for the study of 
NFκB activation by cytokines during SCW 
arthritis. With this approach we were able 
to quantify NFκB activity at sites of interest, 
such as intra-articularly in the knee joint, but 
also at sites remote from the inﬂammatory 
process. Until now, the use of ex vivo cell 
transfer has been described as a strategy to 
achieve localized transgene expression in 
models of experimental arthritis, in order to 
obtain a sustained delivery of e.g. the IL-1 
Receptor antagonist (IL-1Ra) [26,27]. Here 
we describe a novel application of cell trans-
fer for the study of localized transcriptional 
activity of NFκB during inﬂammation. 
In order to quantify NFκB activation in 
an in vivo setting, we generated two trans-
genic NFκB responsive cell lines derived 
from murine EL.4NOB-1 thymoma cells and 
murine NIH 3T3 ﬁbroblast cells. By locally 
injecting the EL.4NOB-1 NFκB reporter 
cells into the murine knee joint we were able 
to speciﬁcally monitor IL-1 induced NFκB 
activation after injection of the monokine. 
Intra-articular IL-1 injection resulted in a 
transient NFκB activation, which decreased 
towards 24 hours after IL-1 injection. This 
decline in IL-1 responsiveness is in accor-
dance with the known retention of IL-1 in 
the murine knee joint cavity which shows 
that already six hours after IL-1 injection, less 
than 10% of the injected IL-1 is retained in 
the knee joint cavity [28]. Since EL.4NOB-1 
reporter cells were retained in the knee joint 
and remained sensitive towards IL-1α up to 
seven days, this makes them suitable for long-
term monitoring of NFκB activity.
In the development of experimental 
arthritis an important role appears to be 
reserved for NFκB or its inducing cytokines. 
Some of the best-studied NFκB inducing 
Figure 6. Streptococcal cell wall injection induced NFκB activity posi-
tively correlates to joint inﬂammation.
NFκB was highly activated in SCW challenged knee joints, and decreases in 
time towards basal NFκB activation (A). This NFκB activity strongly correlated 
with SCW induced knee joint swelling knee joint swelling (spearman’s r = 0.72, 
P<0.0001) which was measured using technetium uptake of the right inﬂamed 
over the left non-inﬂamed knee joint, at various time points after SCW arthritis 
(B). A right/left ratio higher than 1.10 was considered as inﬂammation. In-
duced NFκB activity was determined in knee joints of mice by quantiﬁcation 
of i.a. luciferase activity. Data are presented mean NFκB activity corrected for 
total protein content of the samples±SD. Each group consisted out of at least 
6 mice per group per time point measured in dulplicate. *P<0.05 vs. mice not 
intra-articularly challenged with SCW (naive).  
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cytokines in arthritis are IL-1 and TNFα. 
Although both cytokines can induce NFκB 
activity in a wide variety of cells [29,30], 
their role in experimental arthritis appears 
to be very distinct. By using soluble TNFα 
binding protein or anti IL-1 α/β anti-bodies 
in models of murine SCW arthritis or murine 
collagen type II induced arthritis it became 
clear that TNFα inhibition reduced joint 
swelling, while IL-1 inhibition protected 
against cartilage loss [31,32]. As i.a. injected 
SCW components induce an acute but tran-
sient inﬂammatory arthritis [31], this stimu-
lus was deployed for determination of NFκB 
activation during the acute phase of inﬂam-
mation. Our results show that i.a. injection of 
SCW results in a rapid activation of NFκB in 
the i.a. deposited reporter cells. As expected, 
this NFκB activation was in parallel with the 
observed rapid increase of SCW induced IL-1 
and TNFα release by the synovium. Although 
it is likely that the excessive release of NFκB 
inducing cytokines from the synovium will 
results in increased NFκB activity, SCW can 
also induce production of antagonists or anti-
inﬂammatory cytokines from the synovium, 
like IL-1Ra and IL-10 [33]. This balance of 
pro- versus anti-inﬂammatory proteins could 
be reﬂected in the NFκB activity determined 
in SCW challenged knee-joints.
Since we observed that SCW injection 
results in a rapid release of TNFα, which 
itself is responsible for joint swelling [32], 
we wanted to evaluate whether the TNFα 
mediated process of joint inﬂammation 
corresponded with the onset of SCW 
induced NFκB activity in the joint. As 
can be observed in ﬁgure 6 SCW induced 
NFκB activation was positively correlated 
with joint inﬂammation; high NFκB activ-
ity in the SCW challenged knee joints 
corresponded with severe inﬂammation, 
while basal NFκB activity corresponded to 
no detectable inﬂammation. This positive 
correlation reveals the relation between 
SCW induced joint swelling/inﬂammation 
and NFκB activation, which provides the 
basis for the feasibility of these reporter cells 
Figure 7. Streptococcal cell wall injection induces contralateral NFκB 
activity
 Intra-articular injection of SCW in mice, which had been previously i.a. injected 
with NIH 3T3 NFκB reporter, resulted in a clear NFκB activation in contralater-
al knee joints. Figure A shows that SCW injection resulted in NFκB activation 
in the contralateral non-SCW receiving knee joint. The NFκB activation in the 
SCW challenged knee joint was in parallel with the kinetics of the NFκB activa-
tion in the SCW receiving knee joint. SCW injected i.a. into mice systemically 
treated with neutralizing anti IL-1α/β showed reduced contralateral NFκB 
activity, compared to control IgG treated animals (B). Induced NFκB activity 
was determined in knee joints of mice by quantiﬁcation of i.a. luciferase activ-
ity. Data are presented mean NFκB activity corrected for total protein content 
of the samples±SD of at least ﬁve mice per group per time point. Luciferase 
activity was determined in dissected knee joints and measured in duplicate. 
*P<0.05 vs. mice that only received NIH 3T3 reporter cell injection. 
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as in vivo biomonitors of NFκB activity and 
inﬂammatory processes.
The fact that NFkB activity could be 
clearly observed at sites remote from the 
location of stimulus (IL-1 or SCW) injec-
tion, as can be observed in ﬁgure 2 and 6, 
implies that a localized process can evoke 
systemic activation of NFκB.   SCW injec-
tion resulted in a rapid increase of NFκB 
activation throughout the body, which 
could be due to the excessive production 
of NFκB inducing cytokines such as IL-1 
and TNFα. A similar phenomenon can be 
observed in mice suffering from collagen-in-
duced arthritis, which are locally treated 
through i.a overexpression of IL-1Ra. In 
these mice i.a. adenoviral overexpression 
of IL-1Ra results in an ipsilateral protec-
tion of the ankle joints [26]. This ipsilat-
eral protection is the result of either spill 
over of i.a. produced IL-1Ra or through a 
direct reduction of inﬂammation derived 
cytokines in the knee joint. Recent studies, 
using i.a. adenoviral gene delivery of IL-1 
and TNFα inhibitors have conﬁrmed these 
distal therapeutic effects [34-36]. These 
authors suggest however that therapeutic 
effects observed in distant joints, are not 
likely to be due to systemic leakage of i.a. 
overexpressed inhibitors or cytokines, but 
rather the result of a cell mediated antigen 
speciﬁc immune regulation in the contra-
lateral joint. In our study using an acute 
inﬂammatory stimulus, like SCW we show 
that contralateral responses can already be 
evoked after three hours and furthermore 
we show that this contralateral NFκB acti-
vation is partially IL-1 dependent (Figure 
7B). This quick induction of the contralat-
eral NFκB activation together with the IL-1 
dependency favors a mechanism in which 
distant NFκB activation is directly cytokine 
mediated. This suggests that circulating pro-
inﬂammatory cytokines can pre-sensitize 
the contralateral joint for the development 
of an arthritic event. Since we observed 
that contralateral NFκB activation alone 
did not lead to inﬂammation, an additional 
role for antigen speciﬁc immuneresponse is 
a prerequisite.
The injection of reporter cells can be a 
beneﬁcial approach in the study of local-
ized processes, such as NFκB activation 
in the inﬂamed joint during experimental 
arthritis. For long-term study of NFκB 
activity using reporter cell transfer, autolo-
gous reporter cells should be developed in 
order to minimize the effect of rejection. 
Recently, transgenic NFκB reporter mice 
have been developed for real time imaging 
of NFκB activity in living animals [20]. 
One advantage of these mice is that NFκB 
activation is determined directly in resident 
cells and not, as in our case indirectly in 
transplanted cells. Although these mice 
can be used for imaging of NFκB activity 
in living animals, exogenous injection of 
pro-inﬂammatory cytokines such as IL-1 
results in tissue speciﬁc NFκB activation. 
This NFκB activity was mainly focused to 
tissue of lymphoid origin. Since generation 
of transgenic reporter mice is time consum-
ing and strain background determines 
their susceptibility towards induction of 
experimental arthritis, the use of localized 
deposition of NFκB reporter cells could be 
a simple alternative or additional procedure 
to monitor transcriptional activity in vivo. 
Conclusion
With the development of these stable 
transduced and highly IL-1 and TNFα sensi-
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tive NFκB reporter cell lines, we have creat-
ed a novel approach for monitoring NFκB 
transciption activation in the arthritic joint. 
We show that NFκB activation during SCW 
arthritis parallels the kinetics of development 
of inﬂammatory joint swelling. Further-
more, we show that localized injection of 
either cytokines or arthritogenic stimulus 
can result in NFκB activity at sites remote 
from injection.
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Involvement of IL-1 and IL-18 
in experimental arthritis
Although much of the RA pathogen-
esis remains to be elucidated, it is gener-
ally accepted that IL-1 plays a key role in the 
instigation of the arthritis. As mentioned in 
Chapter 1, IL-1 was originally described as 
an important lymphocytic factor involved in 
the attraction of polymorphonuclear cells and 
was able to inﬂuence cartilage ECM homeo-
stasis by reducing chondrocyte proteoglycan 
production. Neutralization of IL-1 in models 
of experimental arthritis using anti-IL-1α/β 
antibodies and recombinant IL-1Ra showed a 
marked protection against cartilage and bone 
destruction [1,2]. In line with these results, we 
observed that systemic adenoviral mediated 
overexpression of IL-1Ra, before onset of the 
CIA completely blocked the progression of 
the arthritis. The disease activity in IL-1Ra 
treated animals remained repressed for several 
weeks and arthritis did not occur even after 
the expression of the transgene was lost.  Inter-
estingly, the repressed arthritis could be acti-
vated through intraperitoneal injection of PBS 
containing bovine collagen type II (unpublished 
observation). This suggests that antigen-speciﬁc 
reactivation of T-cells is important in the 
induction of arthritis. Together with these 
data we showed a direct involvement of IL-1 
in T-cell proliferation (Chapter 4), which is 
in line with the recently published studies by 
Iwakura and colleagues, who nicely showed the 
role of IL-1 in development of autoimmunity, 
through direct sensitization and activation of 
T-cell immunity [3-6]. Therefore IL-1 appears 
not only to be directly involved the deleterious 
processes affecting cartilage and bone, but also 
plays a determinant role in T-cell activation 
during experimental arthritis. 
As described in Chapter 1 both IL-1 and 
IL-18 are important members of the IL-1 
ligand superfamily, showing great homology, 
not only structurally but also functionally. 
Compared with IL-1, IL-18 can also directly 
The pro-inﬂammatory cytokines Interleukin-1 (IL-1) and Interleukin-18 (IL-18) are crucial media-tors in processes controlling inﬂammation. Both cytokines belong to the IL-1 ligand superfamily, sharing similar structural properties. Furthermore, both IL-1 and IL-18 signal transducing receptor 
complexes are remarkably similar and activation of the intracellular signaling cascade eventually 
leads to activation of NFκB. As both cytokines play important roles in the development of immu-
nity, signaling of these cytokines is eﬃciently ﬁne-tuned. This becomes evident with the discovery 
of circulating and membrane bound modulatory molecules, such as membrane associated decoy 
receptors and soluble receptor antagonists, which regulate signaling at receptor level. Recently 
partial analogues of IL-18 and IL-1 membrane signaling receptors have been described although 
their exact physiological function remained unclear. 
 The aim of the project underlying this thesis was to evaluate the role of IL-1 and IL-18 in experi-
mental arthritis, characterize the recently described soluble receptor analogues and evaluate their 
physiological function in models of experimental arthritis. In this chapter, the contribution of the 
studies previously described in this thesis will be discussed in respect to the present knowledge 
concerning IL-1/IL-18 cytokine signaling modulation. 
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novel class of soluble receptors has been 
described. This non-ligand binding receptor 
is present in the human and mouse serum [11] 
and is highly expressed in the liver (Figure 2) 
[12,13]. Although a lot has been speculated 
concerning the function of this accessory 
receptor molecule as a modulator of IL-1, 
little concrete evidence has yet been provid-
ed. First experiments performed using the 
sIL-1RAcP as a proposed antagonist of IL-1 
signaling on HepG2 cells showed that the 
sIL-1RAcP had to be membrane anchored 
in order to achieve IL-1 inhibition in vitro 
[13], which is in line with the observation 
by Huang et al who showed that a C-termi-
nal truncated IL-1RAcP could not mediate 
IL-1 signaling [14]. Since this membrane-
anchored variant was able to inhibit IL-1 
signaling, it was suggested that the inability 
of sIL-1RAcP to inhibit IL-1 was due to a 
low concentration of antagonist sIL-1RAcP 
at the membrane. Recently, we showed that 
sIL-1RAcP was a functional antagonist of 
IL-1, which was able to ameliorate CIA in 
mice (Chapter 3). 
Through local and systemic overexpres-
sion of sIL-1RAcP in vivo we were able to 
reduce the severity of the CIA, although 
the precise mechanism of action remained 
to be established. In chapter 4 we showed 
that systemic overexpression affected B-cell 
immunity (anti-bovine collagen type II IgG 
levels), without affecting T-cell activity. This 
amelioration of CIA could be easily explained 
by the fact that sIL-1RAcP can interact with 
the IL-1 binding sIL-1R II, forming a high 
afﬁnity IL-1 trap [11]. Although this obser-
vation could indeed be the working mecha-
nism responsible for the observed effects 
in vivo, we also observed a direct effect of 
sIL-1RAcP on IL-1 signaling in cell culture 
systems. This latter observation suggested a 
inﬂuence T-cell immunity, in which it plays a 
key role in the development of Th1 mediated 
immune responses [7,8]. Furthermore and simi-
lar to IL-1, IL-18 serves as a neutrophil attractant 
and activator in vivo [9]. However, direct effects 
of this pro-inﬂammatory cytokine on joint 
destruction and joint inﬂammation remained to 
be studied. In Chapter 2 we describe the effect 
of IL-18 on joint inﬂammation, and cartilage 
destruction. Adenoviral overexpression of 
IL-18 resulted in pronounced joint inﬂamma-
tion and cartilage proteoglycan loss. In line 
with previous ﬁndings [9,10], we showed that 
IL-18 predominantly attracts neutrophils to the 
joint tissue. This effect of IL-18 on cell inﬂux 
and joint swelling was partly TNFα dependent, 
while cartilage proteoglycan loss was not. IL-18 
gene transfer in IL-1-deﬁcient mice abolished 
cartilage proteoglycan loss, while joint inﬂam-
mation remained present. IL-18 induced carti-
lage degradation was further studied in vitro. 
Incubation of patellae with IL-18 in the pres-
ence of IL-1Ra or an ICE-inhibitor completely 
protected against IL-18 mediated cartilage 
degradation. 
These data showed that IL-18 can play a 
prominent role in the initiation of  inﬂamma-
tion and cartilage degradation in vivo. Similar 
to IL-18, IL-1 can also lead to inﬂammation 
and cartilage damage. Although both cytokines 
have overlapping properties combination strate-
gies neutralizing both IL-1 and IL-18 could 
provide beneﬁcial protection against experi-
mental arthritis.
Soluble IL-1 and IL-18 
Receptor analogues
The soluble IL-1 Receptor accessory 
protein
With the discovery of the sIL-1RAcP a 
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direct involvement of sIL-1RAcP on IL-1 
receptor complex formation. High expres-
sion of the IL-1RII on B-cells could make 
B-cells more susceptible for sIL-1RAcP 
induced IL-1 inhibition in contrast to T-cells, 
which expressed less IL-1R II. By using cell 
lines which differed in their receptor expres-
sion for the IL-1RII or IL-1RAcP we were 
able to show that sIL-1RAcP was indeed an 
antagonist of IL-1, which was functional on 
cells expressing either high levels of IL-1RII 
or low levels of IL-1RAcP. Due to the fact 
that the IL-1R II serves as a IL-1 scavenger 
by binding IL-1 and hampers the IL-1RAcP 
from forming a functional complex with the 
IL-1R I, the IL-1R II indirectly determines 
the availability of IL-1RAcP. This reveals a 
mechanism in which sIL-1RAcP functions as 
an antagonist of IL-1, probably dependent on 
the availability of its full-length membrane 
bound IL-1RAcP (Figure 1).  Since IL-1Ra, 
which was used as control antagonist in these 
experiments, competes with IL-1 for the 
occupation of the IL-1RI, this antagonist’s 
activity is not determined by the expression 
of the IL-1RII and IL-1RAcP but is only 
dependent on the relative ratio between 
agonist (IL-1) and antagonist (IL-1Ra). These 
Figure 1.  Mechanism of IL-1 inhibition by sIL-1RAcP. The sIL-1RAcP interferes with the IL-1 signal transduction at two levels. 
The ﬁrst level is extracellular; The sIL-1RAcP interacts with the sIL-1R type II, forming an circulating IL-1 trap [11]. Since a circulating form of the IL-1R type I has also 
been described it could be likely that sIL-1RAcP can also interact with this soluble receptor, although no evidence has been provided yet. The second level of interaction 
is at the membrane level; sIL-1RAcP interacts with the IL-1R type I, preventing the membrane IL-1RAcP from associating, resulting in inhibited IL-1 signal transduction. 
In Chapter 4 we describe the importance of membrane IL-1RAcP expression on cells in sIL-1RAcP mediated IL-1 inhibition. Although the physical interaction between 
sIL-1RAcP and the IL-1R type I has not been described, we suggest a mechanism of accessory receptor competition based on our ﬁndings (Chapter 4). 
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data show that sIL-1RAcP is an inhibitor of 
IL-1 distinct from IL-1Ra. Interestingly, this 
difference between sIL-1RAcP and IL-1Ra 
is that sIL-1RAcP is a non-ligand binding 
molecule and IL-1Ra mainly associates to 
the IL-1RI, which does not result in recruit-
ment of the IL-1RAcP. Based on these facts 
we combined both inhibitors and showed in 
Chapter 5 that combination therapy with 
both inhibitors results in clear and additional 
inhibition of IL-1 signaling and amelioration 
of CIA. 
The IL-18 Binding Protein
To this date no natural occurring IL-18 
neutralizing proteins have been described 
other than the IL-18BP. The therapeutic 
relevance of this protein has been previ-
ously described in the murine CIA model. 
Systemic injection of recombinant IL-18BP 
before clinical manifestation of the experi-
mental arthritis signiﬁcantly reduced the 
severity of the arthritis [15]. In Chapter 6 
we show that localized adenoviral mediated 
gene transfer of the IL-18BP was able to 
protect joints against the deleterious effects 
of the CIA. Furthermore, we showed the 
importance of IL-18 in the onset of local 
inﬂammation. Interestingly, intra-articular 
IL-18BP overexpression in the knee joints 
resulted in an additional protection of the 
distal paw and ankle joint against the CIA. 
We observed a reduction in both the inci-
dence and severity of the arthritis, which is 
due to the direct involvement of IL-18 in 
the recruitment of polymorphonuclear cells 
into the inﬂammatory tissue and the induc-
tion of pro-inﬂammatory cytokines such as 
IL-1 (Chapter 2 and [9]). As IL-18 itself can 
induce cartilage damage, indirectly through 
IL-1β, blockage of IL-18 via IL-18BP nicely 
protected against cartilage damage. Not 
only can blocking of IL-18 result in less 
severe inﬂammation in IL-18BP treated 
animals, it could also retard the development 
of Th1 immunity, which can be observed as 
a signiﬁcant reduction in circulating IgG2a 
antibodies [16]. Taken together, the target-
ing of IL-18 could offer a novel therapy, since 
IL-18 directly promotes T-cell immunity 
and contributes to cartilage damage through 
induction of IL-1 and attraction and activa-
tion of polymorphonuclear cells. 
The soluble IL-18 Rβ
As already mentioned, IL-18 plays an 
important role in T-cell immunity. Together 
with IL-12, IL-18 is able to stimulate the 
development of Th1 maturation. These Th1 
cells play a prominent role in the development 
of CIA. Recently, a soluble variant of the 
IL-18Rβ, which is structurally related to the 
IL-1RAcP, has been described. In rat species, 
sIL-18Rβ is expressed in the brain, in which 
it is suggested to function as a putative regula-
tor of IL-18 [17]. In Chapter 7 we described 
a novel mouse variant of the IL-18Rβ, which 
is highly expressed in tissue of lymphoid 
origin, suggesting a role in immunoregula-
tion. Although this sIL-18Rβ is much shorter 
than its IL-1 relative sIL-1RAcP, in that it 
only possesses one single Ig-like domain, we 
suggest that this soluble receptor analogue 
also functions as a putative modulator of 
IL-18 signaling. Based on the decreased IFNγ 
production by T-cells from mice treated 
with sIL-18Rβ (Chapter 7), sIL-18Rβ could 
well inhibit IL-18 induced generation of Th1 
immunity, although direct evidence needs to 
be provided. Interestingly, we also observed 
increased anti-bovine collagen type II IgG1 
production and reduced IL-10, which is a 
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key effector regulatory cytokine produced 
by regulatory T-cells [18]. Altogether these 
results could reﬂect a transition of a Th1 into 
a Th2 mediated disease, supporting evidence 
for a function of sIL-18Rβ as a regulator of 
IL-18 signaling. This possible role in regu-
lation of T-cell function is further empha-
sized by the expression proﬁle of sIL-18Rβ 
mRNA. Figure 2 shows mRNA expression 
of both soluble accessory proteins in tissues 
of murine origin.
As can be observed, sIL-18Rβ is highly 
expressed in tissue of lymphoid origin and no 
expression of sIL-18Rβ could be observed in 
the so-called immune privileged organs, in 
which immune cell invasion is strictly regu-
lated such as testis, brain and eye. This could 
further emphasize the role of sIL-18Rβ as a 
putative regulator of T-cell immunity. Inter-
estingly and in contrast to the sIL-18Rβ, the 
sIL-1RAcP was not expressed in tissue of 
lymphoid origin, which could underline the 
inability of this soluble receptor to modulate 
T-cell function.
 Since the sIL-18Rβ shares structural simi-
larities with the sIL-1RAcP, the mechanism 
by which both soluble receptors function 
could also be comparable. The sIL-1RAcP 
can interact with the sIL-1R II, which 
results in the formation of a high afﬁnity 
IL-1 trap. Like sIL-1R II, the IL-18BP is 
also a natural occurring cytokine sequester. 
Structurally the IL-18BP only comprises 
one single Ig-like domain [19,20], similar to 
the sIL-18Rβ (Chapter 7). It could there-
fore be possible that the sIL-18Rβ acts as a 
sIL-1RAcP analogue interacting with the IL-
18BP (Figure 3), increasing its IL-18 binding 
afﬁnity. As both IL-1 and IL-18 antagonism 
can efﬁciently ameliorate experimental 
arthritis, as can be observed by overexpressing 
sIL-1RAcP (Chapter 3) or IL-18BP (Chap-
ter 6), we speculated that sIL-18Rβ could 
also reduce arthritis. However, compared 
to sIL-1RAcP, overexpression of sIL-18Rβ 
revealed a distinct but different effect on 
the outcome of the arthritis. As shown in 
Chapter 4 sIL-1RAcP ameliorated CIA by 
reducing levels of circulating anti-bovine 
collagen type II antibodies. In contrast, 
systemic overexpression of sIL-18Rβ aggra-
vated CIA and increased levels of circulating 
anti-BCII antibodies were found (Chapter 
7). To elucidate the role of this novel protein 
additional research has to be done, which 
requires in vitro experiments studying the 
involvement of sIL-18Rβ on IL-18 signaling 
using recombinant sIL-18Rβ. 
Figure 2. mRNA expression of both sIL-1RAcP and the sIL-18Rβ, 
compared with GAPDH (upper panel) in murine tissue. 
The soluble variant of the IL-1RAcP is highly expressed in liver, heart 
and kidney, while the sIL-18Rβ reveals a diﬀerent mRNA expression 
proﬁle. This sIL-18Rβ, which is suggested to be a putative regulator 
of IL-18 signaling, is mainly expressed in tissue of lymphoid origin. 
Interestingly, immune privileged organs such as the testis show no 
expression, underlining the possibility of involvement in regulation 
of T-cell immunity.
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NFκB as a biomarker for inflammation
Since many pro-inﬂammatory cytokines 
are able to induce NFκB directed gene acti-
vation in different subsets of cells, we created 
an easy-to-use bioassay for direct quantiﬁ-
cation of cytokine induced NFκB activity 
(Chapter 8). Different cell types, including 
ﬁbroblasts, chondrocytes and thymocytes 
were stable transfected with a luciferase 
reporter gene under the control of an NFκB 
responsive promoter. These cell lines have 
been used in the previous chapters for quan-
tiﬁcation of cytokine activity and antagonist 
efﬁcacy, including the sIL-1RAcP (Chap-
ters 3-5) and the IL-18BP (Chapter 6). This 
methods chapter does not only describe the 
use of reporter cell lines for screening of 
cytokine inhibitor efﬁcacy, but also shows 
the applicability for the in vitro screening of 
siRNA functionality. Since cytokine signal-
ing can also be inhibited at the intracellular 
level, as described in Chapter 1, these cell 
lines could also be used for selecting a func-
tional intracellular target for interference of 
cytokine signaling. Of particular interest 
would be the adaptor protein MyD88 or 
IRAK, which are both crucial mediators of 
IL-1 and IL-18 signaling. Furthermore, with 
the use of siRNA we could also attempt to 
knockdown the expression of membrane 
IL-1RAcP or IL-18Rβ, leading to decreased 
sensitivity of cells towards either IL-1 or IL-
18. 
Of great interest, NFκB reporter cell lines 
can also be used for the in vivo imaging of 
NFκB activity. We showed in Chapter 9 
Figure 3. Possible mechanisms by which 
sIL-18Rβ modulates IL-18 signaling. 
The proposed interactions depicted in this 
ﬁgure are hypothetic and further research 
is needed to elucidate the function of the 
IL-18Rβ in vivo. IL-18BP; IL-18 binding protein. 
IL-18Rα; also known as the IL-1Rrp. IL-18Rβ; 
also known as the IL-1R accessory protein like. 
Activation of signal transduction by IL-18 will 
eventually lead to activation of intra-cellular 
signal transduction and pro-inﬂammatory 
gene transcription.
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that by transplantation of NFκB luciferase 
reporter cells in mice suffering from SCW 
induced arthritis we were able to monitor 
the NFκB activity during inﬂammation. 
Furthermore, this NFκB activation was not 
only restricted to the SCW challenged knee 
joints, but also lead to systemic activity of 
NFκB. In this chapter we propose that this 
systemic NFκB activation is due to systemic 
spill over of pro-inﬂammatory cytokines 
e.g. IL-1, which is produced at sites of SCW 
induced inﬂammation. The observed NFκB 
activation signiﬁcantly correlated with 
amount of inﬂammation, providing a ratio-
nal for using NFκB reporter cell lines for 
the quantiﬁcation of localized inﬂammatory 
processes, as can be observed in models of 
experimental arthritis. 
Like NFκB activation at sites remote from 
inﬂammation, similarities can be observed 
between this phenomenon and the treat-
ment of a localized inﬂammation using over-
expression of pro-inﬂammatory cytokine 
antagonists. Intra-articular overexpression 
of the IL-1Ra in the CIA will lead to addi-
tional protection of the distal hindpaw and 
ankle joints in mice [21]. We also observed a 
comparable effect using the IL-18BP (Chap-
ter 5). Whether this effect is due to reduced 
cytokine spill over from protected knee joints 
or distribution of locally produced cytokine 
antagonist remains to be established. 
Future perspectives
In this thesis studies concerning the role 
of IL-1 and IL-18 and the effects of inhibi-
tion of these pro-inﬂammatory cytokines 
in experimental arthritis are described. The 
main focus was to elucidate the function of 
natural occurring soluble receptor proteins 
of the IL-1 and IL-18 receptor family, and 
describe their possible therapeutic relevance. 
The present set of data showed that the 
sIL-1RAcP indeed was a inhibitor of IL-1 
functional in experimental arthritis. Since 
we suggest that sIL-1RAcP interferes with 
IL-1 signaling at membrane level through 
competition with the mIL-1RAcP and it 
has been shown that sIL-1RAcP interacts 
at extra cellular level with the sIL-1R II, 
it will be challenging to show functional 
interaction between the sIL-1RAcP and the 
IL-1RI. This will be the crucial evidence, 
which has to be provided in order to support 
our model of sIL-1RAcP interference at 
membrane level. From our studies it appears 
that the mechanism of action by which 
sIL-1RAcP interferes with IL-1 signaling 
is distinct from IL-1Ra.  The mechanism 
by which sIL-1RAcP inhibits IL-1 signal-
ing appears dependent on the availability 
of membrane IL-1RAcP. IL-1Ra inhibits 
IL-1 signaling by competing with IL-1 for 
occupation of the IL-1R I. This difference 
between the well-studied IL-1Ra, which has 
already been brought to the clinic and the 
sIL-1RAcP, could provide additive therapy 
for neutralizing IL-1. Since sIL-1RAcP does 
not interfere with the antagonistic activity of 
IL-1Ra and mainly affects humoral immuni-
ty, the effective amount of IL-1Ra could be 
reduced, leaving the T-cell function intact. 
This reduction of IL-1Ra could be beneﬁcial 
resulting in less severe side effects.
The other IL-1 family member, IL-18 has 
also been given an important function in the 
initiation of inﬂammation and its role in the 
RA pathogenesis becomes more and more 
evident. It has become clear that inhibition of 
IL-18 in experimental arthritis using either 
neutralizing IL-18 antibodies or the IL-18BP 
is of therapeutic interest. Both systemic and 
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localized intra-articular neutralization of 
IL-18 were able to ameliorate the disease. 
Since IL-18 is a pro-inﬂammatory cytokine, 
which can promote the development of 
T-cell immunity and IL-1 induced cartilage 
destruction, neutralization of IL-18 may 
provide a novel therapy for treating RA. 
As for the sIL-18Rβ, much remains to be 
elucidated. In this thesis we characterized 
the expression of the protein in different 
mouse tissues and evaluated the role of this 
putative IL-18 regulator by systemic overex-
pression using a gene therapeutic approach. 
Systemic overexpression lead to aggravated 
CIA, which we suppose was due to diver-
gence of a Th1 to a Th2 mediated inﬂam-
mation. Since we also observed reduced 
levels of circulating IL-10, which is a key 
effector regulatory cytokine produced by 
regulatory T-cells, this observed effect could 
also be a result of reduced Treg function in 
vivo. In line with these results we recently 
observed that IL-18 stimulation of puriﬁed 
splenic T-cells resulted in the induction of 
CD4+/CD25+ T-cells, suggesting a role for 
IL-18 in the induction of regulatory T-cells. 
If this population is indeed a regulatory 
T-cell subset needs further investigation. 
The effects of sIL-18Rβ overexpression in 
vivo provide a novel and interesting ﬁeld of 
research, although puriﬁed recombinant 
protein will be needed to gather further 
evidence for the regulatory role of this 
novel protein on T-cell function.
Conclusion
In summary we conclude that both IL-1 
and IL-18 play a prominent role in the 
instigation of experimental arthritis. In this 
process, soluble antagonists fulﬁll an impor-
tant function modulating signal transduc-
tion of IL-1 and IL-18 on target cells. These 
soluble antagonists of IL-1 and IL-18, like 
the sIL-1RAcP, IL-18BP and probably 
also the sIL-18Rβ that were studied in the 
chapters of this thesis, appear to be actively 
involved in regulating IL-1 and IL-18 signal 
transduction.  With this present knowledge 
concerning soluble receptor analogues, we 
can now add an additional layer of cytokine 
antagonism to the ever-growing complex-
ity of regulation of cytokine signaling.
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Signal transduction by IL-1 and IL-18 is 
strictly regulated by a diversity of regulat-
ing and antagonizing molecules, such as 
membrane associated decoy receptors and 
speciﬁc receptor antagonists. Recently, circu-
lating receptors which are partial analogues 
of the membrane receptor for IL-1 and IL-18 
have been described e.g. sIL-1RAcP, IL-
18BP and sIL-18Rβ. Yet, concerning their 
physiological function little is known. 
The aim underlying this project, described 
in this thesis is to study the role of IL-1 and 
IL-18 in murine models of experimen-
tal arthritis, especially collagen-induced 
arthritis. Since IL-1 and IL-18 signal trans-
duction is an important aspect which can 
be regulated at different levels by receptor 
antagonists and soluble membrane receptors, 
we also characterized the recently described 
soluble membrane receptor analogues and 
studied their possible physiological function 
in models of experimental arthritis.
In the general introduction (Chapter 1) 
we give an overview of the present knowl-
edge concerning the cytokines IL-1 and 
IL-18. Special focus has been given to their 
role in RA and murine models of experi-
mental arthritis. Furthermore, the receptor 
components enabling signal transduction 
and the recently described soluble variants 
of these receptors will be described into 
further detail. In Chapter 2 we describe a 
novel aspect of IL-18 in the development of 
articular pathology. Adenoviral mediated 
gene transfer of IL-18 into the murine knee 
joint, revealed a direct role for IL-18 in 
the development of inﬂammation. Interest-
ingly, IL-18 also induced cartilage proteogly-
can depletion indirectly, via the production 
of IL-1β. These results reveal that besides the 
important role in T-cell immunity, IL-18 
also plays a prominent role in the induction 
of inﬂammation and cartilage destruction. 
In the following Chapters 3 to 5 we 
study the role of the recently described sIL-
1RAcP in murine experimental arthritis. 
Chapter 3 shows that this soluble variant 
of the membrane IL-1RAcP, which is also 
Cytokines, which enable communication between the diﬀerent subtypes of cells of the immune system, are crucial components responsible for an eﬃcient regulation of the immune system. In this complex network of diﬀerent regulatory cytokines, two key players have evolved, named 
interleukin-1 (IL-1) and interleukin-18 (IL-18). Both IL-1 and IL-18 are involved in the instigation 
and maintenance of inﬂammatory processes. Based on their structural and functional similarity, 
both IL-1 and IL-18 belong to the “IL-1 ligand super family”.  
 Their pro-inﬂammatory characteristics make IL-1 and IL-18 prominent players in the pathogen-
esis of  rheumatoid arthritis (RA). This disease is mainly orchestrated by a speciﬁc auto-immune 
regulated chronic inﬂammation, aﬀecting bone and cartilage. This process will eventually lead 
to severe impairment or even loss of articular function. IL-1 and IL-18 are highly expressed in 
synovial tissue of patients suﬀering from RA. From mouse experimental arthritis models it has 
become clear that especially IL-1 is directly involved in the destruction of articular cartilage, 
while IL-18 has a more profound eﬀect on T-cell regulation especially Th1 maturation. Since these 
interleukins play an important role in the pathogenesis of RA,  targeting IL-1 and IL-18 could lead 
to the development of novel therapies. 
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detectable in the human blood circulation, is 
involved in the regulation of IL-1 sensitiv-
ity. Murine recombinant sIL-1RAcP, puri-
ﬁed using afﬁnity chromatography, was 
used for in vitro experiments. To study the 
effect of sIL-1RAcP on IL-1 signaling, an 
IL-1 sensitive reporter cell line was devel-
oped in which a luciferase reporter gene was 
under the regulation of NFκB (cell lines are 
described in Chapters 8 and 9 in further 
detail). On this cell line sIL-1RAcP was 
able to inhibit IL-1 induced NFκB activity. 
After showing the IL-1 antagonistic activity 
of sIL-1RAcP, we overexpressed sIL-1RAcP 
both locally in the murine knee joint and 
systemically in the blood circulation in the 
murine collagen-induced arthritis model. 
Both local and systemic overexpression of 
sIL-1RAcP resulted in a signiﬁcant protec-
tion against cartilage and bone destruction, 
with systemic treatment giving the best 
result. From the results described in this 
chapter, we conclude that sIL-1RAcP is an 
IL-1 antagonist, which can be used for treat-
ment of collagen-induced arthritis. However, 
the precise mechanism by which sIL-1RAcP 
blocks IL-1 signal transduction and amelio-
rated experimental arthritis needed to be 
further studied. 
In Chapter 4 we studied the in vitro and 
in vivo mechanism of action of sIL-1RAcP. 
By using systemic adenoviral gene transfer of 
sIL-1RAcP we were able to study the effect 
of sIL-1RAcP in comparison to IL-1Ra 
on T- and B-cell function during collagen-
induced arthritis. Systemic overexpression 
of sIL-1RAcP resulted in a reduction of 
circulating levels of anti-bovine collagen 
II IgG’s, of which IgG2a and the total IgG 
were signiﬁcantly reduced. Also IL-1Ra 
treated animals showed reduced circulating 
levels of anti-bovine collagen II IgG2a. In 
parallel with this observation circulating 
IL-6, which is known to be a B-cell acti-
vator, was also reduced by both treatments. 
In contrast to the observed effect on B-cell 
activity, sIL-1RAcP appeared not to affect 
T-cell proliferative activity or IL-1 induced 
NFκB activity on T-cell populations.  On the 
contrary, IL-1Ra also reduced T-cell activity 
efﬁciently.  Because of the fact that B-cells 
are known to highly express the IL-1R II on 
their membranes compared to T-cells, which 
could determine the difference in antagonis-
tic activity between sIL-1RAcP and IL-1Ra 
on T- and B-cells, we studied the expression 
of IL-1 receptor components on puriﬁed 
T- and B-cell populations of mice suffering 
from collagen–induced arthritis. Conform 
literature, we observed a high expression of 
the IL-1R II on B-cells compared to T-cells. 
Using reporter cell lines varying in expres-
sion for the IL-1R II or the IL-1RAcP we 
could reveal that sIL-1RAcP was a func-
tional antagonist on cells either express-
ing high amounts of the IL-1R II or low 
amounts of the IL-1RAcP. Due to the fact 
that the IL-1R II serves as an IL-1 scaveng-
ing receptor which hampers the IL-1RAcP 
from forming a functional complex with the 
IL-1R I, the sIL-1R II indirectly determines 
the availability of IL-1RAcP. This reveals a 
mechanism in which sIL-1RAcP functions 
as an antagonist of IL-1 probably depen-
dent on the availability of its full-length 
membrane bound IL-1RAcP.  Since IL-1Ra 
antagonized IL-1 signaling independent on 
membrane IL-1R II or IL-1RAcP expres-
sion, this underlines that IL-1Ra functions as 
a pure receptor antagonist, competing with 
IL-1 for occupation of the IL-1R I.  This 
difference in antagonistic activity is further 
studied in Chapter 5. In this chapter we 
show that combinations of both antagonists 
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can lead to additive inhibition of IL-1. Also 
combination of both antagonist as a treat-
ment for collagen-induced arthritis resulted 
in signiﬁcant amelioration of the experimen-
tal arthritis. These results underline that sIL-
1RAcP is an inhibitor of IL-1 distinct from 
IL-1Ra.
The following Chapters 6 and 7 are dedi-
cated to the role of IL-18 and the recently 
described soluble receptors, which are partial 
analogues of the IL-18 receptors, in murine 
experimental arthritis. Since it has been 
recently reported that IL-18 plays a promi-
nent role in the development of experimental 
arthritis, we evaluate in chapter 6 the effects 
of adenoviral mediated overexpression of the 
IL-18 antagonist IL-18BP on the outcome 
of collagen-induced arthritis. Adenoviral 
overexpression of IL-18BP lead to functional 
expression of the binding protein, which 
inhibited IL-18 induced NFκB activity in 
vitro. This IL-18 neutralizing strategy was 
applied intra-articularly through adenoviral 
mediated overexpression of IL-18BP before 
clinical manifestation of the collagen-induced 
arthritis. This local approach protected both 
bone and cartilage against the detrimental 
effects of the arthritis. Not only did IL-
18BP protect the treated knee joints, it also 
protected the distal joints of ankle and toes. 
With this study we emphasize the important 
role of IL-18 as a pro-inﬂammatory cytokine 
in the development of experimental arthritis. 
Furthermore, we show that IL-18, beside 
its important role in development of T-cell 
immunity, is also involved in the develop-
ment local joint pathology, sequentially 
to the ﬁndings described in chapter 2. 
Therefore IL-18BP could offer joint protec-
tion when used as a therapeutic strategy for 
the treatment of rheumatoid arthritis. 
Like the sIL-1RAcP, a short form of the 
IL-18Rβ has recently been found. Chapter 7 
describes the characterization of the murine 
variant of this protein, which is mainly 
expressed in tissue of lymphoid origin, like 
thymus, lymph nodes and spleen. Further 
study of this protein revealed a possible 
regulating role on Th1/Th2 function during 
collagen-induced arthritis, in which systemic 
overexpression of this protein resulted in 
aggravation of the experimental arthritis. 
As a research spin-off techniques have 
been developed having broader applica-
tions than for which they were originally 
developed and used in previous chapters. 
Chapter 8 describes the characterization 
of the reporter cell lines, which have been 
used throughout this thesis, in which the 
luciferase reporter gene is under the tran-
scriptional control of a NFκB regulated 
promoter. Several reporter cell lines have 
been developed, derived from ﬁbroblast, 
chondrocyte and thymocyte, which all react 
with different sensitivity towards a panel of 
pro-inﬂammatory cytokines including IL-1, 
IL-18, TNFα and IL-17. These reporter cell 
lines have proven to be a valuable test system 
for the study of antagonistic activity of the 
soluble receptor analogues (sIL-1RAcP 
in Chapter 3-5 and IL-18BP in Chapter 
6). However, these reporter cell lines can 
also be used for the validation of siRNA 
directed towards intracellular mediators of 
signal transduction leading to NFκB activa-
tion. In Chapter 9 the developed reporter 
cell lines were used for the study of NFκB 
activity caused by inﬂammatory processes 
as can be observed during mouse models of 
experimental arthritis. Using intra-articular 
reporter cell transfer we are able to moni-
tor local NFκB activity during processes 
of inﬂammation in living animals. This 
approach enables the study of NFκB induced 
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inﬂammation during experimental arthritis 
or during the therapeutic interventions of 
the experimental arthritis.
In the ﬁnal chapter (Chapter 10) we 
summarize and discuss the results described 
in this thesis. In summary we can conclude 
that both IL-1 and IL-18 play a prominent 
role in the instigation of experimental 
arthritis. In this process, soluble antagonists 
fulﬁll an important function modulating 
signal transduction of IL-1 and IL-18 on 
target cells. These soluble antagonists of IL-
1 and IL-18, like the sIL-1RAcP, IL-18BP 
and probably also the sIL-18Rβ that were 
studied in the chapters of this thesis, appear 
actively involved in regulating IL-1 and 
IL-18 signal transduction. With this pres-
ent knowledge concerning soluble receptor 
analogues, we can now add an additional 
layer of cytokine antagonism to the ever-
growing complexity of regulation of cyto-
kine signaling.
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Signaal overdracht door zowel IL-1 als 
IL-18 wordt strikt gereguleerd door een 
verscheidenheid aan regulerende en antago-
nerende moleculen, waaronder membraan-
geassocieerde IL-1 aﬂeidingsreceptoren (ook 
wel decoyreceptoren genoemd) of speciﬁeke 
receptorantagonisten. Recent zijn echter ook 
circulerende receptoren beschreven, welke 
gedeeltelijk analoog zijn met de membraan-
receptoren voor IL-1 en IL-18. Echter, van 
deze oplosbare receptoren, waaronder het 
sIL-1RAcP, IL-18BP en het sIL-18Rβ, is de 
fysiologische functie nog onbekend.
Het doel van dit proefschrift is het evalu-
eren van de rol van IL-1 en IL-18 in experi-
mentele artritis. Hierbij is speciale aandacht 
geschonken aan de rol die beide cytokines 
spelen gedurende het ontstaan van collageen-
geïnduceerde arthritis. Omdat cytokine 
signaal overdracht van IL-1 en IL-18 een 
belangrijk aspect vormt dat op verschillende 
niveaus gereguleerd kan worden door recep-
tor anatgonisten en oplosbare membraan 
receptoren of analogen hiervan, is darnaast 
aandacht besteed aan het karakteriseren 
van de recentelijk beschreven oplosbare 
membraanreceptoren en het evalueren van 
hun mogelijke fysiologische rol in experi-
mentele artritis.
In de algemene introductie (Hoofd-
stuk 1) wordt een globale schets van de 
huidige kennis omtrent de cytokines IL-1 
en IL-18 gegeven. Speciale aandacht gaat uit 
naar de rol van deze cytokines in muismo-
dellen van experimentele artritis en reuma-
toïde artritis, de rol van de receptoren die 
de signaaltransductie mogelijk maken, en de 
recent beschreven oplosbare varianten van 
deze signalerende receptoren. In Hoofd-
stuk 2 wordt de rol van IL-18 in het ontstaan 
van gewrichtspathologie nader bestudeerd. 
Gebruik makend van adenovirale overex-
Voor een eﬃciënte regulering van het immuunsysteem, zijn cytokines cruciale factoren die de communicatie tussen de verschillende celtypen van het immuunsysteem mogelijk maken. In dit complexe netwerk van cytokines zijn interleukine-1 en interleukine-18 twee essentiële eiwitten. 
Zowel IL-1 als IL-18 zijn betrokken bij de initiatie en het onderhouden van ontsteking, waarbij 
beide cytokines een pro-inﬂammatoir karakter hebben. Op grond van hun structurele en func-
tionele gelijkenis behoren IL-1 en IL-18 tot de zogenoemde ‘IL-1 ligand superfamilie’. 
 Gezien de rol van IL-1 en IL-18 in het ontstaan van ontsteking is het dan ook niet verwonderlijk 
dat beide een belangrijke bijdrage leveren aan de pathogenese van reumatoïde artritis (RA). In 
dit ziektebeeld, dat voornamelijk wordt bepaald door een auto-immuun gedirigeerde chronische 
ontsteking, worden gewrichtskraakbeen en bot dermate aangetast dat het proces uiteindelijk 
zal leiden tot het verlies van gewrichtsfunctie. In het synovium van patiënten die lijden aan RA 
komen zowel IL-1  als IL-18 in hoge mate tot expressie. Uit dierexperimentele artritismodellen 
is gebleken  dat IL-1 direct verantwoordelijk is voor de afbraak van kraakbeen. Zo is voor IL-18 
aangetoond dat dit cytokine een belangrijke rol speelt tijdens de ontwikkeling van naïeve T-
cellen naar Th1 eﬀectorcellen. Aangezien beide interleukines een essentiële bijdrage leveren aan 
het ontstaan van deze gewrichtspathologie, zijn ze een potentieel target voor het ontwikkelen 
van nieuwe therapieën. 
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pressie van IL-18 in het kniegewricht van 
muizen, hebben we aan kunnen tonen dat 
IL-18 direct bij kan dragen aan het ontstaan 
van gewrichtsontsteking en dat het indirect, 
via de productie van IL-1β, kan bijdragen 
aan het ontstaan van kraakbeenschade. De 
resultaten laten zien dat naast de belangrijke 
rol die IL-18 speelt in de ontwikkeling van 
T-cel immuniteit, het ook een prominente 
rol heeft in het ontstaan van gewrichtsont-
steking en kraakbeenschade.
In de daarop volgende Hoofdstukken 
3 tot en met 5 wordt de rol van de recen-
telijk beschreven oplosbare variant van het 
Interleukine-1 Receptor Accessory Protein 
(sIL-1RAcP) beschreven. Hierbij laten we in 
Hoofdstuk 3 zien dat deze oplosbare vari-
ant, die ook in de humane bloedcirculatie 
voorkomt, betrokken is bij de regulatie van 
IL-1 gevoeligheid. Afﬁniteitchromatograﬁe 
opgezuiverd muis recombinant sIL-1RAcP 
werd gebruikt in in vitro experimenten. 
Hiervoor werd een cellijn ontwikkeld waar-
bij IL-1 geïnduceerde NFκB activatie result-
eerde in luciferase expressie (waarvan de 
karakteristieke cytokine respons beschreven 
staat in Hoofdstuk 8 en 9). Op deze cellijn 
was sIL-1RAcP instaat IL-1 signaal over-
dracht te blokkeren. Hieropvolgend werd 
sIL-1RAcP zowel lokaal in de muizenknie 
als systemisch in de bloedcirculatie tot over-
expressie gebracht in het collageen-geïn-
duceerde artritis muizenmodel. Zowel lokaal 
als systemische overexpressie resulteerde in 
een signiﬁcante verlaging van de ernst van 
de kraakbeen en bot schade die normaal 
gedurende collageen-geïnduceerde artritis in 
de muizenknie kan worden waargenomen. 
Hierbij leidde systemische overexpressie met 
behulp van een adenovirale vector uitein-
delijk tot het best gewenste resultaat. Uit de 
resultaten van dit hoofdstuk blijkt dat het 
sIL-1RAcP kan dienen als een IL-1 antago-
nist die functioneel is in de behandeling van 
collageen-geïnduceerde artritis. Echter het 
precieze mechanisme waarmee sIL-1RAcP 
de IL-1 signaal overdracht kan blokkeren 
diende nader onderzocht te worden.
In het hierop volgende Hoofdstuk 4 
wordt het IL-1 antagonerende werkings-
mechanisme van sIL-1RAcP zowel in vivo 
als in vitro opgehelderd. Hiervoor zijn de 
effecten van systemische overexpressie van 
sIL-1RAcP in het muizen collageen-geïn-
duceerde artritis model op T- en B-cel 
immuniteit bestudeerd, en vergeleken met 
de al reeds veel bestudeerde IL-1 receptor 
antagonist (IL-1Ra). Systemische overex-
pressie van sIL-1RAcP resulteerde in een 
verlaging van circulerende antilichamen 
gericht tegen collageen type II, waarbij met 
name IgG2a alsook het totaal IgG signiﬁ-
cant waren gereduceerd. Dit was echter ook 
het geval voor IL-1Ra behandelde muizen. 
Parallel met deze observatie was ook het 
circulerend IL-6 in beide behandelingsgro-
epen gereduceerd. In tegenstelling tot de 
gevonden suppressieve effecten op B-cel 
immuniteit had sIL-1RAcP geen effect op 
T-cell proliferatieve activiteit alsook IL-1 
geïnduceerde NFκB activatie. Dit in tegen-
stelling tot IL-1Ra, dat in staat was zowel 
T- als B-cel functie te beïnvloeden. Gezien 
het feit dat B-cellen een hoge expressie 
van de IL-1RII vertonen, wat mogelijk het 
verschil in antagonistische activiteit tussen 
sIL-1RAcP en IL-1Ra zou kunnen bepalen 
werd de receptor expressie van de verschil-
lende IL-1 receptor componenten bepaald 
op zowel T- als B-cel populaties van runder 
collageen type II geïmmuniseerde DBA/1 
muizen. Hieruit bleek dat ook B-cellen 
uit geïmmuniseerde muizen een zeer hoge 
expressie vertoonde van de IL-1 “decoy“ 
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receptor. Met behulp van reporter cellijnen 
variërend in receptor expressie voor de 
IL-1R II alsook de IL-1RAcP, kon worden 
aangetoond dat sIL-1RAcP een functionele 
IL-1 antagonist is op cellen met of een hoge 
IL-1R II, of een lage IL-1RAcP expressie. 
Hieruit blijkt dat het sIL-1RAcP antago-
nisme waarschijnlijk wordt bepaald door 
de relatieve expressie van de membraan IL-
1RAcP. Gezien het feit dat de IL-1R II de 
IL-1 gevoeligheid van cel kan beïnvloeden 
door het wegvangen van IL-1 alsmede het 
wegzuigen van het IL-1RAcP voor formatie 
van een functioneel receptor complex met 
de IL-1R I, zou de antagonistische activiteit 
van sIL-1RAcP met name kunnen worden 
bepaald door de beschikbaarheid van zijn 
full-length membraan gebonden IL-1RAcP. 
Aangezien IL-1Ra het IL-1 signaal op iedere 
reporter cel antagoneerde, bevestigt deze 
observatie het IL-1 inhiberend mechanisme 
van IL-1Ra wat berust op directe competitie 
met IL-1 voor bezetting van de IL-1R type 
I en dus onafhankelijk is van IL-1RAcP en 
IL-1R type II expressie. Door dit verschil in 
antagonerend mechanisme tussen sIL-1RAcP 
en IL-1Ra is in Hoofdstuk 5 de combinatie 
van beide antagonisten bestudeerd in vitro 
en in vivo in de collageen-geïnduceerde 
artritis. In dit hoofdstuk laten we zien dat 
een combinatie van zowel IL-1Ra met sIL-
1RAcP kan leiden tot additieve inhibitie 
van het IL-1 signaal. Deze combinatie van 
beide eiwitten leidt tot signiﬁcante verbeter-
ing van de CIA. Verder onderschrijven de 
resultaten beschreven in dit hoofdstuk dat 
het mechanisme van IL-1 remming door IL-
1Ra terdege anders is dan het mechanisme 
waarmee sIL-1RAcP het IL-1 signaal remt. 
De hierop volgende Hoofdstukken 6 
en 7 zijn gewijd aan de verheldering van de 
rol van IL-18 en haar recentelijk beschreven 
oplosbare varianten, die gedeeltelijk analoog 
zijn aan de IL-18 receptor, in modellen van 
experimentele artritis. Aangezien onlangs is 
aangetoond dat IL-18 een zeer belangrijke 
rol speelt bij het ontstaan van experimentele 
artritis, wordt in Hoofdstuk 6 onderzocht 
of CIA te behandelen is middels gentherapie, 
waarbij intra-articulair IL-18 Bindingspro-
teïne (IL-18BP) tot  overexpressie wordt 
gebracht. Adenovirale overexpressie van 
het IL-18BP leidde tot functionele expressie 
van het eiwit, dat IL-18 geïnduceerde NFκB 
activatie signiﬁcant kon blokkeren. Deze IL-
18 neutraliserende interventie werd toege-
past in het collageen-geïnduceerde muis 
model, waarbij het IL-18BP intra-articulair 
tot overexpressie werd gebracht. Deze lokale 
aanpak leidde niet alleen tot een bescherm-
ing van bot en kraakbeen in de behandelde 
kniegewrichten, maar resulteerde ook in 
een additionele bescherming van distale 
gewrichten van de poten. Met deze studie 
onderschrijven we de belangrijke rol van 
IL-18 als een pro-inﬂammatoir cytokine, 
betrokken bij het ontstaan van experimentele 
artritis. Verder laat deze studie zien dat IL-18 
naast een belangrijke rol in T-cel immuniteit 
ook een belangrijke rol speelt in de lokale 
pathologie, wat aansluit op de bevindingen 
van hoofdstuk 2. IL-18BP zou in potentie 
gewrichtsbescherming kunnen geven.  
Overeenkomstig met de sIL-1RAcP is 
er onlangs ook een analoog van het IL-18 
Receptor Accessory Proteïne beschreven, dat 
voorkomt in de hersenen van de rat. Hoofd-
stuk 7 beschrijft de karakterisatie van de 
muizen variant, die met name tot expressie 
komt in lymfoide weefsels, waaronder 
thymus, lymfeknopen en de milt. Verder 
blijkt dat dit eiwit een mogelijke reguler-
ende rol heeft in de Th1/Th2 balans tijdens 
CIA, waarbij de experimentele artritis wordt 
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verergerd bij systemische overexpressie van 
het eiwit. 
Als spin-off van het onderzoek zijn nog 
reportercellijnen ontwikkeld en geanaly-
seerd die een bredere toepassing genieten 
dan datgene waarvoor de in voorafgaande 
hoofdstukken zijn beschreven.  In Hoofd-
stuk 8 worden de reportercellijnen gekara-
kteriseerd waarin een reportergen lucif-
erase onder controle staat van een NFκB 
gereguleerde promotor. Er zijn verscheidene 
reportercellijnen gemaakt, uitgaande van 
ﬁbroblasten, chondrocyten en thymocyten, 
die elk met variërende gevoeligheid op pro-
inﬂammatoire cytokines reageren, w.o. IL-1, 
IL-18, TNFα en IL-17. Deze stabiele report-
ercellijnen zijn een vaste waarde gebleken bij 
het bestuderen van de mogelijke antagoner-
ende werking van de verschillende oplosbare 
receptoranalogen (w.o. sIL-1RacP; Hoofd-
stuk 3 tot en met 5 en IL-18BP; Hoofdstuk 
6), maar ook voor het valideren van siRNA 
gericht tegen intracellulaire mediatoren van 
de signaal transductie die leidt tot NFκB 
activatie.  In Hoofdstuk 9 zijn de ontwik-
kelde reporter cellijnen gebruikt voor het 
bestuderen van NFκB activiteit als gevolg 
van het ontstekingsproces, zoals kan worden 
bestudeerd gedurende experimentele artritis. 
Hierbij kan met behulp van intra-articulaire 
reporter celtransfer lokale NFκB activiteit 
tijdens processen van ontsteking in levende 
muizen worden geanalyseerd. Deze aanpak 
maakt het mogelijk om NFκB geïnduceerde 
ontstekingsprocessen tijdens experimentele 
artritis of tijdens therapeutische interventies 
te bestuderen.
In het laatste hoofdstuk (Hoofdstuk 10) 
worden de resultaten van dit proefschrift 
samengevat en bediscussieerd.  Resumer-
end kan worden gesteld dat zowel IL-1 als 
IL-18 een  prominente rol innemen in het 
ontstaan van experimentele artritis. Hierbij 
speelt modulatie van de signaaloverdracht 
op target cellen voor IL-1 als IL-18 een 
belangrijke rol, die in belangrijke mate 
gereguleerd kan worden door oplosbare 
antagonisten. Deze oplosbare IL-1 en IL-
18 antagonisten w.o. de in dit proefschrift 
bestudeerde receptor analogen sIL-1RAcP, 
IL-18BP en mogelijk ook het IL-18Rβ 
blijken actieve regulatoren van de IL-1 en 
IL-18 signaal overdracht. Met de kennis 
omtrent deze oplosbare receptoranalogen, 
voegen we een additioneel niveau van 
antagonisme toe aan het steeds complexer 
wordende mechanisme van cytokine regu-
latie.  
&Curriculum VitaeList of PublicationsDankwoord
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Ruben Smeets werd geboren op 4 septem-
ber 1976 te Helmond. Van 1989-1993 door-
liep hij de Henricus MAVO te Helmond, 
en behaalde vervolgens in 1996 zijn VWO 
diploma aan het Dr. Knippenberg College 
te Helmond. In datzelfde jaar begon hij aan 
de studie Biomedische Gezondheidsweten-
schappen aan de Katholieke Universiteit 
Nijmegen (KUN). Binnen dit studietraject 
is gekozen voor het hoofdvak Toxicologie, 
waarvoor een stage werd doorlopen op 
de afdeling Farmacologie en Toxicologie 
aan de faculteit Medische Wetenschappen 
van de KUN, onder begeleiding van Drs. 
Sylvie Terlouw en Dr. Roos Masereeuw. 
Hieruit voortvloeiend werd een stageverslag 
geschreven getiteld: “ Regulation of organic 
anion uptake in proximal tubular cells of 
rat kidney”. Ter afronding van zijn tweede 
hoofdvak Pathobiologie, werd een stage-
project uitgevoerd op het onderzoekslabo-
ratorium Experimentele Reumatologie aan 
het Academisch Ziekenhuis Nijmegen St. 
Radboud onder begeleiding van Drs. Arjen 
Blom en Dr. Peter van Lent. Ter afsluiting van 
deze stage werd een stage verslag getiteld:“ 
Involvement of synovial lining macrophages 
in osteophyte formation” en een scriptie 
getiteld; “Interleukin-18” geschreven. In 
december 2000 werd het doctoraal examen 
Biomedische Gezondheidswetenschappen 
met goed gevolg afgelegd. 
Gedurende zijn studie aan de KUN is 
hij ondermeer studentlid geweest in de 
opleidingscommissie Biomedische gezond-
heidswetenschappen en de facultaire studen-
tenraad.
Van november 2000 tot november 2004 
was hij werkzaam als junior onderzoeker op 
het  onderzoekslaboratorium Experimentele 
Reumatologie verbonden aan het Acade-
misch Ziekenhuis Nijmegen St. Radboud 
(thans UMC St. Radboud). Gedurende deze 
periode werd het onderzoek verricht wat ten 
grondslag ligt aan de resultaten beschreven 
in dit proefschrift. 
Hij heeft op diverse congressen lezingen 
mogen geven over zijn onderzoeksresultaten, 
waaronder de ACR (American College of 
Rheumatology  2002, 2004), EWRR (Euro-
pean Workshop for Rheumatology Research 
2002) en EULAR (European League against 
Rheumatism 2002) waarvoor hij een “Best 
Abstract Award” kreeg. In 2003 ontving hij 
op grond van zijn gepresenteerde onderzoek 
een Young Investigators Award op de IAIS 
(International Association of Inﬂammation 
Societies) te Vancouver, Canada. Tevens was 
hij in oktober 2004 uitgenodigd op de IRA 
(Inﬂammation Research Association) 2004 
meeting om zijn resultaten te presenteren als 
een van de ﬁnalisten tijdens de “Gordon van 
Arman Award competition” in Bolton Land-
ing, New York.
Tezamen met Dr. Fons van de Loo, Dr. 
Leo Joosten en Prof. Dr. Wim van den Berg 
heeft hij recent en met succes een onderzoek 
voorstel geschreven wat een vervolg zal zijn 
op de in dit proefschrift beschreven onder-
zoeksresultaten.  
Sinds november 2004 is hij werkzaam als 
post-doc onderzoeker op het onderzoeks-
laboratorium Experimentele Reumatologie 
van UMC St. Radboud. 
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Ruben Smeets was born on the 4th of 
September 1976 in the town of Helmond, the 
Netherlands. From 1989 till 1993 he studied 
at the Henricus MAVO and he received his 
VWO diploma in 1996 at the Dr. Knippenberg 
College which are both located in Helmond. 
In this same year he started with his study 
Biomedical Health Sciences at the Faculty 
of Medicine of the University of Nijmegen 
(recently renamed Radboud University), the 
Netherlands. During his masters, he stud-
ied Toxicology and Pathobiology.  For his 
major Toxicology he performed scientiﬁc 
research at the department of Pharmacology 
and Toxicology of the Faculty of Medicine 
at the University Nijmegen.  This research 
on regulation of organic anion uptake in 
proximal tubular cells of rat kidney, was 
under the supervision of Drs. S. Terlouw and 
Dr. R. Masereeuw. For his major Pathobiol-
ogy he performed scientiﬁc research at the 
department of experimental rheumatology 
at the University Medical Center Nijmegen, 
the Netherlands. The research performed at 
this department concerned involvement of 
synovial lining macrophages in osteophyte 
formation, which was under the supervision 
of Drs. A. Blom and Dr. P van Lent. 
In December 2000 he received his masters 
degree. During his study at the University 
Nijmegen he was a member of the Medical 
Faculty Student Counsil. 
From November 2000 till November 2004 
he worked as a junior scientiﬁc researcher at 
the department of Experimental Rheumatol-
ogy at the University Medical Center Nijme-
gen under the supervision of Dr. F. van de 
Loo and Prof. Dr. W. van den Berg. During 
this period research was performed, which 
has been described in this thesis. 
He presented his work at several scientiﬁc 
conventions, including the ACR (American 
College of Rheumatology 2002, 2004), 
EWRR (European Workshop for Rheu-
matology Research 2002) and the EULAR 
(European League Against Rheumatism 
2002). At this latter convention he received 
a “Best Abstract Award”. Based on his scien-
tiﬁc research presented at the IAIS (Interna-
tional Association of Inﬂammation Societies) 
2003 in Vancouver, Canada, he received a 
Young Investigators Award. In addition, he 
was selected and invited to present his work 
as one of the ﬁnalists in the “Gordon van 
Arman Award Competition” at the at the 
2004 meeting of the IRA (Inﬂammation 
Research Association) in Bolton Landing, 
New York. 
Recently and in cooperation with Dr. F. 
van de Loo, Dr L. Joosten and Prof. Dr. W. 
van den Berg, he has written a scientiﬁc grant 
proposal with success, which will be a sequel 
to the research presented in this theses.
Starting from November 2004 he will be 
working as a post-doctoral research scientist 
at the department of Experimental Rheu-
matology and Advanced Therapeutics at the 
University Medical Center Nijmegen, The 
Netherlands.
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Hierbij gaat natuurlijk mijn dank uit aan 
iedereen, die ook maar enige interesse heeft 
getoond in wat ik in al die jaren heb gedaan, 
gepresenteerd en beschreven. En achteraf 
gezien kan je dat maar beter niet doen, want 
dat levert weer een aantal pagina’s extra aan 
typwerk op. Resumerend kan ik beter stel-
len dat het uiteindelijk meer een nawoord is 
geworden, met daarin verwerkt het dank-
woord.
Voor de totstandkoming van dit proef-
schrift wil ik allereerst Wim bedanken. 
Wim Bedankt! 
Zonder Wim was er geen laboratorium 
experimentele reumatologie en zonder labo-
ratorium kun je geen experimenten doen. 
Ik wil je bedanken voor je openheid zowel 
tijdens het werk als na het werk, waarbij het 
vaak uitmondde in gezelligheid. Zo ook op 
de vele congressen die ik heb mogen bezoek-
en. Ook al was je vaak ver weg of onderweg, 
je was toch altijd dichtbij, via internet dan 
welteverstaan. Wim bedankt voor je tijd, 
energie en vertrouwen.
Zo, nu op naar de tweede en ook zeer 
belangrijke persoon. Ja Fons, ook jij moet 
eraan geloven. Voor jou ook een kleine 
rede. Fons ik ben blij dat wij het altijd goed 
met elkaar konden en nog steeds, zelfs na 
het afronden van een proefschrift met alle 
stress van dien, kunnen vinden. Zowel op 
persoonlijk vlak als op de werkvloer. Ik wil 
je bedanken voor je betrokkenheid en uitste-
kende begeleiding. Ook al was je zelf druk, je 
maakte altijd tijd vrij als er weer eens een van 
de manuscripten geherstructureerd diende te 
worden, of als ik er even wetenschappelijk 
gezien niet meer uit kon komen. Eigenlijk 
kan bij jou ook wel gezegd worden; Zonder 
jou ook geen proefschrift! Ik hoop dat onze 
samenwerking voorlopig nog even vrucht-
baar blijft dan dat hij al was.
En dan nu het geschreven woord voor 
mijn peet-co-promotor, de IL-18 goeroe, Leo. 
Ondanks dat je niet echt een co-promotor 
van mij was, heb jij je wel altijd zo gedragen. 
Tijdens de vroege kofﬁeronde was er altijd 
even tijd om de gebeurtenissen van voor-
gaande dagen door te spreken op je kamer. 
Bedankt voor onze goede samenwerking, 
je te voorbarig geïmmuniseerde DBA/1 
muizen, waarvan ik dan gretig gebruik van 
kon maken en natuurlijk je tijd die je ook 
deels in ‘mijn onderzoek’ hebt gestoken.
Bij het doen van experimenten, die aan 
de basis kunnen komen te liggen van een 
manuscript heb je natuurlijk ondersteuning 
nodig. Deze analytische ondersteuning heb 
ik gekregen van Onno en Miranda. Allereerst 
Tja, het is AF! Na vier jaar van pipetteren, ploeteren en veel schrijven ben ik nu nog niet uitge-schreven. Ik zal jullie nu maar niet langer in spanning laten zitten wie wel en niet vernoemd wordt in het dankwoord. Het dankwoord is immers het meest gelezen en misschien wel bedis-
cussieerde deel (al dan niet in het openbaar) van het proefschrift. Eigenlijk is een dankwoord een 
klein eerbetoon, maar dan voor velen. 
 Maar ook voor mij is dit een heel belangrijk deel van mijn proefschrift. Bij het schrijven van dit 
stuk wordt het raamwerk, waarbinnen ikzelf heb mogen en kunnen functioneren, in een keer 
duidelijk. 
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een persoonlijk woord voor jou, Onno. Ik wil 
je bedanken voor de perfecte ondersteuning op 
dierexperimenteel gebied. Ondanks je lichte 
allergie, maakte je toch altijd tijd om even 
mee de artritis in muizen te scoren, of als een 
razende de muizen te injecteren….jezus, tegen 
jou valt niet op te werken. Hiervoor mijn dank. 
Verder en niet over het hoofd te zien, wil ik 
Miranda bedanken. Miranda bedankt voor je 
hulp, met name tijdens mijn laatste jaar, waarin 
jij veel van mijn werk uit handen kon nemen, 
wanneer ik weer eens aan het schrijven was. 
Soms denk ik bij mezelf, of die laatste en vaak 
zeer uitgebreide experimenten met betrekking 
tot regulatoïre T-cellen je niet al te veel stress 
hebben opgeleverd. Waarschijnlijk niet, want 
je wist ze altijd goed en op tijd uit te voeren. 
Hiervoor mijn dank! Maar juich nog niet te 
vroeg, er komt nog een andere junior onder-
zoeker na mij, op een vervolg onderwerp.
“Zonder studenten is het leven van en AiO een 
stuk zwaarder”. Daarom wil ik jullie, Walter en 
Manja heel erg bedanken voor jullie enorme 
inzet en interesse in het onderzoek en het werk 
wat jullie verzet hebben. Walter, ik wens je 
veel succes toe als AiO en Manja veel succes en 
plezier in je nieuwe baan. 
Zo dit schiet lekker op. Nu dan de vakbroe-
ders, mijn mede AiO’s. Toen ik, nu vier jaar 
geleden, begon op de afdeling waren er vele 
mannelijke AiO’s. Maar door een demogra-
ﬁsche factor is hierin een drastische verande-
ring gekomen. Zo zijn er nu vele vrouwelijke 
AiO’s, en blijk ik de laatste der Mohikanen te 
zijn. Toch wil ik even stilstaan bij de AiO’s, 
waarvan sommige al geruime tijd de afdeling 
verlaten hebben, maar waarvan ik nog vaag 
het gezicht in een spelonk van mijn gedachten 
kan op oprakelen. Ja, dan heb ik het natuurlijk 
over Alwin en Andrew, de AA-tjes en ADHD-
tjes van onze afdeling. Maar ja voor het goed 
blijven functioneren in het wetenschappelijk 
onderzoek moet je misschien wel een beetje 
gek zijn. Verder kan ik natuurlijk niet heen om 
onze Alfons, die recentelijk is gepromoveerd. 
Alfons, het was altijd plezierig met je te werken 
als mijn mede compagnon-AiO in onze werk-
groep. We moeten eigenlijk een keertje een 
whisky proeverij samen doen. Als jij nu een 
ﬂesje single malt whisky regelt, zorg ik voor 
de glazen. Dan kunnen we het er eens rustig 
over hebben wat er nu allemaal daadwerkelijk 
is gebeurd op Hawaï.
Ja en dan hebben we nog Karin. Hé, Karin 
mijn trouwe congresganger, mijn roomie. 
Zeker lekker geslapen hé op de ARC 2004 
in San Antonio. Ik zal nog een keer met je op 
congres gaan. Voor jou is nu ook het einde 
in zicht. Ik wens je heel veel succes met de 
afronding. Je kunt er niet op tijd genoeg mee 
beginnen. 
Verder wens ik (voor mijn gevoel op chro-
nologische volgorde) Marije, Esmeralda, Mieke 
en Shahla erg veel succes toe in hun resterende 
tijd als AiO/junior onderzoeker. 
Tja, Twan voor jou een aparte alinea. Ik 
weet niet hoe ik jou zou  moeten classiﬁceren. 
Arts of AiO, of wat voor andere benaming ze 
daar voor hebben. Natuurlijk wens ik jou als 
artsonderzoeker erg veel succes toe in je onder-
zoek. En een bedankje voor de publicatie 
samen is hier wel op zijn plaats. 
Een aparte positie is gereserveerd voor 
Erik (alias Koning Vossie). Erik aan jou een 
persoonlijk woordje gericht. Na het “show 
me what you are working with” en de leuke 
congressen die we samen hebben mogen 
bezoeken, wil ik je toch even bedanken voor 
je assistentie ter voorbereiding van de lay-out 
van dit proefschrift. Ik wens jou erg veel succes 
in je verder carrière en natuurlijk veel geluk 
samen met Wendy.
De Flex-plek-roomies hebben een zeer 
belangrijke en zelfs misschien wel ontwik-
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kelende en stimulerende rol in mijn AiO/junior 
onderzoeker tijd gespeeld. Daarom wil ik jullie, 
Arjen, als mijn voormalig stage begeleider, 
Nozomi, en de in symbiose verkerende bioche-
mie medewerker Reinout, welke zelfs af en toe 
meer parasitair  was en je daarmee het leven op 
sommige dagen aanzienlijk zuur kon maken, 
erg bedanken voor de prettige werksfeer 
samen. Maar toch kan ik er niet om heen om 
jou, Reinout even te bedanken voor je hulp, 
met name op het gebied van de ICT. 
Ook bij ons geldt; ‘‘om de secretaresse kun 
je niet heen”. Marianne, bedankt voor je hulp 
die je me geboden hebt, en natuurlijk voor de 
prettige en gezellige samenwerking. Verder 
wil ik Monique nog even bedanken. Misschien 
dacht je dat je helemaal niet meer aan bod 
zou komen, maar dat is dan fout gedacht. Ja 
jij als ‘ﬂippo koningin’ bedank ik voor de vele 
immunisaties van muizen welke je alleen dan 
wel samen met mij hebt gedaan. Verder wil 
ik alle nog niet bij naam genoemde analisten 
van de afdeling bedanken voor hun prettige 
samenwerking. Dat zijn dan welteverstaan en 
in volgorde van U-tje; Elly, Fieke, Birgitte, 
Liduine en Annet en natuurlijk Astrid (ik ben 
je nog niet vergeten!). 
Zo ook wil ik de werkgroepleiders Peter 
(curly bill), Peter en Tim en de overige post-
docs Erik en Henkie (dat rokje stond je trou-
wens erg leuk!), bedanken voor de prettige 
samenwerking en nuttige discussies.
Ook wil ik de medewerkers van het Centraal 
Dieren Laboratorium hierbij bedanken voor 
hun goede zorgen voor de proefdieren.
Furthermore, I would like to thank Michael 
Martin for his time and of course with the provided 
help during the preparation of the manuscripts 
concerning the sIL-1RAcP. Furthermore and also of 
his department I would like to thank Olaf, for the 
construction of the sIL-1RAcP producing cell line. 
From the Amgen cooperation, I would like to thank 
Dirk Smith for performing the sIL-1RAcP ELISA 
and the useful discussions. 
Mocht ik nu onverhoopt iemand vergeten 
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